---
document_datetime: 2024-06-24 16:31:20
document_pages: 89
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/ocrevus-h-c-004043-x-0039-epar-assessment-report-variation_en.pdf
document_name: ocrevus-h-c-004043-x-0039-epar-assessment-report-variation_en.pdf
version: success
processing_time: 84.4979838
conversion_datetime: 2025-12-28 09:15:01.92993
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 April 2024 EMA/CHMP/171408/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Ocrevus

International non-proprietary name: Ocrelizumab

Procedure No. EMEA/H/C/004043/X/0039

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1.                                                                                                       | Background information on the procedure ............................................6                                |                                                                                                           |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1                                                                                                      | Submission of the dossier                                                                                            | ....................................................................................6                     |
| 1.2                                                                                                      | Legal basis, dossier content..................................................................................6      |                                                                                                           |
| 1.3                                                                                                      | Information on Paediatric requirements                                                                               | .................................................................6                                        |
| 1.4                                                                                                      | Information relating to orphan market exclusivity                                                                    | ...................................................6                                                      |
| 1.4.1                                                                                                    | Similarity                                                                                                           | ........................................................................................................6 |
| 1.5                                                                                                      | Scientific advice..................................................................................................6 |                                                                                                           |
| 1.6                                                                                                      | Steps taken for the assessment of the product                                                                        | .......................................................6                                                  |
| 2. Scientific discussion ..............................................................................7 | 2. Scientific discussion ..............................................................................7             |                                                                                                           |
| 2.1                                                                                                      | Problem statement..............................................................................................7     |                                                                                                           |
| 2.1.1                                                                                                    | Disease or condition                                                                                                 | .........................................................................................7                |
| 2.1.2                                                                                                    | Epidemiology...................................................................................................8     |                                                                                                           |
| 2.1.3                                                                                                    | Aetiology and pathogenesis                                                                                           | ...............................................................................8                          |
| 2.1.4                                                                                                    | Clinical presentation, diagnosis                                                                                     | ..........................................................................8                               |
| 2.1.5                                                                                                    | Management                                                                                                           | ...................................................................................................8      |
| 2.2                                                                                                      | About the product                                                                                                    | ...............................................................................................8          |
| 2.3                                                                                                      | Type of Application and aspects on development.....................................................9                 |                                                                                                           |
| 2.4                                                                                                      | Quality aspects...................................................................................................9  |                                                                                                           |
| 2.4.1                                                                                                    | Introduction                                                                                                         | ....................................................................................................9     |
| 2.4.2                                                                                                    | Active Substance..............................................................................................9      |                                                                                                           |
| 2.4.3                                                                                                    | Finished Medicinal Product...............................................................................11          |                                                                                                           |
| 2.4.4                                                                                                    | Discussion on chemical, and pharmaceutical aspects                                                                   | ..........................................14                                                              |
| 2.4.5                                                                                                    | Conclusions on the chemical, pharmaceutical and biological aspects                                                   | .....................14                                                                                   |
| 2.5                                                                                                      | Non-clinical aspects...........................................................................................14    |                                                                                                           |
| 2.5.1                                                                                                    | Introduction                                                                                                         | ..................................................................................................14      |
| 2.5.2                                                                                                    | Pharmacology................................................................................................14       |                                                                                                           |
| 2.5.3                                                                                                    | Pharmacokinetics                                                                                                     | ...........................................................................................14             |
| 2.5.4                                                                                                    | Toxicology.....................................................................................................15    |                                                                                                           |
| 2.5.5                                                                                                    | Ecotoxicity/environmental risk assessment........................................................16                  |                                                                                                           |
| 2.5.6                                                                                                    | Discussion on non-clinical aspects                                                                                   | ....................................................................16                                    |
| 2.5.7                                                                                                    | Conclusion on the non-clinical aspects                                                                               | ..............................................................17                                          |
| 2.6                                                                                                      | Clinical aspects                                                                                                     | .................................................................................................17       |
| 2.6.1                                                                                                    | Introduction                                                                                                         | ..................................................................................................17      |
| 2.6.2                                                                                                    | Clinical pharmacology.....................................................................................18         |                                                                                                           |
| 2.6.3                                                                                                    | Discussion on clinical pharmacology                                                                                  | .................................................................27                                       |
| 2.6.4                                                                                                    | Conclusions on clinical pharmacology................................................................27               |                                                                                                           |
| 2.6.5                                                                                                    | Clinical efficacy                                                                                                    | ..............................................................................................28          |
| 2.6.6                                                                                                    | Discussion on clinical efficacy...........................................................................48         |                                                                                                           |
| 2.6.7                                                                                                    | Conclusions on the clinical efficacy                                                                                 | ...................................................................48                                     |
| 2.6.8                                                                                                    | Clinical safety                                                                                                      | ................................................................................................48        |
| 2.6.9                                                                                                    | Discussion on clinical safety.............................................................................67         |                                                                                                           |
| 2.6.10                                                                                                   | Conclusions on the clinical                                                                                          | safety....................................................................75                              |
| 2.7.1                                                                                                    | Safety concerns                                                                                                      | .............................................................................................76           |

<div style=\"page-break-after: always\"></div>

| 2.7.2                                                                                                 | Pharmacovigilance plan...................................................................................76         |                                                                                                        |
|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 2.7.3                                                                                                 | Risk minimisation measures                                                                                          | ............................................................................78                         |
| 2.7.4                                                                                                 | Conclusion.....................................................................................................83   |                                                                                                        |
| 2.8                                                                                                   | Pharmacovigilance                                                                                                   | ............................................................................................83         |
| 2.8.1                                                                                                 | Pharmacovigilance system...............................................................................83           |                                                                                                        |
| 2.8.2                                                                                                 | Periodic Safety Update Reports submission requirements                                                              | ....................................84                                                                 |
| 2.9                                                                                                   | Non-Conformity of paediatric studies...................................................................84           |                                                                                                        |
| 2.10                                                                                                  | Product information                                                                                                 | .........................................................................................84            |
| 2.10.1                                                                                                | User consultation..........................................................................................84       |                                                                                                        |
| 2.10.2                                                                                                | Labelling exemptions                                                                                                | ....................................................................................84                 |
| 2.10.3                                                                                                | Quick Response (QR) code.............................................................................84             |                                                                                                        |
| 2.10.4                                                                                                | Additional monitoring....................................................................................84         |                                                                                                        |
| 3. Benefit-Risk Balance ...........................................................................84 | 3. Benefit-Risk Balance ...........................................................................84               | 3. Benefit-Risk Balance ...........................................................................84  |
| 3.1                                                                                                   | Therapeutic Context                                                                                                 | ..........................................................................................84           |
| 3.1.1                                                                                                 | Disease or condition                                                                                                | .......................................................................................84              |
| 3.1.2                                                                                                 | Available therapies and unmet medical need                                                                          | .....................................................84                                                |
| 3.1.3                                                                                                 | Main clinical studies........................................................................................85     |                                                                                                        |
| 3.2                                                                                                   | Favourable effects.............................................................................................85   |                                                                                                        |
| 3.3                                                                                                   | Uncertainties and limitations about favourable effects............................................85                |                                                                                                        |
| 3.4                                                                                                   | Unfavourable effects..........................................................................................85    |                                                                                                        |
| 3.5                                                                                                   | Uncertainties and limitations about unfavourable effects ........................................86                 |                                                                                                        |
| 3.6                                                                                                   | Effects Table                                                                                                       | ....................................................................................................87 |
| 3.7                                                                                                   | Benefit-risk assessment and discussion................................................................88            |                                                                                                        |
| 3.7.1                                                                                                 | Importance of favourable and unfavourable effects ............................................88                    |                                                                                                        |
| 3.7.2                                                                                                 | Balance of benefits and risks ...........................................................................88         |                                                                                                        |
| 3.7.3                                                                                                 | Additional considerations on the benefit-risk balance ..........................................88                  |                                                                                                        |
| 3.8                                                                                                   | Conclusions......................................................................................................89 |                                                                                                        |
| 4.                                                                                                    | Recommendations...............................................................................89                    |                                                                                                        |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA                  Anti-drug antibodies

AE                    Adverse event

AESI                 Adverse event of special interest

ARR                  Annualized Relapse Rate

AUC                  Area under the curve

CCOD               Clinical cutoff date

CI                    Confidence interval

Cmax               Maximum serum concentration

CSR                 Clinical Study Report

CTD                 Common Technical Document

DMT                 Disease-modifying treatment

ECLA                Electrochemiluminescent assay

EDSS               Expanded Disability Status Scale

ELISA              Enzyme-linked immunosorbent assay

EMA                 European Medicines Agency

EU                   European Union

FDA                 Food and Drug Administration

FPI                  First patient in

GMR                Geometric mean ratio

HCPs                Healthcare professionals

HPQ                 Healthcare Professional Questionnaire

IBD                 International Birth Date

IR                   Injection reaction

IRR                 Infusion related reaction

IV                   Intravenous

LIR                 Local injection reaction

NCI CTCAE      National Cancer Institute Common Terminology Criteria for Adverse Events

PD                  Pharmacodynamic

PK                  Pharmacokinetic

PPK                Population PK

PPMS              Primary progressive multiple sclerosis

PPQ                Patient Preference Questionnaire

PRO                Patient-reported outcome

PY                   Patient years

RMS                Relapsing forms of multiple sclerosis

SAE                 Serious adverse event

SC                   Subcutaneous

<div style=\"page-break-after: always\"></div>

| SCE     | Summary of Clinical Efficacy                                           |
|---------|------------------------------------------------------------------------|
| SCP     | Summary of Clinical Pharmacology                                       |
| SCS     | Summary of Clinical Safety                                             |
| SFU     | Safety follow-up                                                       |
| SIR     | Systemic injection reaction                                            |
| SOC     | System Organ Class                                                     |
| T1Gd    | T1 gadolinium-enhancing                                                |
| TASQ-IV | Treatment Administration Satisfaction Questionnaire for ocrelizumab IV |
| TASQ-SC | Treatment Administration Satisfaction Questionnaire for ocrelizumab SC |
| USA     | United States of America                                               |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1 Submission of the dossier

Roche Registration GmbH submitted on 8 September 2023 extensions of the marketing authorisation.

Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (920 mg) and a new route of administration (subcutaneous use). The RMP (version 9.1) is updated accordingly.

The Marketing Authorisation Holder (MAH) applied for an addition of a new strength, addition of a new pharmaceutical form and an addition of a new route of administration.

The MAH applied for the following indication for Ocrevus 920mg solution for injection:

Ocrevus is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features, and for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

Furthermore, the PI is brought in line with the latest QRD template version.

## 1.2 Legal basis, dossier content

## The legal basis for this application refers to:

Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I of Regulation (EC) No 1234/2008, 2 point (c) - Extensions of marketing authorisations.

## 1.3 Information on Paediatric requirements

N/A

## 1.4 Information relating to orphan market exclusivity

## 1.4.1 Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5 Scientific advice

The MAH received Scientific advice from the CHMP on 22 April 2022 (EMA/SA/0000075948). The Scientific advice pertained to quality, non-clinical and clinical aspects.

## 1.6 Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Thalia Marie Estrup Blicher             Co-Rapporteur: N/A

| The application was received by the EMA on                                                   | 8 September 2023   |
|----------------------------------------------------------------------------------------------|--------------------|
| The procedure started on                                                                     | 28 September 2023  |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on | 18 December 2023   |

<div style=\"page-break-after: always\"></div>

| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                            | 20 December 2023   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 11 January 2024    |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                       | 25 January 2024    |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                           | 22 February 2024   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                         | 26 March 2024      |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 11 April 2024      |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Ocrevus on | 25 April 2024      |

## 2. Scientific discussion

## 2.1 Problem statement

Ocrelizumab  is  a  recombinant  humanized,  glycosylated,  monoclonal  IgG1  antibody  that  selectively targets and depletes CD20-expressing B cells, while preserving the capacity of B cell reconstitution and preexisting humoral immunity. Ocrelizumab IV 600 mg (Ocrevus®) was first granted marketing approval in the Unites States of America (USA) on 28 March 2017. It was subsequently approved in the European Union (EU) on 8 January 2018 and is currently approved in over 100 countries worldwide.

Ocrelizumab is approved to be administered by IV infusion every 6 months. The initial 600 mg dose is administered as two separate IV infusions: first as a 300 mg infusion, followed by a second 300 mg infusion 2 weeks later. Subsequent doses of ocrelizumab are administered as a single 600 mg IV infusion that lasts from 2 to 3.5 hours every 6 months.

To provide an additional delivery option of ocrelizumab, the Applicant has developed a subcutaneous (SC) formulation of ocrelizumab. The SC formulation is a combination of ocrelizumab with rHuPH20, human  recombinant  hyaluronidase,  which  is  approved  to  improve  dispersion  of  large  SC  injection volumes  (i.e.,  it  functions  as  a  permeation  enhancer).  The  SC  formulation  of  ocrelizumab  is  to  be administered as a single 10-minute SC injection every 6 months.

## 2.1.1 Disease or condition

Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disorder of the central nervous system (CNS) that is characterised by inflammation, demyelination, and oligodendrocyte and neuronal loss.

In the EU, ocrelizumab IV is indicated for:

- Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
- Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

<div style=\"page-break-after: always\"></div>

## 2.1.2 Epidemiology

MS is the most common progressive neurological disease of adults worldwide [Collaborators 2019]. The disease usually begins between the ages of 20 and 40 and is twice as common in women as in men. There is increasing incidence and prevalence of MS in both developed and developing countries.

## 2.1.3 Aetiology and pathogenesis

The cause of MS is unknown but the most striking pathogenic mechanism in MS is the immune system's attack  and  destruction  of  the  body's  own  myelin  sheath.  Many  cells  and  molecules  of  the  immune system-likely  unleashed  by  T-cell  activation-participate  in  demyelination.  The  entire  cascade  of immune system events eventually culminates in myelin destruction. The key features of this cascade are not fully understood, including the precise ordering of events, the antigens targeted by T cells, and the contributions of B lymphocytes, or B cells, and other cells of the immune system.

## 2.1.4 Clinical presentation, diagnosis

The  majority  of  MS  patients  (approximately  85%)  present  with  subacute  relapses  or  attacks,  with symptoms  and  signs  referable  to  the  CNS.  The  relapse/attack  is  followed  by  a  complete  or  partial remission/return to normal, only to be followed at a future date by another relapse usually in a different CNS  location,  thus  presenting  as  RRMS.  The  first  such  attack  is  referred  to  as  a  clinically  isolated syndrome. Some patients (approximately 15%) present with a gradually progressive course, without an initial well-defined attack. This is termed primary progressive MS. Most of these patients present with features of a spinal cord syndrome.

The diagnostic criteria for MS have been continuously evolved and include MRI with intravenous (IV) contrast  agent  containing  gadolinium,  lumbar  puncture  for  cerebrospinal  fluid  examination,  physical examinations, and electrophysiological tests.

## 2.1.5 Management

MS  management  includes  treatment  of  acute  relapses  with  high-dose  steroids,  DMTs,  including injectables like interferons, glatiramer acetate, oral DMTs (teriflunomide, dimethyl fumarate, fingolimod, ozanimod,  siponimod,  cladribine),  and  infusions  (e.g.,  natalizumab,  alemtuzumab,  ocrelizumab, mitoxantrone), as well as symptomatic treatments for managing MS symptoms (e.g., bladder problems, fatigue, spasticity).

## 2.2 About the product

Ocrelizumab  is  a  recombinant  humanized,  glycosylated,  monoclonal  IgG1  antibody  that  selectively targets and depletes CD20-expressing B cells, while preserving the capacity of B cell reconstitution and preexisting humoral immunity. Ocrelizumab IV 600 mg (Ocrevus®) was first granted marketing approval in the Unites States of America (USA) on 28 March 2017. It was subsequently approved in the European Union (EU) on 8 January 2018 and is currently approved in over 100 countries worldwide.

Ocrelizumab is approved to be administered by IV infusion every 6 months. The initial 600 mg dose is administered as two separate IV infusions: first as a 300 mg infusion, followed by a second 300 mg infusion 2 weeks later. Subsequent doses of ocrelizumab are administered as a single 600 mg IV infusion that lasts from 2 to 3.5 hours every 6 months.

To provide an additional delivery option of ocrelizumab, the Applicant has developed a subcutaneous (SC) formulation of ocrelizumab. The SC formulation is a combination of ocrelizumab with rHuPH20, human  recombinant  hyaluronidase,  which  is  approved  to  improve  dispersion  of  large  SC  injection volumes  (i.e.,  it  functions  as  a  permeation  enhancer).  The  SC  formulation  of  ocrelizumab  is  to  be administered as a single 10-minute SC injection every 6 months.

<div style=\"page-break-after: always\"></div>

## 2.3 Type of Application and aspects on development

## The development programme/compliance with guidance/scientific advice

The purpose of this application is to seek marketing approval of the ocrelizumab SC formulation for the approved ocrelizumab IV indications based on data from the pivotal Phase III Study CN42097 (thereafter referred  to  as  OCARINA  II)  and  the  supportive  Phase  Ib  Study  CN41144  (thereafter  referred  to  as OCARINA I).

## General comments on compliance with GMP, GLP, GCP

GMP

No issues have been identified during assessment of the Ocrevus dossier, which call for a pre-approval inspection.

## GLP

No issues with GLP status for the submitted studies were identified during the assessment of the Ocrevus X-39 dossier.

GCP

The Applicant claims that OCARINA II and OCARINA I were conducted in accordance with the principles of Good Clinical Practice, the principles of the Declaration of Helsinki, and local laws and regulations of the countries in which the studies were conducted. The appropriate Ethics Committees and Institutional Review Boards reviewed and approved each of the studies.

No audits were conducted in any of the two studies.

## 2.4 Quality aspects

## 2.4.1 Introduction

A new ocrelizumab formulation has been developed to enable subcutaneous administration (ocrelizumab SC), which offers a faster administration time and less invasive route of administration compared to intravenous (IV) infusions.

The ocrelizumab SC finished product is provided as a sterile, clear to slightly opalescent, and colourless to pale brown solution for subcutaneous injection with no preservatives. Each 50 mL single-dose vial contains 920 mg/23 mL (nominal) of ocrelizumab as active substance.

Other ingredients are sodium acetate (sodium acetate trihydrate and glacial acetic acid), methionine, trehalose, polysorbate 20, recombinant human hyaluronidase (rHuPH20) and water for injections.

The active substance used for production of ocrelizumab SC finished product is the same as that approved for ocrelizumab IV finished product. Therefore, where relevant, product and process knowledge from ocrelizumab IV are applied to the ocrelizumab SC Module 3.2 content.

## 2.4.2 Active Substance

## 2.4.2.1 General Information

Ocrelizumab  is  a  recombinant,  humanized,  glycosylated,  monoclonal  IgG1  antibody  with  a  H2L2 polypeptide structure that consists of two identical heavy chains of 452 amino acids and two identical light chains of 213 amino acids and targets CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Ocrelizumab selectively targets and depletes CD20-expressing B cells, while preserving the  capacity  of  B-cell  reconstitution  and  preexisting  humoral  immunity.  The  molecular  mass  is approximately 148 kDa.

<div style=\"page-break-after: always\"></div>

## 2.4.2.2 Manufacture, process controls and characterisation

The active substance process supplying the ocrelizumab SC finished product is the approved ocrelizumab active substance process that also supplies the commercial ocrelizumab IV finished product; thus, the active  substance  process  has  been  validated  to  deliver  ocrelizumab  consistently  with  the  expected product quality as per prior approval.

Due to differences in patient dosing strategy, ocrelizumab SC-specific risk assessments were performed to  demonstrate  the  relevance  of  the  completed  ocrelizumab  process  validation  studies  where  dosedependent criteria were applied.

## Clearance of raw materials

The raw material clearance evaluation for the approved Ocrelizumab IV active substance process is considered applicable to Ocrelizumab SC.

## Leachables

The original leachables testing performed for the approved ocrelizumab active substance process study supports ocrelizumab SC.

## Use and Reuse of Purification Resins and Membranes

The data supporting reuse, regeneration, and sanitization of resins and membranes from the approved ocrelizumab active substance process is directly applicable to ocrelizumab SC.

## Characterisation

Critical quality attributes (CQAs) for ocrelizumab have been previously identified as part of the initial marketing application for ocrelizumab IV. However, all ocrelizumab quality attribute (QA) classifications were reassessed to incorporate considerations specific to the subcutaneous route of administration. The reassessment concludes that the majority of the QA classifications remain unchanged The categories of potential impurities and control of impurities for ocrelizumab SC are the same as for ocrelizumab IV.

## 2.4.2.3 Specification, analytical procedures, reference standards, batch analysis, and container closure

The release and end-of-shelf life specification of active substance, the analytical procedures used to test active  substance  for  release  and/or  stability,  the  validation  of  those  analytical  procedures,  and  the justification of specification for the active substance used to manufacture ocrelizumab SC are the same as for ocrelizumab IV.

Four ocrelizumab active substance batches manufactured were utilized for the ocrelizumab SC finished product process performance qualification (PPQ) campaign. General information and batch release data for these active substance batches have been provided.

The same reference standard, as previously approved for ocrelizumab IV, is used for active substance and finished product testing. Also, the active substance container closure system is the same as for ocrelizumab IV.

## 2.4.2.4 Stability

As the active substance is stored and assigned the same expiry period irrespective of whether it is used to produce ocrelizumab IV or ocrelizumab SC, all of the previously performed stability studies are directly applicable.

The post-approval active substance stability protocol and stability commitment remain unchanged.

<div style=\"page-break-after: always\"></div>

## 2.4.3 Finished Medicinal Product

## 2.4.3.1 Description of the product and Pharmaceutical Development

Ocrelizumab SC finished product is presented in 50 mL vials as a sterile, single-dose, clear to slightly opalescent, and colorless to pale brown solution with no preservatives. Each single-dose vial contains 920 mg/23 mL (nominal) of ocrelizumab. rHuPH20 is the permeation enhancer to increase the dispersion and absorption of large drug volumes administered via the SC route.

The finished product is formulated as 40 mg/mL ocrelizumab SC with the following excipients: sodium acetate  (sodium  acetate  trihydrate  and  glacial  acetic  acid),  methionine,  trehalose,  polysorbate  20, recombinant human hyaluronidase (rHuPH20) and water for injections. The container closure system consists of a Type I borosilicate glass vial with a fluororesin-laminated rubber stopper and crimped with an aluminum seal fitted with a plastic flip-off cap.

## Formulation development

A summary of the Ocrelizumab SC formulation development has been provided.

For physicochemical characteristics of ocrelizumab, reference to the already approved (ocrelizumab IV) sections S.1.3 and S.3.1 was made which is accepted as the active substance used in the approved IV finished product is the same as that used in ocrelizumab SC finished product.

The excipients used in ocrelizumab SC finished product are sodium acetate (sodium acetate trihydrate and  glacial  acetic  acid),  methionine,  trehalose,  polysorbate,  rHuPH20  and  water  for  injections. Compatibility with these excipients and ocrelizumab was demonstrated by long-term stability data for the finished product and formulation development studies. The IV and SC finished product stability is, overall, highly similar.

The finished product does not contain any overages.

The finished product is intended to be administered manually using a syringe attached to a subcutaneous infusion set (e.g., winged/butterfly) with or without a syringe pump. The finished product is stable when stored at the recommended storage temperature which is highly similar to the commercial ocrelizumab IV  finished  product.  Potency  data  indicate  that  the  finished  product  maintains  biological  activity throughout the recommended storage duration at the recommended temperature .

## Manufacturing process development

The finished product manufacturing process development program was designed to ensure that robust and aseptic processes are in place across all steps, starting from the production of initial clinical batches to commercial manufacturing. Process design studies that support all acceptable manufacturing process parameters are described in Module 3.2, Section P.3.5 Process Design Studies. The differences in the manufacturing processes of the commercial product and clinical trial material are considered adequately explained and discussed.

## Finished Product comparability

The comparability assessment included quantitative and qualitative comparisons of release and stability data of ocrelizumab SC finished product manufactured using the to-be-commercialized process, against the clinical finished product manufactured . Both quantitative and qualitative comparisons demonstrate that the product quality is highly similar between the clinical and commercial finished products.

The applicant intends to implement a Real-time release testing (RTRT) approach for finished product manufacturing. Real-time release testing is a component of the overall control strategy to confirm that the finished product is acceptable for release, and ensure suitable quality of the finished product based on  information  collected  during  manufacture.  The  Applicant's  applications  of  RTRT  are  intended  to accelerate availability of patient supply by reducing the time between completion of manufacture and the release of the product.

<div style=\"page-break-after: always\"></div>

In conclusion, the Applicant's understanding of the process and the product from process characterisation and validation,  the  parallel  testing  data,  the  RTRT  risk  assessment,  and  the  pharmaceutical  quality system altogether support the implementation of the proposed RTRT approach.

## Container closure system

The initial clinical finished product container closure consists of a 20 mL vial and the subsequent clinical and commercial finished product container closure system consists of a 50 mL vial. Both are Type I borosilicate  glass  vials  with  the  same  glass  composition  and  sourced  from  the  same  manufacturer, stoppered with a 20 mm fluororesin-laminated rubber stopper and crimped with a 20 mm aluminum seal with a plastic flip-off cap.

These components are considered suitable for packaging sterile liquid products and comply with relevant pharmacopeial requirements (USP/Ph. Eur./JP).

The results of the extractable studies performed with commercial stoppers and vials and the results of the  leachable  studies  performed  with  the  finished  product  demonstrate  that  the  primary  packaging components are suitable and safe for use with the finished product. The ocrelizumab SC finished product is compatible with the primary packaging components in the container closure system, as demonstrated by long-term stability data for the finished product.

## In-use stability

The compatibility of the finished product with syringes and infusion sets has been demonstrated. Stability and  compatibility  studies  are  conducted  to  confirm  the  physicochemical  stability  of  the  solution  for injection under the recommended in-use conditions.

Once transferred aseptically from the vial to the disposable syringe, the ocrelizumab SC finished product solution is physicochemically stable for 30 days when stored at 2˚C -8˚C and protected from light and for an additional 8 hours when stored at 9˚C -30˚C in diffuse daylight. Ocrelizumab SC finished product does not contain any antimicrobial preservative; therefore, sterility of the solution must be ensured during in-use handling by maintaining appropriate aseptic conditions.

## 2.4.3.2 Manufacture of the product and process controls

The name, address, and responsibility of each manufacturer, production site or facility involved in the manufacturing and testing has been provided.

Process parameters for finished product manufacturing were evaluated for their criticality with respect to predetermined quality attributes. The evaluated parameters cover the manufacturing process from thawed active substance to final vial inspection. The acceptable ranges defined for the CPPs and nonCPPs in the finished product manufacturing process are considered adequate.

The manufacturing process consists of thawing of active substance, compounding, filtration and filling.

Testing is performed on samples collected at specified points of the manufacturing process to assess process consistency, verify microbial control, and to ensure the finished product is acceptable for release.

## Process validation/verification

Three consecutive PPQ batches were included that represent the full range of batch sizes for commercial manufacturing. The data from the PPQ batches showed that all CQAs met their acceptance criteria, all IPCs and validation samples met their acceptance criteria or action limits, respectively, all CPPs and nonCPPs were maintained within their acceptable ranges, and process performance was consistent between the  PPQ  batches.  Results  from  the  process  design  studies  in  combination  with  the  PPQ  campaign demonstrate that the finished product manufacturing process is robust and consistently yields finished product that meets the acceptance criteria. The ranges and values selected for the PPs are acceptable to support commercial manufacturing.

Altogether,  the  development  and  validation  of  the  ocrelizumab  SC  process  are  built  upon  a comprehensive science- and risk-based approach. This incorporates process and product understanding

<div style=\"page-break-after: always\"></div>

developed from ocrelizumab SC finished product-specific studies, and applicable commercial ocrelizumab IV  studies.  Platform  knowledge  gained  from  similar  molecules  and  processes  and  together,  these elements are part of an overall quality by design approach taken for the development of ocrelizumab SC.

## 2.4.3.3 Product specification, analytical procedures, batch analysis

The finished  product  specifications  used  for  the  release/stability  testing  are  considered  appropriate, including  adequate  tests  for  appearance,  particles,  pH,  osmolality,  identity,  content,  polysorbate  20 content, purity, potency/activity, endotoxin, sterility and container closure integrity.

Ocrelizumab SC finished product release and shelf-life acceptance criteria for CQAs that are intrinsic to the molecule (e.g., size and charge variants) are aligned with the acceptance criteria for ocrelizumab IV finished product. Overall, the specifications and justifications for the specifications for ocrelizumab SC finished product are considered comprehensive and adequate.

## Analytical procedures

The analytical procedure for each test used to analyze ocrelizumab SC finished product is adequately described. The compendial analytical procedures (tests performed according to pharmacopoeia) do not deviate from their respective monographs and were adequately verified to be suitable for their intended use. All non-compendial analytical procedures are fully validated in accordance with ICH Q2(R1). Many analytical  procedures  used  to  test  ocrelizumab  SC  samples  are  already  used  for  testing  commercial ocrelizumab IV at the same testing site. In light of the formulation differences between the proposed ocrelizumab  SC  compared  to  the  commercial  ocrelizumab  IV,  the  methods  have  been  validated  or confirmed to be suitable for their intended use.

## Reference materials

The  same  primary  and  secondary  reference  standards  approved  for  commercial  ocrelizumab  active substance and ocrelizumab IV will be used for ocrelizumab SC, which is considered acceptable.

## Batch analysis

All batch analysis results meet the specifications that were in effect at the time of testing and release for each batch. In addition, all available release data from the finished product batches produced during the PPQ campaign meet the commercial release specification acceptance criteria.

## 2.4.3.4 Stability of the product

The proposed shelf-life for ocrelizumab SC finished product is 24 months at 2°C-8°C, protected from light. The proposed shelf-life is based on available stability data from primary and supportive ocrelizumab SC batches. The stability of the commercial 30 mg/mL ocrelizumab IV finished product further supports the shelf life for 40 mg/mL ocrelizumab SC, since ocrelizumab IV and ocrelizumab SC are derived from the same ocrelizumab active substance.

Stability protocols for long-term stability study at 5°C and for accelerated stability study (25°C) have been provided.

In  conclusion,  the  results  from  stability  studies  of  ocrelizumab  SC  finished  product  demonstrate consistent stability behavior across the primary and supportive batches.

The Applicant commits further that after approval, at least one commercial finished product batch will be added to the stability monitoring program annually if production occurs during the calendar year. Deterioration of the distributed finished product will be reported to the Agency if observed during stability studies at the recommended long-term storage condition. Appropriate actions will be proposed according to applicable regulations, and the Applicant's internal procedures and quality management system.

Based on the stability data provided, the proposed shelf life of 24 months at 2°C-8°C, protected from light for the ocrelizumab finished product is found acceptable.

<div style=\"page-break-after: always\"></div>

## 2.4.3.5 Adventitious agents

There are no changes to the adventitious agents safety evaluation. This section as approved in the MAA for ocrelizumab IV is applicable also for ocrelizumab SC.

## 2.4.4 Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been  presented  in  a  satisfactory  manner.  The  results  of  tests  carried  out  indicate  consistency  and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5 Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.5 Non-clinical aspects

## 2.5.1 Introduction

A  type  II  variation  for  Ocrevus  920  mg  solution  for  injection  for  all  currently  authorized  Ocrevus intravenous (IV) indications was submitted in 2023, to apply for a line extension for an SC formulation.

The nonclinical strategy to support this Line Extension Application of the Marketing Authorization for Ocrevus → EMEA/H/C/004043 for SC administration of ocrelizumab leverages the available comprehensive nonclinical data packages (including pharmacology, pharmacokinetics/toxicokinetics, and toxicology) for IV administration of ocrelizumab (refer to MAA  EMEA-H-C-4043)  and  Hylenex → recombinant (hyaluronidase  human  injection)  (BLA  021859;  Halozyme  Therapeutics,  Inc.  [San  Diego,  California; US]).

In monkeys, SC administration was tested in a formulation similar to the IV formulation without coadministration of rHuPH20. To support the proposed clinical SC formulation with recombinant human hyaluronidase  enzyme  (also  known  as  ENHANZE → drug  product  [EDP]  and  hereafter  referred  to  as rHuPH20 [EDP],  additional  local  tolerance  studies  were  conducted  with  this  formulation  in  rats  and minipigs.

## 2.5.2 Pharmacology

The in vitro and in vivo pharmacology of ocrelizumab has already been extensively characterised in the assessment of the IV formulation (MAA EMEA-H-C-4043). No new studies were therefore submitted for the pharmacology of ocrelizumab. A study on the pharmacology, pharmacokinetics and local tolerance in cynomolgus monkeys was included in the original submission (Study 05-0025-1466), where it was shown that the degree of B cell depletion was similar between SC and IV administration routes. The SC formulation used in the study was the same as the IV formulation and did not include co-administration with  recombinant  human  hyaluronidase  enzyme  (rHuPH20).  However,  it  is  assumed  that  the pharmacological  results  for  the  formulation  without  rHuPH20  is  transferable  to  the  Ocrevus  SC formulation under review.

## 2.5.3 Pharmacokinetics

The pharmacokinetics of ocrelizumab has already been extensively characterised in the assessment of the  IV  formulation  (MAA  EMEA-H-C-4043).  No  new  studies  were  therefore  submitted  for  the

<div style=\"page-break-after: always\"></div>

pharmacokinetics of ocrelizumab. A study on the pharmacology, pharmacokinetics and local tolerance in monkeys was included in the original submission (Study 05-0025-1466). The SC formulation used in the study was the same as the IV formulation and recombinant human hyaluronidase enzyme (rHuPH20) was not co-administered in the study. Extensive ADA formation was observed in Study 05-0025-1466, as 15/18 animals developed ADA during the study across dose groups, resulting in an increased clearance of ocrelizumab (5 of 6 for SC 1 dose, 6 of 6 for SC split dose, and 4 of 6 for IV). The ADA levels in some of the recovery animals appeared to have affected the serum concentrations of ocrelizumab at terminal timepoints and, therefore, PK parameters were calculated after excluding data from these animals. ADA formation was also observed in the original dossier for the IV formulation, especially for the lower doses of ocrelizumab. No PK data is available for the effect of rHuPH20 on ocrelizumab in non-clinical species and how this may affect the absorption of ocrelizumab after SC administration. Thus, no comparison of PK profiles between the proposed clinical SC formulation and the authorized IV formulation has been provided by the Applicant. However, it is considered acceptable that no further PK characterization is performed in non-clinical species also taking the ADA formation into account in the animals, which is not transferable to humans.

## 2.5.4 Toxicology

The  toxicity  of  ocrelizumab  has  been  thoroughly  investigated  in  nonclinical  studies  following  IV administration (refer to MAA EMEA-H-C-4043). No new studies on systemic toxicities after single or repeat dosing as well as genotoxicity, carcinogenicity and reproductive toxicities for ocrelizumab SC have been  conducted.  New  local  tolerance  studies  in  rats  and  minipigs  for  ocrelizumab  SC  have  been conducted to bridge between the existing data for ocrelizumab IV and ocrelizumab SC and the studies are assessed below. While the PD/PK study in monkeys were performed on the IV formulation without co-administration of rHuPH20, new local tolerance studies in rats and minipigs were conducted with the proposed clinical SC formulation of ocrelizumab with rHuPH20.

No  new  standalone  studies  on  recombinant  human  hyaluronidase  enzyme  (rHuPH20)  have  been conducted. rHuPH20 has been extensively characterized in mice and cynomolgus monkeys in previous procedures  (e.g.  Herceptin  (containing  trastuzumab))  with  no  relevant  toxicological  findings  in  the general toxicity  studies  (e.g.  Hylenex → BLA 021859 (Halozyme Therapeutics, Inc.)). Though no new assessment of rHuPH20 is included in this procedure, the SmPC is aligned with previously authorised products specifically concerning information on rHuPH20.

## 2.5.4.1 Toxicokinetic data

## Tolerance and toxicokinetic data

Several local tolerance studies have been conducted with ocrelizumab; a study in monkeys at 150 mg/mL without  co-administration  of  rHuPH20,  as  well  as  studies  in  rats  and  minipigs  with  the  clinical  SC formulation with rHuPH20.

Swelling  and  redness  were  observed  at  the  injection  sites  of  monkeys  administered  ocrelizumab subcutaneously, when ocrelizumab was administered at high doses without co-administration of rHuPH20 (Study 05-0025-1466). The severity and duration of the injection site swelling increased as the SC dose volume was increased, and swelling only resolved by day 6 and day 8 for groups dosed with 0.5 mL and 1 mL, respectively. Redness and swelling were accompanied with clinical findings of local inflammation. According to the original assessment report for Ocrevus IV (MAA EMEA-H-C-4043), the SC formulation was discontinued at the time of assessment due to the severity of the local tolerance findings.

Based  on  tissue  cross-reactivity  and  pharmacologic  relevance,  the  cynomolgus  monkey,  a  binding species, was determined to be the only appropriate species for use in the nonclinical toxicology program of ocrelizumab in the original procedure (MAA EMEA-H-C-4043). In the present procedure, rats have been used as an alternative relevant toxicological species for investigating local tolerance instead of monkeys. This is justified by the Applicant as an investigative study in rats (Study 06-0367) showed that the  inflammation  in  the  rat  skin  was  more  localized  and  severe  than  generally  observed  in  the

<div style=\"page-break-after: always\"></div>

cynomolgus monkeys (Study 05-0025-1466). Therefore, the rat was determined to be a sensitive and appropriate model to evaluate formulation optimization for ocrelizumab SC. Furthermore, local tolerance was investigated  in  minipigs  to  support  the  findings  in  rats,  as  the  skin  of  minipigs  are  considered morphologically and functionally similar to human skin. Based on the justification from the Applicant and in light of the principles of 3R, it is accepted that no further local tolerance studies in monkeys were performed.

A dose-range finding study in rats was conducted to investigate the local effects at increasing doses of ocrelizumab (Study 06-0367). A clear dose-response correlation was observed when ocrelizumab was administered in rats without co-administration of rHuPH20, and at high dose levels of 150 mg/mL, a severe inflammatory response was observed while histological evidence of injection site inflammation was minimal at 30 mg/mL ocrelizumab. SC administration of ocrelizumab in rats with the proposed clinical SC formulation co-administered with 1000 U/mL rHuPH20 was in general well tolerated at lower doses. A dose dependent increase in inflammatory response as well as edema and fibrosis at the injection site  was  observed  in  Study  18-1377.  However,  the  effects  were  minimal  at  40  mg/mL  in  the  GLPcompliant Study 18-1665, which is considered the NOAEL in rats. In minipigs, the proposed clinical SC formulation co-administered with 1000 U/mL rHuPH20 with a dose of 40 mg/mL and a dose volume of 6 mL was also well tolerated, and this is considered the NOAEL in minipigs (Study 18-1979).

In  conclusion,  the  local  tolerance  studies  in  monkeys,  rats  and  minipigs  demonstrated  that  while ocrelizumab is not tolerated at high dose levels without the co-administration of rHuPH20, lower levels are well tolerated when co-administered with rHuPH20. Overall, dose levels of up to 40 mg/mL were well tolerated in non-clinical species, when co-administered with rHuPH20.

The Applicant provided exposure data from the local tolerance study in monkeys where TK measurements were included (Study 05-0025-1466), to compare with clinical exposure levels following IV and SC dosing in patients. However, severe local effects were observed in monkeys at the only dose level included of 150 mg/mL, and no safety margin could be determined. TK measurements were not included in the local tolerance studies in rats and minipigs so direct comparison with the exposure in patients is not possible. Instead, the Applicant provided body weight normalized doses for both rats and minipigs at the identified NOAEL values, corresponding to 80 mg/kg in rats (bw: 250 g) and 24 mg/kg in minipigs (bw: 10 kg), respectively.  The  body  weight  normalized  dose  in  humans  at the  clinical  dose  concentration is  15.3 mg/kg by assuming a bodyweight of 60 kg. Thereby, a safety margin of 5.22 and 1.57 is calculated for rats and minipigs, respectively. It is generally considered that the non-clinical data supports that the treatment is well tolerated at clinically relevant dose levels.

## 2.5.5 Ecotoxicity/environmental risk assessment

As the drug substance is a monoclonal antibody no ERA is required according to EMA 2006 guidance and Q&amp;A document. However, in spite of this, the Applicant performed several acute toxicity studies with ocrelizumab in the aquatic compartment, which all showed that the maximal tested concentration was tolerated  by  the  test  systems.  Furthermore,  ocrelizumab  was  biodegradable.  No  further  data  is considered necessary for the SC formulation as the new formulation is not considered to affect the fate of ocrelizumab in the environment. Further, rHuPH20 is a recombinant human enzyme and as per ERA guidance, no environmental assessment is considered warranted.

In conclusion, the active substance ocrelizumab and the excipient rHuPH20 are natural substances, the use  of  which  will  not  alter  the  concentration  or  distribution  of  the  substance  in  the  environment. Therefore, ocrelizumab and rHuPH20 are not expected to pose a risk to the environment.

## 2.5.6 Discussion on non-clinical aspects

No new pharmacological (PD), pharmacokinetic (PK) or repeat dose toxicity studies for systemic effects were  submitted  for  the  SC  Ocrevus  formulation.  In  order  to  bridge  between  the  existing  data  for ocrelizumab IV and ocrelizumab SC, new local tolerance studies in rats and minipigs for ocrelizumab SC have been conducted by the Applicant, in addition to an existing PD/PK/local toxicity study performed in cynomolgus monkeys, which was submitted with the original IV formulation of Ocrevus.

<div style=\"page-break-after: always\"></div>

In general, it is accepted that no further PD or PK studies are submitted to support the SC formulation of Ocrevus. The pharmacology of ocrelizumab after SC administration has been sufficiently demonstrated, although this was administered without prior treatment with rHuPH20. Extensive ADA formation was observed in monkeys after SC administration, which was shown to increase clearance of ocrelizumab  during  the  study,  however,  ADA  formation  was  also  observed  after  IV  injection,  and increased with lower dose levels. No comparison of PK profiles was provided by the Applicant between the approved IV formulation and the proposed clinical SC formulation, as TK measurements were not included as part of the local tolerance tests in rats and minipigs. However, it is considered acceptable that no further PK characterization is performed in non-clinical species also taking the ADA formation into account in the animals, which is not transferable to humans.

In terms of local tolerance, the Applicant demonstrated that ocrelizumab was well tolerated at low doses in rats and minipigs when co-administered with rHuPH20. The Applicant sufficiently justified using rats and minipigs as an alternative non-clinical species for testing local tolerance, so that no further local tolerance tests in monkeys would be required. NOAEL levels were established in both rats and minipigs at  40  mg/mL.  By  converting  the  NOAEL  values  to  body  weight  normalized  doses,  the  Applicant demonstrated sufficient safety margins to clinical dose levels, supporting that the treatment should be locally well tolerated.

## 2.5.7 Conclusion on the non-clinical aspects

The submitted dossier for the SC formulation of ocrelizumab is in general considered sufficient to support approval of Ocrevus SC from a non-clinical perspective. Section 4.6 and 5.3 of the SmPC is generally considered to reflect the outcome of the studies on Ocrevus SC formulation.

Overall,  the  non-clinical  study  submitted  with  the  present  application  is  considered  adequate  and sufficient to support SC administration of ocrelizumab.

## 2.6 Clinical aspects

## 2.6.1 Introduction

Safety and tolerability, PK, PD, and immunogenicity are assessed in the initial OCARINA I study, a dose escalation study in 2 parts, in RMS and PPMS patients. The SC dose selected based on data obtained in OCARINA I was evaluated in the pivotal OCARINA II study. Both studies are summarized in Table 1.

## ● Tabular overview of clinical studies

Table 1 Studies contributing to PK and PD evaluation

| Study Number         | Study Design                                                                                                                                                    | Population                                                                             | No. of Patients   | Dose,Route, Regimen                                   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------|-------------------------------------------------------|
| CN41144 (OCARINA I)  | PhaseIb,open-label, multicenter study to investigatethePK,safety and tolerability of SC ocrelizumab                                                             | Patients with RMS or PPMS, previously treatedwith ocrelizumab (A)or treatment-naive(B) | 134 A: 88 B:46    | 40,200,600,920 and 1200 mg SC; 600 mg IV              |
| CN42097 (OCARINA II) | Phase Ill,randomized, open-label,parallel group, multicenter study to evaluate the PK,PD safety, immunogenicity, radiologicalandclinical effectsofSCocrelizumab | PatientswithRMS or PPMS (no anti- CD20treatmentin thelast2years)                       | 236 IV:118 SC:118 | 920 mg SC; 600 mg IV (2x 300mginfusions2 weeks apart) |

IV=intravenous;PD=pharmacodynamic;PK=pharmacokinetic;PPMS=primaryprogressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; SC=subcutaneous.

<div style=\"page-break-after: always\"></div>

A subcutaneous (SC) formulation has been developed for administration of 920 mg ocrelizumab as a single SC injection over approximately 10 minutes to be given every 6 months for the same indications as currently approved for ocrelizumab IV. The main objective of Study OCARINA II is to show noninferiority of the SC formulation compared to the approved IV formulation of ocrelizumab.

## 2.6.2 Clinical pharmacology

## 2.6.2.1 Pharmacokinetics

Ocrelizumab concentration in  human  serum  samples was measured with an enzyme  linked immunosorbent assay (ELISA) using established and validated immunoassay procedures. A validated bridging ELISA was used to measure ADAs to ocrelizumab in human serum, and a validated bridging electro chemiluminescent assay (ECLA) was used to measure anti-rHuPH20 antibodies in human plasma. The ocrelizumab ADA assay had limited drug tolerance (500 ng/mL ADA could be detected in presence of 10 µg/mL ocrelizumab).

Two  clinical  studies  in  multiple  sclerosis  (MS)  patients  were  conducted  with  the  ocrelizumab  SC formulation, Study CN41144 (OCARINA I) and Study CN42097 (OCARINA II). The PK of ocrelizumab after SC injection or IV infusion was assessed by Pop PK analysis using NONMEM and R.

All data from OCARINA II available at the cut-off March 10, 2023 were used for Pop PK analysis. The OCARINA I based IV SC model was fitted to the data of Study CN42097 (OCARINA II). All parameters were fixed (equal to the values of the original IV model), except for SC absorption parameters and Q which were re-estimated. Effects of age were re-evaluated and an effect of age on ka included. Table 2 shows parameter estimates of the IV model and Table 3 the re-estimated parameters of the final IV SC Model 500.

<div style=\"page-break-after: always\"></div>

Table 2 Parameter estimates for Ocrelizumab IV population PK model

<!-- image -->

| Parameter     | Parameter   | Estimate   | RSE (%)   | 95%CI         |             |           |
|---------------|-------------|------------|-----------|---------------|-------------|-----------|
| CLinf (L/day) | θ1          | 0.17       | 1.26      | 0.166-0.174   |             |           |
| V(L)          | 02          | 2.78       | 1.35      | 2.71-2.85     |             |           |
| V2(L)         | 03          | 2.68       | 2.76      | 2.53 -2.82    |             |           |
| Q (L/day)     | θ4          | 0.294      | 7.46      | 0.251-0.337   |             |           |
| Kdes (year')  | θ5          | 1.11       | 5.95      | 0.979-1.24    |             |           |
| CLto (L/day)  | 66          | 0.0489     | 2.62      | 0.0464-0.0514 |             |           |
| CLro2 (L/day) | 07          | 0.0199     | 8.16      | 0.0167-0.0231 |             |           |
| CLinf.WT°     | 08          | 0.684      | 5.19      | 0.615-0.754   |             |           |
| V1.WT         | 99          | 0.397      | 8.4       | 0.331-0.462   |             |           |
| V2.WTa        | θ10         | 0.853      | 6.46      | 0.745-0.961   |             |           |
| Q.wT a        | 011         | 0.75 Fix   | NA        | NA            |             |           |
| CLTO.WT a     | 012         | 0.981      | 7.82      | 0.831-1.13    |             |           |
| V1,Male       | 013         | 1.12       | 2.08      | 1.07 -1.16    |             |           |
| CLinf.BCD19 C | 014         | 0.0403     | 13.6      | 0.0295-0.051  |             |           |
|               |             |            |           |               | Variability | Shrinkage |
|               | Q(1,1)      | 0.0535     | 5.07      | 0.0482-0.0588 | CV=23.1%    | 7.1%      |
| mmunom        | Q(1,2)      | 0.026      | 11.3      | 0.0202-0.0318 | R=0.528     | NA        |
| w?v1          | Q(2,2)      | 0.0453     | 8.23      | 0.038-0.0526  | CV=21.3%    | 31.30%    |
|               | Q(3,3)      | 0.239      | 8.91      | 0.197-0.281   | CV=48.9%    | 53.30%    |
| W²cLro        | Q(4,4)      | 0.125      | 12.3      | 0.095-0.156   | CV=35.4%    | 47.20%    |
| OTAD≤1        | ≥(1,1)      | 0.0346     | 9.01      | 0.0285-0.0407 | CV=18.6%    | 28.7%     |
| TAD>1         | E(2,2)      | 0.0487     | 1.31      | 0.0474-0.0499 | CV=22.1%    | 17.9 %    |

<div style=\"page-break-after: always\"></div>

Table 3 Estimated parameters for the final model 500

TheNONMEMcontrol streamandoutput filescanbefoundinAppendix2.

<!-- image -->

PE:ParameterEstimate;SE:StandardError;RSE:RelativeStandardError,RSE=100-SE/PE; 95% Cl: 95% confidence interval; CV: coefficient of variation.

Source:500ParEst.csv(DiagnosticPlots.R)

The final Model 500 was evaluated by diagnostic plots including Visual Predictive Checks (VPCs) and NPDE.  Figure  1  and  Figure  2  show  VPCs  for  Cycle  1  of  OCARINA  II  data  stratified  for  route  of administration.

<div style=\"page-break-after: always\"></div>

Figure 1 Prediction corrected VPC for IV and SC administration

<!-- image -->

The lines show the median （red),and the 5th and 95th percentiles（blue)of the observed concentrations（circles).The shaded regions show the90% confidence intervalson these quantitiesobtained by simulations.Theleft panels usenormal scale and therightpanelsusesemi-logscale.

<div style=\"page-break-after: always\"></div>

Figure 2 Visual predictive check, model 500

Thelinesshowmedian（red),andthe5thand95thpercentiles（blue)oftheobserved concentrations.Theshadedregionsshowthe90%confidenceintervalsonthesequantities obtained by simulations. The simulated values were computed from 1000 trials simulated using dosing,sampling,andthecovariatevaluesoftheanalysisdataset.

<!-- image -->

## Absorption

The  applied  sampling  frequency  enables  exposure  metrics  to  be  calculated  by  NCA.  Table  4  give  a summary of exposure for the first two weeks and for Cycle 1 based on NCA of observations.

Source:5ooPredCheck s\\_Conc\\_05\\_95.png

<div style=\"page-break-after: always\"></div>

Table 4 Summary statistics of Ocrelizumab PK parameters following IV and SC administration

|                | (ug/mL)   | AUCw1-12 (ug/mL*day)   | AUCw1-24 (ug/mL*day)   | Ctouah (ug/mL)   |
|----------------|-----------|------------------------|------------------------|------------------|
| IV Formulation |           |                        |                        |                  |
| N              | 115       | 111                    | 107                    | 62               |
| Mean           | 149       | 3250                   | 3430                   | 0.595            |
| SD             | 37.8      | 923                    | 1040                   | 0.529            |
| CV%            | 25.4      | 28.4                   | 30.3                   | 88.9             |
| Min            | 68.5      | 1530                   | 1650                   | 0.00             |
| Median         | 145       | 3020                   | 3100                   | 0.48             |
| Max            | 236       | 5490                   | 5840                   | 2.53             |
| GeometricMean  | 144       | 3120                   | 3280                   |                  |
| Geometric Cv%  | 26.4      | 29.1                   | 30.5                   |                  |
| SC Formulation |           |                        |                        |                  |
| N              | 117       | 117                    | 117                    | 59               |
| Mean           | 147       | 3600                   | 3830                   | 0.771            |
| SD             | 48.4      | 1010                   | 1130                   | 0.534            |
| CV%            | 32.9      | 28.2                   | 29.4                   | 69.2             |
| Min            | 39.6      | 1130                   | 1160                   | 0.00             |
| Median         | 145       | 3630                   | 3830                   | 0.67             |
| Max            | 326       | 6080                   | 6730                   | 2.29             |
| Geometric Mean | 138       | 3440                   | 3650                   |                  |
| GeometricCV%   | 38.3      | 32.8                   | 34.3                   |                  |

IV=intravenous,PK=pharmacokinetic,SC=subcutaneous,SD=standard deviation

The PK data for non-inferiority analysis was derived by the population PK method. Exposure metrics were predicted  for  Cycle  1  of  OCARINA  II  by  Model  500  using  individual  Bayesian  post-hoc  parameter estimates.  The  model  diagnostics  indicated  large  eta-shrinkage  on  most  disposition  parameters  and bioavailability. The bioavailability was estimated to 81.4%.

Following 920 mg SC ocrelizumab, the predicted mean Cmax was 132 µg/mL, tmax was reached after approximately 4 days (range 2-13 days) and the predicted AUCtau was 3730 µg/mL×day at Cycle 1 (Table 5).

Table 5 Summary of predicted exposure measures, model 500 (actual dosing history)

| Exposure                | Am   |   N | mean           | sd             | median         | min            | max            | Q25            | Q75            |
|-------------------------|------|-----|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Week1-12AUC (μg/mL:day) | SC   | 116 | 3500           | 914            | 3500           | 1180           | 5940           | 2910           | 4170           |
| Week1-12AUC (μg/mL:day) | IV   | 116 | 2750           | 796            | 2570           | 1390           | 4690           | 2120           | 3450           |
| Cycle 1 AUC (μg/mL day) | SC   | 116 | 3730           | 1030           | 3720           | 1200           | 6590           | 2990           | 4470           |
| Cycle 1 AUC (μg/mL day) | IV   | 116 | 2970           | 921            | 2730           | 1490           | 5340           | 2240           | 3720           |
| Cycle 1 Cmax (μg/mL)    | SC   | 116 | 132            | 31.9           | 133            | 35.6           | 207            | 113            | 157            |
| Cycle 1 Cmax (μg/mL)    | IV   | 116 | 137            | 29.5           | 135            | 67.3           | 219            | 115            | 155            |
| Cycle 1 Tmax (day)      | SC   | 116 | 3.83           | 1.5            | 3.75           | 1.75           | 13.2           | 3.00           | 4.00           |
| Cycle 1 Tmax (day)      | IV   | 116 | Endof infusion | Endof infusion | Endof infusion | Endof infusion | Endof infusion | Endof infusion | Endof infusion |
| Cycle 1 Ctrough (μg/mL) | SC   | 116 | 0.626          | 0.492          | 0.503          | 0.0112         | 2.26           | 0.269          | 0.926          |
| Cycle 1 Ctrough (μg/mL) | IV   | 116 | 0.575          | 0.504          | 0.451          | 0.0319         | 2.41           | 0.204          | 0.819          |

Source:500grid\\_Table7\\_with\\_Tmax.csv(ComputeExposure\\_with\\_Tmax.R)

Data  from  4  patients,  two  of  each  subgroup,  with  major  protocol  violations  or  incomplete  dose administration were excluded.

<div style=\"page-break-after: always\"></div>

Figure 3 Box plots of predicted exposure by route, model 500

Theboxplotsofindividualexposureestimatesareplottedbyrouteof administration.

<!-- image -->

Figure 3 shows a comparable Cmax in Cycle 1 which is due to the split IV dose. The proposed 920 mg SC dose results in a higher exposure expressed as AUC compared to the approved IV dose.

AUC across Week 1 to Week 12 is the primary parameter for non-inferiority assessment and the time expected for complete absorption. AUCw1-12 constitute most (about 93%) of the AUC to Week 24 (tau). Non -inferiority  was  established  based on the lower end of the two-sided 90% CI of the GMR of the AUCw1-12 which was &gt; 0.8.

The GMR was calculated from a linear regression model of log model estimated AUCW1-12 for IV and SC,  adjusted  for  stratification  factors:  baseline  body  weight  [&lt;70kg  vs  ≥70kg],  disease  subtype [relapsing  forms  of  multiple  sclerosis  {RMS}  vs  primary  progressive  multiple  sclerosis{PPMS}]  and region [United States vs Rest of the World] (Table 6).

<div style=\"page-break-after: always\"></div>

## Table 6 OCARINA II: non-inferiority analysis AUC (week 1-12)

```
in Comparison with OcR Iv,PK-evaluable Set
```

```
Protocol:CN42097（C1inical Cut-off Date:10MAR2023)
```

```
Geometric 908CI 908CI PK Parameter Comparison n Mean Ratio[l] Lower Bound Upper Bound AUC over the first 12 weeks OCRSCV80CRIV116V8116 1.2851 1.2258 1.3473 (day*mcg/mL) OCRIVN=116 and0CRSCN=116 n represents the number of patients in the analysis model. Estimates are from a linear regressionmodel:log(PK parameter)-Treatment+baseline body weight（<70kg vs>=70kg)+disease subtype（RMS vs PPMS)+region（United States vsRestof the world）. [l]Geometric Mean Ratio of test treatment group （SC arm)to reference treatment group （Iv arm). AUC-area under the concentration-time curve CI-confidence interval t_pk_est_AUCW12_PK_PKS.out 06JUL202322:16 Page1of1
```

## Distribution

N/A

## Elimination

N/A

## Dose proportionality and time dependencies

N/A

## Special populations

A predominate part of the OCARINA II study population were White (89.8%); 84.3% of subjects had a CRCL &gt;90 ml/min, while 15.7% had a CRCL of 50-90 ml/min; 62.1% of subjects were female and 37.9% were male. There was no clinically relevant influence of sex on any of the random effects of Model 500. Effects of body weight was included on ocrelizumab disposition parameters. Body weight ranged from 42-194 kg. An effect of age on ka was included in the Pop PK Model 500, with a decline in absorption rate with age. Age ranged from 17-65 years. The SC dose was not studied in subjects &gt;65 years of age.

## Pharmacokinetic interaction studies

N/A

## Pharmacokinetics using human biomaterials

N/A

## 2.6.2.2 Pharmacodynamics

## Mechanism of action

Ocrelizumab is a recombinant humanized monoclonal antibody directed against CD20-expressing B-cells. The  precise  mechanism  by  which  ocrelizumab  exerts  its  therapeutic  effects  in  multiple  sclerosis  is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B  lymphocytes.  Following  cell  surface  binding  to  B  lymphocytes,  ocrelizumab  results  in  antibodydependent cellular cytolysis and complement-mediated lysis of the B-cells.

## Primary and Secondary pharmacology

<div style=\"page-break-after: always\"></div>

Because ocrelizumab binds to CD20, its presence in blood interferes with the B-cell count based on the surface antigen CD20 itself. Thus, another cell-surface marker that largely mirrors CD20 expression during  B-cell  development  is  used:  CD19.  B-cell  counts  described  in  this  document  refer  to  flow cytometric counts of CD19 + cells in blood. An additional analysis was performed to evaluate the effect of  ocrelizumab  SC  and  IV  on  B-cell  subsets  (IgD  transitional,  memory,  naive,  double  negative,  and plasma cells).

Treatment with ocrelizumab SC and ocrelizumab IV led to a rapid and sustained depletion of CD19 + B cells in blood (Figure 4), as well as B-cell subsets.

Figure 4 Figure of proportion of patients with CD19 abs results below or equal to 5 cells/µL over time by visit during controlled period (controlled period analysis), safety-evaluable - all set

ControlledPeriod(ControlledPeriodAnalysis),Safety-evaluable-AllSet Protocol:CN42097(ClinicalCut-offDate:10MAR2023)

<!-- image -->

Abs-Absolute Value.

Baseline: the last assessment before the first expogure.

m

g\\_lb\\_propn\\_cdT9.sas

g\\_1b\\_propn\\_cdT9CP\\_SEALL.pdf

31JUL2023-10:08

## Immunogenicity

OCARINA I: Post-baseline, the incidence of treatment-emergent ADAs to ocrelizumab was 0 of 88 postbaseline evaluable patients (0%) in Group A, and 0 of 46 post-baseline evaluable patients (0%) in Group B.

Post-baseline, the incidence of treatment-emergent anti-rHuPH20 antibodies was 1 of 87 post-baseline evaluable patients (1.1%) in Group A.

Post-baseline, the incidence of treatment-emergent anti-rHuPH20 antibodies was 2 of 45 post-baseline evaluable patients (4.4%) in Group B.

## OCARINA II:

No treatment-emergent ADAs to ocrelizumab or rHuPH20 were reported in either treatment arm based on, respectively, serum and plasma samples collected.

<div style=\"page-break-after: always\"></div>

## 2.6.3 Discussion on clinical pharmacology

Validated methods were used for quantification of ocrelizumab and for immunogenicity testing of ADAs against ocrelizumab or the SC vehicle, rHuPH20. The first post-dose samples for test of ADAs against ocrelizumab  were taken  4-,  12-  and  24-weeks  post-dose  in  OCARINA  I  and  24  weeks  post-dose  in OCARINA II. The late samples will allow for detection of persistent ADAs, however, there is potential to miss detection of immunogenicity at early onset due to limited drug tolerance of the ADA assay. The SmPC mentions that transient ADAs may not be detected between baseline and every 6-month posttreatment which has been accepted.

A Pop PK model for ocrelizumab IV and SC was used to describe the PK of OCARINA II data. The modelling and simulation were conducted using NONMEM and R. The final model built from a previous IV model was updated with data from OCARINA I across two data cut-offs in a sequential manner. Data from OCARINA II was fitted with re-estimation of absorption parameters and Q. The model diagnostics did not indicate any major misspecifications and could describe the observed data in Cycle 1. The bioavailability was estimated to 81.4%.

OCARINA II was described as a non-inferiority trial to compare 920 mg SC ocrelizumab to 600 mg (=2x300 mg) IV ocrelizumab. Data from 4 patients were excluded. One IV dosed subjects with extreme high body weight of 194 kg, did not impact the outcome of the non-inferiority test. Exposure metrics were predicted for Cycle 1 of OCARINA II. The applied sampling frequency enables exposure metrics to be calculated by NCA. AUCs derived by non-compartment analysis and observed Cmax and Ctrough values for Cycle 1 were provided upon request for comparison. Mean observed exposures were generally higher that the model predicted exposure measures. The NCA data confirms the SC dose results in a higher  exposure  based  on  AUC  than  the  approved  IV  treatment.  The  mean  ratio  of  the  analysis  of OCARINA II model predicted AUCs W1-12, is 1.2851 with a 90%CI of 1.2258 - 1.3473. The GMR is &gt;0.8 and thus fulfilling the one-sided non-inferiority criteria outlined in the SAP. The results show a nominally significant difference between the two treatments and that ocrelizumab SC 920 mg exposure expressed as AUC is higher than the approved ocrelizumab IV 600 mg.

The pharmacodynamic objective in the studies was to evaluate the effect of SC ocrelizumab compared with IV ocrelizumab on the PD marker for the mechanism of action of ocrelizumab (B-cell depletion).

Ocrelizumab is a recombinant humanized monoclonal antibody directed against CD20-expressing B-cells. Following  cell  surface  binding  to  B  lymphocytes,  ocrelizumab  results  in  antibody-dependent  cellular cytolysis and complement-mediated lysis of the B-cells. Once absorbed to the systemic circulation, the mechanism of action is the same as with the approved IV administration.

Ocrelizumab selectively targets and depletes CD20-expressing B-cells. B-cell depletion is therefore the expected PD action of ocrelizumab; hence B-cell count in peripheral blood was used as the PD marker. The PD marker is considered adequate. B cell depletion was similar after administration of 920 mg ocrelizumab SC and 2 x 300 mg IV.

Overall, no treatment-emergent ADAs to ocrelizumab were observed. However, immunogenicity status following  SC  ocrelizumab  is  not  considered  adequately  described,  due  to  poor  assay  sensitivity  and sparse sampling.

A total of 3 out of 132 patients (2.3%) had treatment-emergent anti-rHuPH20 antibodies in OCARINA I and no treatment-emergent anti-rHuPH20 antibodies was observed in OCARINA II. No safety concerns have been observed in patients with anti-rHuPH20 antibodies.

The Applicant provided an exposure-safety analysis considering the SC and IV data in different exposure ranges as requested. No meaningful difference was seen over the different exposure quartiles for SAEs, serious infections, infections, IRs and IRRs. The exposure-safety analysis confirms that the increased exposure that is seen for the SC formulation does not translate into a worse safety profile.

## 2.6.4 Conclusions on clinical pharmacology

Overall the clinical pharmacology is considered adequately described.

<div style=\"page-break-after: always\"></div>

## 2.6.5 Clinical efficacy

Ocrelizumab SC is currently being investigated in two clinical trials: the pivotal Phase III Study CN42097 (hereinafter referred to as OCARINA II; Table 7) and the supportive Phase Ib Study CN41144 (hereinafter referred to as OCARINA I).

In  this  section,  the  supportive  magnetic  resonance  imaging  (MRI)  data  (secondary  and  exploratory radiological endpoints) and annualized relapse rate (ARR) data (exploratory clinical endpoint) collected in OCARINA II from the start of the study until the clinical cut off date (CCOD) are presented. There were no efficacy endpoints in OCARINA I.

Table 7 Summary of studies contributing to efficacy evaluation

<!-- image -->

| Study Number, Phase                           | Study Design                                             |                                                | Population No.of Patients                                                                | Dose, Route, and Regimen                                                                                                                                                                                                                                           | Data Clinical Cutoff Date       |
|-----------------------------------------------|----------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| CN42097 (OCARINA II), inferiority, Phase IIlI | Non- randomized, open-label, parallel group, multicenter | Adult patients (18-65 years) with RMS or PPMSa | 236 patients randomized in 1:1 ratio to receive either ocrelizumabSC or IV as first dose | ControlledPeriod: Either 920 mg ocrelizumab administered as single SC injection, or 600 mg ocrelizumab administered as two 300 mg IV infusions SC OcrelizumabTreatment Period: All patients: 920 mg ocrelizumabadministeredas single SC injection, every 24 weeks. | Primary analysis: 10 March 2023 |

IV = intravenous; PPMS =primary progressive multiple sclerosis; RMS =relapsing multiple sclerosis;

SC=subcutaneous.

- a Patients who had previously received anti-CD20s (including ocrelizumab) were excluded from study if the last treatment was less than 2 years before screening, and/or if B-cell count was below lower limit of normal.

## 2.6.5.1 Dose response studies

N/A

## 2.6.5.2 Main study

CN42097 (OCARINA II) is a Phase III non-inferiority, randomized, open-label, parallel group, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, radiological, and clinical  effects  of  SC  administration  of  ocrelizumab  compared  with  the  IV  infusion  of  ocrelizumab  in patients with either relapsing MS (RMS) or primary progressive MS (PPMS).

## Methods

The study consists of the following study phases (Figure 5):

- Screening
- Treatment (controlled period and SC ocrelizumab treatment period)
- Safety follow-up (SFU)

<div style=\"page-break-after: always\"></div>

Eligible patients were randomly assigned in a 1:1 ratio to one of two treatment arms: ocrelizumab SC arm (hereinafter referred to as OCR SC) or ocrelizumab IV arm (hereinafter referred to as OCR IV). The treatment phase of the study consisted of three ocrelizumab doses as follows:

- During the controlled period (i.e., until, but not including, the time of the second dose of ocrelizumab [Week 24 visit]):

- For patients assigned to OCR SC: Dose 1 of ocrelizumab administered as 920 mg single SC injection on Week 1/Day 1

- For patients assigned to OCR IV: Dose 1 of ocrelizumab administered as two 300 mg IV infusions separated by 2 weeks, i.e., on Week 1/Day 1 and Week 2/Day 14.

- During the SC ocrelizumab treatment period (i.e., Week 24 and Week 48 doses of ocrelizumab SC), patients in the OCR SC arm continued to receive 920 mg SC at Week 24 and Week 48, and patients in the OCR IV arm switched to 920 mg SC at Week 24 and continued to receive 920 mg SC at Week 48.
- For all patients:
- Dose 2 of ocrelizumab administered as 920 mg single SC injection at Week 24
- Dose 3 of ocrelizumab administered as 920 mg single SC injection at Week 48

Home administration of OCR SC is also permitted for eligible patients at Week 48, as described in the protocol.

<div style=\"page-break-after: always\"></div>

Figure 5 Study design

<!-- image -->

ADA=anti-drug antibody;EDSS=expandeddisability statusscale;IV=intravenous; MRI=MagneticResonanceImage;OCR=ocrelizumab;PK=pharmacokinetics;PPMS=primary progressivemultiplesclerosis;RMS=relapsing multiple sclerosis;SC=subcutaneous

## Study Participants

Patients with RMS or PPMS were enrolled in Study CN42097.

The key inclusion criteria were as follows:

- Age 18-65 years
- Diagnosis of PPMS or relapsing forms of MS (RMS) according to the revised McDonald 2017 criteria (Thompson et al. 2018)
- EDSS score, 0-6.5, inclusive, at screening
- Neurological stability for ≥ 30 days prior to both screening and baseline
- Disease duration from onset of MS symptoms of less than 15 years for patients with expanded disability status scale (EDSS) score &lt; 2.0 at screening

The key exclusion criteria were as follows:

- Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV antimicrobials within 8 weeks prior to and during screening or treatment with oral antimicrobials within 2 weeks prior to and during screening
- History of confirmed or suspected progressive multifocal leukoencephalopathy

<div style=\"page-break-after: always\"></div>

- Immunocompromised state
- Receipt of a live-attenuated vaccine within 6 weeks prior to randomization (Influenza vaccination was permitted if the inactivated vaccine formulation was administered)
- Inability to complete an MRI or contraindication to gadolinium administration
- Contraindications to mandatory premedications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders that could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids (e.g., mineralocorticoids and glucocorticoids) or immunosuppressants during the course of the study
- Systemic corticosteroid therapy within 4 weeks prior to screening

## Treatments

Eligible patients were randomized once during the study to one of the two treatment arms: OCR SC or OCR IV (Table 8). Subsequently, all patients will receive two doses of ocrelizumab SC.

The ready-to-use SC ocrelizumab co-formulated with rHuPH20 does not require mixing with rHuPH20. Ocrelizumab SC will be provided as a sterile, single-dose liquid at a concentration of 40 mg/mL and contains no preservatives. The ocrelizumab in the ocrelizumab SC formulation is co-formulated with rHuPH20 at a concentration of 1000 U/mL.

During  the  controlled  period,  patients  assigned  to  OCR  IV  received  600  mg  of  ocrelizumab  IV administered as two 300-mg IV infusions on Study Week 1 and Week 2. Ocrelizumab IV was provided as a sterile, single-dose liquid at a concentration of 30 mg/mL and contains no preservatives.

<div style=\"page-break-after: always\"></div>

Table 8 Ocrelizumab dosing regimen

<!-- image -->

| TreatmentPhase                 | Arm       | Arm                                                                          | Arm       | Arm                                   |
|--------------------------------|-----------|------------------------------------------------------------------------------|-----------|---------------------------------------|
| ControlledPeriod               | OCR IV    | OCR IV                                                                       | ocr sc    | ocr sc                                |
|                                | Dose 1    | 600 mg IV dose (IV Infusion 1 [Study Week 1] + IV Infusion 2 [Study Week 2]) | Dose 1    | 920 mg SC injection 1 (Study Week 1)  |
| SC Ocrelizumab TreatmentPeriod | oCr IV/SC | oCr IV/SC                                                                    | ocr sc/sc | ocr sc/sc                             |
| SC Ocrelizumab TreatmentPeriod | Dose 2    | 920 mg SC injection 1 (Study Week 24)                                        | Dose 2    | 920 mg SC injection 2 (Study Week 24) |
| SC Ocrelizumab TreatmentPeriod | Dose 3    | 920 mg SC injection 2 (Study Week 48)                                        | Dose 3    | 920 mg SC injection 3 (Study Week 48) |

IV=intravenous; SC=subcutaneous; OCR IV=ocrelizumab intravenous; OCR IV/SC=patients who were randomized to OCR IV in the controlled period and received ocrelizumab SC as subsequent doses in the SC ocrelizumab treatment period; OCR SC=ocrelizumab subcutaneous; OCR SC/SC=patients who were randomized to OCR SC in the controlled period and received ocrelizumab SC as subsequent doses in the SC ocrelizumab treatment period. Notes:

There should be a minimum of 22 weeks between all SC doses.

There should be a minimum of 20 weeks between the administration of the final ocrelizumab IV infusion (at Week 2) and the first ocrelizumab SC dose (at Week 24).

To  minimize  the  risk  of  injection  reactions  (IRs),  patients  treated  with  ocrelizumab  SC  received mandatory premedications of 20 mg dexamethasone and 5 mg desloratadine given orally 1-2 hours before  each  ocrelizumab  SC  administration.  After  the  CCOD,  the  protocol  was  amended  so  that premedication could be given shortly before SC injection.

To  minimize  the  risk  of  infusion-related  reactions  (IRRs),  all  patients  who  received  ocrelizumab  IV treatment received mandatory prophylactic treatment with 100 mg methylprednisolone administered by slow IV infusion to be completed approximately 30 minutes before the start of each ocrelizumab infusion.

In the rare case when the use of dexamethasone or desloratadine was contraindicated for the patient or was not available, an equivalent dose of an alternative steroid or antihistaminic could have been used as premedication prior to the injection. Corticosteroids and antihistamine medications are considered as equivalent in terms of anti-inflammatory potency to the premedication given to patients treated with ocrelizumab IV. Oral analgesics (such as acetaminophen) were permitted.

<div style=\"page-break-after: always\"></div>

Table 9 Premedications used prior to IV infusion or SC injection

| Prior toEach IVAdministration of Ocrelizumab                                                                                                                                                                                                                                                                      | Prior to Each SC Administration of Ocrelizumab                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mandatory 100 mg methylprednisolone, given by slow IV infusion, 30 minutes before start of infusion a Mandatory 50 mg diphenhydramine, given orally or IV infusion, 30-60 minutes before start of infusion a Oral analgesic as needed and as tolerated (if using acetaminophen, not to exceed 4 g/day, per label) | Mandatory 20 mg dexamethasone, given orally, 1-2 hours before administration a Mandatory 5 mg desloratadine, given orally, 1-2 hours before administration a Recommended oral analgesic as needed and as tolerated (if using acetaminophen, not to exceed 4 g/day, per label) |

IV=intravenous; SC =subcutaneous.

- After the CCOD, the protocol was amended so that premedication could be given shortly before SC injection (Section 3.1.2).

Hypotension, as a symptom of IRR, may occur during IV study drug infusions. Therefore, withholding antihypertensive treatments should be considered for 12 hours prior to and throughout each study drug infusion.

## Objectives

This study evaluates the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of SC administration of ocrelizumab compared with the IV infusion in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

Table 10 Overview of efficacy assessments

| Endpoint                                       | Definition                                                                                                                                        | AssessmentTimePoints                                                                                                                                                                                                   |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SecondaryRadiological Endpoints                | SecondaryRadiological Endpoints                                                                                                                   |                                                                                                                                                                                                                        |
| Total number of T1Gd+lesions at Week8andWeek24 | As detected by brain MRI scans analyzed by a blindedcentralizedreadingcenter                                                                      | BrainMRIat screening,baseline,Weeks8,12,24,48,unscheduled,and ET visits andseparatelyforeachMSsubtype(RMSorPPMS)                                                                                                       |
| Total number of new atWeek12 and Week 24       | AsdetectedbybrainMRIscans analyzedbya orenlargingT2lesionsblindedcentralizedreadingcenter                                                         | BrainMRlatscreening,baseline,Weeks8,12,24,48,unscheduled,andET visits NeworenlargingT2lesionsanalysisperformedforWeek12andWeek24, relativetothepreviousscan,forallpatients andseparatelyforeachMSsubtype (RMS or PPMS) |
| ExploratoryRadiological Endpoints              | ExploratoryRadiological Endpoints                                                                                                                 |                                                                                                                                                                                                                        |
| Totalnumberofnew atWeek8                       | As detected bybrainMRl scans analyzed by a orenlargingT2lesionsblindedcentralizedreadingcenter                                                    | visits NeworenlargingT2lesions analysisperformedforWeek8(relativetothe PPMS),persecondaryradiologicalmainestimand                                                                                                      |
| Exploratory Clinical Endpoints                 | Exploratory Clinical Endpoints                                                                                                                    |                                                                                                                                                                                                                        |
| Annualizedrelapse rate (in RMS patients)       | Definedasnumberofrelapsesperpatient-year Theprotocol definitionof arelapseisdescribed in CSR 1121154,Appendix 16.1.1,Protocol v2.0, Section 4.5.6 | Neurologicexaminationatscreening,baseline,Weeks12,24,48,unscheduled, ET, and SFU visits                                                                                                                                |

ET=early termination; MS multiple sclerosis; IV=intravenous; PPMS =primary progressive multiple sclerosis; RMS =relapsing multiple sclerosis; SFU=safety follow-up.

## Sample size, Randomisation and blinding (masking)

236 patients. 1:1 randomisation.

This was an open-label study.

## Statistical methods

Hypothesis  testing  was  not  performed  for  efficacy.  All  secondary  and  exploratory  analyses  were performed using descriptive statistics.

## Results

## Participant flow

A total of 236 patients were enrolled in the study: 118 were randomized to the OCR SC arm (patients only treated with ocrelizumab SC) and 118 were randomized to the OCR IV arm (patients first treated with ocrelizumab IV and then SC).

As of the CCOD, 236 patients had entered the controlled period (118 in OCR SC and 118 in OCR IV) and all received at least one dose of ocrelizumab. Of these 236 patients, 126 patients had completed the 24week controlled period and entered the SC ocrelizumab treatment period (63 in OCR SC and 63 in OCR IV). Over the treatment phase (controlled period + SC ocrelizumab treatment period), 5 patients had discontinued treatment and were considered to have entered the SFU at the time of the last exposure. No patients had completed the study yet at the time of the CCOD.

Note: 2 patients (1 in OCR SC and 1 in OCR IV) withdrew consent and did not return for the Week 24 SFU visit.

Overall, the treatment withdrawal rate was low and similar between the OCR SC and OCR IV arms.

Of the 236 patients who had entered the controlled period, 2 patients in OCR IV discontinued treatment and entered the SFU, 1 due to pregnancy and 1 due to withdrawal by subject.

<div style=\"page-break-after: always\"></div>

Of the 126 patients who had entered the SC ocrelizumab treatment period, 3 patients discontinued treatment and entered the SFU, 2 in OCR SC due to withdrawal by subject and lack of efficacy, and 1 in OCR IV due to withdrawal by subject.

Of the 5 patients who had entered the SFU, 1 in OCR IV discontinued from the study due to withdrawal by subject.

## Recruitment

First Patient Enrolled: 3 May 2022 Data cut-off: 10 March 2023

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 11 Baseline MS disease history, safety-evaluable - all set

MS Disease History, Safety-evaluable - All Set Protocol: CN42097 (Clinical Cut-off Date: 10MAR2023)

|                                                       | OCR IV (N=118)   | OCR SC (N=118)   | All Patients (N=236)   |
|-------------------------------------------------------|------------------|------------------|------------------------|
| Current phenotype of MS                               |                  |                  |                        |
| n                                                     | 118              | 118              | 236                    |
| RRMS                                                  | 105 (89.0%)      | 105 (89.0%)      | 210 (89.0%)            |
| PPMS                                                  | 12 (10.2%)       | 11 (9.3%)        | 23 (9.7%)              |
| aSPMS                                                 | 1 (0.8%)         | 2 (1.7%)         | 3(1.3%)                |
| Duration since Ms Symptoms Onset (years)              |                  |                  |                        |
| n                                                     | 117              | 117              | 234                    |
| Mean (SD)                                             | 6.84 (7.09)      | 7.67 (8.30)      | 7.26 (7.72)            |
| Min- Max                                              | 0.2 - 38.7       | 0.3 -41.8        | 0.2 - 41.8             |
| Median                                                | 4.38             | 4.20             | 4.36                   |
| Duration since Ms Symptoms                            |                  |                  |                        |
| Onset Category n                                      | 117              | 117              | 234                    |
| <=3 Years                                             | 47 (39.8%)       | 52 (44.1%)       | 99 (41.9%)             |
| >3to<=5 Years                                         | 16 (13.6%)       | 10 (8.5%)        | 26 (11.0%)             |
| >5 to <=10 Years                                      | 24 (20.3%)       | 20 (16.9%)       | 44 (18.6%)             |
| >10 Years                                             | 30 (25.4%)       | 35 (29.7%)       | 65 (27.5%)             |
| Duration since Ms Diagmosis                           |                  |                  |                        |
| (years) n                                             | 118              | 118              | 236                    |
| Mean (SD)                                             | 4.78 (5.81)      | 5.70 (6.81)      | 5.24 (6.34)            |
| XHW - UTN                                             | 0.1 - 28.7       | 0.1 -41.8        | 0.1 - 41.8             |
| Median                                                | 2.35             | 3.10             | 2.73                   |
| Duration since Last Reported MS Relapse (years)       |                  |                  |                        |
| n                                                     | 89               | 85               | 174                    |
| Mean (SD)                                             | 1.81 (2.41)      | 2.26 (3.04)      | 2.03 (2.74)            |
| XW - UT                                               | 0.1 - 10.6       | 0.1 - 11.2       | 0.1 - 11.2             |
| Median                                                | 0.59             | 0.59             | 0.59                   |
| Prior Treatment with Any Ms Disease Modifying Therapy |                  |                  |                        |
| Prior to Baseline n                                   | 118              | 118              | 236                    |
| Yes                                                   | 59( (50.0%)      | 65 (55.1%)       | 124 (52.5%)            |
| No                                                    | 59 (50.0%)       | 53 (44.9%)       | 112 (47.5%)            |
| Prior Treatment with Any Steroids as Ms Therapy prior |                  |                  |                        |
| to baseline n                                         | 118              | 118              | 236                    |
| Yes                                                   | 117 (99.2%)      | 118 (100%)       | 235 (99.6%)            |
| No                                                    | 1 (0.8%)         | 0                | 1 (0.4%)               |

While the baseline counts for Gd-enhancing T1 lesions are influenced by a larger variability in OCR IV, in general, MRI characteristics were balanced across the arms. Of the 104 patients in OCR SC and 103 patients in OCR IV who had MRI assessments at baseline (OCR SC and OCR IV, respectively):

- The mean (SD) number of Gd-enhancing T1 lesions was: 0.54 (1.66) and 0.98 (2.52).
- The majority patients had 0 Gd-enhancing T1 lesions: 69.5% and 66.1%.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 12 Analysis sets, randomised population

Analysis Populations, Randomized Population Protocol: CN42097 (Clinical Cut-off Date: 10MAR2023)

|                                    |             | OCR SC (N=118)   | OCR SC (N=118)   |
|------------------------------------|-------------|------------------|------------------|
| PK-evaluable                       |             |                  |                  |
| Included                           | 116 (98.3%) | 116 (98.3%)      | 232 (98.3%)      |
| Excluded                           | 2 (1.7%)    | 2 (1.7%)         | 4 (1.7%)         |
| Safety-evaluable - all Included    | 118(100%)   | 118(100%)        | ）236(100%)       |
| Safety-evaluable - SC Included     | 63  (53.4%) | 118(100%)        | 181 (76.7%)      |
| Excluded                           | 55 (46.6%)  | 0                | 55 (23.3%)       |
| Efficacy-evaluable-MRI Included    | 118 (100%)  | 118 (100%)       | 236(100%)        |
| Full Analysis Set                  | 118(100%)   | 118(100%)        | 236 (100%)       |
| Immunogenicity-evaluable           |             |                  |                  |
| Included                           | 116 (98.3%) | 118 (100%)       | 234 (99.2%)      |
| Excluded                           | 2 (1.7%)    | 0                | 2 2(0.8%)        |
| Other endpoints-evaluable Included | 118 (100%)  | 118(100%)        | 236(100%)        |

All percentages are based on N.

## Outcomes and estimation

Secondary Efficacy Endpoints

## Secondary Radiological Endpoints

The number of evaluable patients at each time point was (OCR SC and OCR IV, respectively):

- Week 8 (T1Gd+ lesions): n=112 and n=112
- Week 12 (T2 lesions): n=116 and n=116
- Week 24 (T1Gd+ lesions and T2 lesions): n=61 and n=65

## T1Gd+ lesions (Table 13)

Over the treatment phase and SFU, no major differences in number of T1Gd+ lesions and lesion rates were observed between the two arms at Weeks 8 and 24, in both the RMS and PPMS populations. The numbers of T1Gd+ lesions and lesion rates were low in both arms and populations.

Treatment Phase or SFU - At Week 8: Of the patients who had a readable MRI assessment at the Week 8 visit, 17 and 24 T1Gd+ lesions were detected in OCR SC and OCR IV, respectively, all in the RMS population.

Treatment Phase or SFU - At Week 24: Of the patients who had a readable MRI assessment at the Week 24 visit, 2 T1Gd+ lesions were detected in OCR SC, all in the RMS population.

<div style=\"page-break-after: always\"></div>

Table 13 Summary of number of T1Gd+ lesions by visit during treatment phase or SFU, efficacyevaluable - MRI set

Summaryof Number of TlGd+Lesions byVisit during Treatment Phase or SFU for RMS and PPMS Population, Efficacy-evaluable - MRI Set Protocol: CN42097 (Clinical Cut-off Date: 10MAR2023)

<!-- image -->

n is the number of patients with a readable MRI assessment at the visit.

## T2 lesions (Table 14, Table 15 and Table 16)

Over the treatment phase and SFU, no major differences in number of new or enlarging T2 lesions (with respect to the previous scheduled available visit) and lesion rates were observed between the two arms at Weeks 12 and 24, in both the RMS and PPMS populations. The numbers of new or enlarging T2 lesions and lesion rates were low in both arms and populations.

Note: One patient in OCR IV had an MS relapse 13 days after their first ocrelizumab IV dose. The relapse was reported at an unscheduled visit and lasted 7 days, with an initial NCI CTCAE Grade of 2 and a most extreme  Grade  of  3.  The  patient  was  administered  methylprednisolone  IV  1  g/day  for  4  days  as recommended therapy for treatment of relapses per Protocol, Section 4.4.2. At the Week 8 visit, 68 new or enlarging T2 lesions were observed on the patient's MRI scan, as well as 9 T1Gd+ lesions. At the Week 12 visit, the number of new or enlarging T2 lesions observed decreased to 3. This value is the main reason for the difference between mean (SD) numbers of new or enlarging T2 lesions at Week 8

<div style=\"page-break-after: always\"></div>

between OCR SC (0.77 [1.81]) and OCR IV (1.41 [6.61]). The second largest number of new or enlarging T2 lesions at Week 8 in OCR IV was 13.

Treatment Phase or SFU - At Week 12: Of the patients who had a readable MRI assessment at the Week 12 visit and at a previous scheduled MRI visit, 6 and 7 new or enlarging T2 lesions were detected in OCR SC and OCR IV, respectively, all in the RMS population.

Treatment Phase or SFU - At Week 24: Of the patients who had a readable MRI assessment at the Week 24 visit and at a previous scheduled MRI visit, 2 new or enlarging T2 lesions were detected in OCR SC, all in the RMS population.

<div style=\"page-break-after: always\"></div>

Table 14 Summary of number of new or enlarging T2 lesions by visit during treatment phase or SFU, efficacy-evaluable - MRI set

RMS and PpMS Population, Efficacy-evaluable -MRI Set Protocol:CN42097 (Clinical Cut-off Date:10MAR2023)

<!-- image -->

| visit               | OCRIV (N=118)   | OCR SC (N=118)   |
|---------------------|-----------------|------------------|
| Week 8              |                 |                  |
| Value at Visit      |                 |                  |
| n                   | 113             | 113              |
| Mean (SD)           | 1.41 (6.61)     | 0.77 (1.81)      |
| Median              | 0.00            | 0.00             |
| Min -Max            | 0.0-68.0        | 0.0 -11.0        |
| Number of Lesions   |                 |                  |
| n                   | 113             | 113              |
| 0                   | 77 (65.38)      | 78 (66.1%)       |
| 1                   | 16 (13.6%)      | 18 (15.3%)       |
| 2                   | 7 (5.9%)        | 7(5.9%)          |
| 3                   | 5(4.2%)         | 3(2.5%)          |
| >3                  | 8(6.8%)         | 7(5.9%)          |
| Week 12             |                 |                  |
| Value atvisit       |                 |                  |
| n                   | 116             | 116              |
| Mean (SD)           | 0.06_(0.36)     | 0.05 (0.26)      |
| Median              | 0.00            | 0.00             |
| X-                  | 0.0 -3.0        | 0.0 -2.0         |
| Number of Lesions   |                 |                  |
| n                   | 116             | 116              |
| 0                   | 112 (94.98)     | 111 (94.1%)      |
| 1                   | 2 (1.7%)        | 4 (3.48)         |
| 2                   | 1 0.8%)         | 1 (0.8%)         |
| 3 >3                | 1 0.8%) 0       | 0 0              |
| Week24              |                 |                  |
| Value atvisit       |                 |                  |
| n                   | 65              | 61               |
| Mean (SD)           | 0.00(0.00)      | 0.03 (0.18)      |
| Median              | 0.00            | 0.00             |
| Min -Max            | 0.0-0.0         | 0.0-1.0          |
| Number of Lesions   |                 |                  |
| n                   | 65              | 61               |
| 0                   | 65 (55.18)      | 59 (50.08)       |
| 1 2                 | 0:0             | 2 (1.78) 0       |
| 3                   |                 | 0                |
| >3                  | 0               | 0                |
| Week 48             |                 |                  |
| Value at Visit      | 0               | 0                |
| n Mean (SD)         | NE (NE)         | NE(NE)           |
| Median XW-          | NE NE - NE      | NE NE - NE       |
| 123 >3              |                 | 0 0              |
| Number of Lesions 0 | 0 0 0           | 0 0 0            |

nisthenumberofpatientswithareadableMRIassessmentat thevisitandataprevious scheduled MRIvisit scheduledavailablevisit.

t\\_mri\\_sum.sas t\\_mri\\_sum\\_NEWT2\\_EMRI.out 10AUG2023 10:52 Page 1 of 1 Editedtofitononepage.

<div style=\"page-break-after: always\"></div>

Table 15 Rate of new or enlarging T2 lesions as detected by brain MRI during the treatment phase or SFU on week 12 for RMS, PPMS, and RMS+PPMS populations, efficacy-evaluable - MRI set

|                                                        | RMS             | RMS              | PPMS           | PPMS            | RMS+PPMS      | RMS+PPMS       |
|--------------------------------------------------------|-----------------|------------------|----------------|-----------------|---------------|----------------|
|                                                        | OCRIV (N = 106) | OCR SC (N = 107) | OCRIV (N = 12) | OCR SC (N = 11) | OCRIV (N=118) | OCR SC (N=118) |
| Numberofpatientswitha readableMRlassessmentatthe visit | 104             | 105              | 12             | 11              | 116           | 116            |
| Totalnumberoflesions                                   | 7               | 6                | 0              | 0               | 7             | 6              |
| Lesion rate,unadjusted                                 | 0.07            | 0.06             | 0.00           | 0.00            | 0.06          | 0.05           |
| 95% CI                                                 | (0.03, 0.14)    | (0.02, 0.12)     | (0.00,0.31)    | (0.00,0.34)     | (0.02, 0.12)  | (0.02, 0.11)   |
| n                                                      | 104             | 105              | NA             | NA              | 116           | 116            |
| Lesion rate, adjusted                                  | 0.05            | 0.05             | NA             | NA              | 0.05          | 0.04           |
| 95% CI                                                 | (0.01, 0.25)    | (0.01, 0.20)     | NA             | NA              | (0.01, 0.23)  | (0.01, 0.18)   |

Cl=confidence interval; IV=intravenous; MRI =magnetic resonance imaging; NA=not applicable;

SC=subcutaneous;SFU=safetyfollow-up.

The timepoint is based on the visit label reported by the site.

NeworenlargingT2lesioncount measurement isperformedwithrespect to thepreviousscheduled available visit.

TheunadjustedlesionrateisthetotalnumberoflesionsdividedbythenumberofpatientswithareadableMRI assessmentatthevisitandits95%CliscalculatedusingexactmethodbasedonthePoissondistribution nrepresentsthenumberofpatientsintheanalysismodel.

Theadjustedrateandtwo-sided95%ClarefromaNegativeBinomialregressionmodel,withlog(lesioncount) as the response variable, adjusted for geographical region (United States of America vs. Rest of the world).

<div style=\"page-break-after: always\"></div>

Table 16 Rate of new or enlarging T2 lesions as detected by brain MRI during the treatment phase or SFU on week 24 for RMS, PPMS, and RMS+PPMS populations, efficacy-evaluable - MRI set

|                                                        | RMS             | RMS              | PPMS           | PPMS            | RMS + PPMS    | RMS + PPMS     |
|--------------------------------------------------------|-----------------|------------------|----------------|-----------------|---------------|----------------|
|                                                        | OCRIV (N = 106) | OCR SC (N = 107) | OCRIV (N = 12) | OCR SC (N = 11) | OCRIV (N=118) | OCR SC (N=118) |
| Numberofpatientswitha readableMRlassessmentatthe visit | 59              | 56               | 6              | 5               | 65            | 61             |
| Total numberof lesions                                 | 0               | 2                | 0              | 0               | 0             | 2              |
| Lesionrate,unadjusted                                  | 0.00            | 0.04             | 0.00           | 0.00            | 0.00          | 0.03           |
| 95% CI                                                 | (0.00,0.06)     | (0.00, 0.13)     | (0.00, 0.61)   | (0.00, 0.74)    | (0.00, 0.06)  | (0.00, 0.12)   |
| n                                                      | 56              | 56               | NA             | NA              | 65            | 61             |
| Lesion rate, adjusted                                  | 0.00            | 0.00             | NA             | NA              | 0.00          | 0.00           |
| 95% CI                                                 | (0.00,0.00)     | (0.00,0.00)      | NA             | NA              | (0.00, 0.00)  | (0.00, 0.00)   |

Cl=confidence interval; IV=intravenous; MRI=magnetic resonance imaging; NA=not applicable;

OCR=ocrelizumab;PPMS=primary progressive multiple sclerosis;RMS=relapsing multiplesclerosis;

SC=subcutaneous;SFU=safetyfollow-up.

Thetimepointisbasedonthevisit labelreportedbythesite

NeworenlargingT2lesioncountmeasurementisperformedwithrespecttothepreviousscheduledavailable visit.

Theunadjustedlesionrateisthetotalnumberof lesionsdividedbythenumberofpatientswithareadableMRI assessment at thevisitandits95%CliscalculatedusingexactmethodbasedonthePoissondistribution.

nrepresentsthenumberofpatientsintheanalysismodel.

Theadjustedrateandtwo-sided95%ClarefromaPoissonregressionmodel,withlog(lesioncount)asthe responsevariable,adjustedforgeographicalregion(UnitedStatesofAmericavs.Restof theworld).

SourceS: t\\_newet21\\_WK24\\_EMRI, t\\_newet21\\_WK24\\_RMS\\_EMRI, t\\_newet21\\_WK24\\_PPMS\\_EMRI.

## Exploratory Radiological and Clinical Endpoints

Table 17 Rate of new or enlarging T2 lesions as detected by brain MRI during the treatment phase or SFU on week 8 for RMS, PPMS and RMS+PPMS populations, efficacy-evaluable - MRI set

|                                                         | RMS            | RMS              | PPMS           | PPMS            | RMS+PPMS      | RMS+PPMS      |
|---------------------------------------------------------|----------------|------------------|----------------|-----------------|---------------|---------------|
|                                                         | OCRIV (N =106) | OCR SC (N = 107) | OCRIV (N = 12) | OCR SC (N = 11) | OCRIV (N=118) | OCRSC (N=118) |
| Numberofpatientswith a readableMRlassessmentatthe visit | 101            | 102              | 12             | 11              | 113           | 113           |
| Totalnumberoflesions                                    | 158            | 86               | 1              | 1               | 159           | 87            |
| Lesionrate,unadjusted                                   | 1.56           | 0.84             | 0.08           | 0.09            | 1.41          | 0.77          |
| 95% CI                                                  | (1.33, 1.83)   | (0.67, 1.04)     | (0.00, 0.46)   | (0.00, 0.51)    | (1.20, 1.64)  | (0.62, 0.95)  |
| n                                                       | 101            | 102              | 12             | 11              | 113           | 113           |
| Lesion rate, adjusted                                   | 1.14           | 0.63             | 0.00           | 0.00            | 1.04          | 0.58          |
| 10 %96                                                  | (0.62, 2.10)   | (0.34, 1.16)     | (0.00,0.00)    | (0.00, 0.00)    | (0.56, 1.91)  | (0.32, 1.07)  |

Cl=confidenceinterval;IV=intravenous;MRl=magneticresonanceimaging;NA=notapplicable;

OCR=ocrelizumab;PPMS=primaryprogressive multiplesclerosis;RMS=relapsing multiple sclerosis;

SC=subcutaneous;SFU=safetyfollow-up.

Thetimepoint isbasedonthevisit labelreportedbythesite.

NeworenlargingT2lesioncountmeasurementisperformedwithrespecttothepreviousscheduledavailable visit.

TheunadjustedlesionrateisthetotalnumberoflesionsdividedbythenumberofpatientswithareadableMRI

assessmentatthevisitandits95%CliscalculatedusingexactmethodbasedonthePoissondistribution.

nrepresentsthenumberofpatientsintheanalysismodel

The adjusted rate and two-sided 95%Cl are from a NegativeBinomial(RMS and RMS+PPMS) orPoisson (UnitedStatesofAmericavs.Restof theworld).

<div style=\"page-break-after: always\"></div>

Treatment Phase or SFU - At Week 8: Of the patients who had a readable MRI assessment at the Week 8 visit and at a previous scheduled MRI visit, 87 and 159 new or enlarging T2 lesions were detected in OCR SC and OCR IV, respectively, most of them in the RMS population (86 and 158, respectively).

## Exploratory Clinical Endpoints

Annualized  Relapse  Rate  in  RMS  patients:  In  the  RMS  population,  almost  no  patients  experienced relapses during the controlled period up to Week 24 (99.1% [106 patients] in OCR SC and 99.1% [105 patients] in OCR IV). One patient (0.9%) in each arm had 1 relapse, yielding an unadjusted relapse rate (per year) of 0.02 in each arm, during a total follow-up time of 43.33 patient-years (PY) in OCR SC and 42.53 PY in OCR IV.

## Summary of main efficacy results

Table 18 summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 18 Summary of efficacy for trial CN42097 (OCARINA II)

| Title: A Phase III, non - inferiority, randomized, open - label, parallel group, multicenter study to investigate the pharmacokinetics, pharmacodynamics, safety and radiological and clinical effects of subcutaneous ocrelizumab versus intravenous ocrelizumab in patients with multiple sclerosis   | Title: A Phase III, non - inferiority, randomized, open - label, parallel group, multicenter study to investigate the pharmacokinetics, pharmacodynamics, safety and radiological and clinical effects of subcutaneous ocrelizumab versus intravenous ocrelizumab in patients with multiple sclerosis                                                                                                              | Title: A Phase III, non - inferiority, randomized, open - label, parallel group, multicenter study to investigate the pharmacokinetics, pharmacodynamics, safety and radiological and clinical effects of subcutaneous ocrelizumab versus intravenous ocrelizumab in patients with multiple sclerosis                                                                                                              | Title: A Phase III, non - inferiority, randomized, open - label, parallel group, multicenter study to investigate the pharmacokinetics, pharmacodynamics, safety and radiological and clinical effects of subcutaneous ocrelizumab versus intravenous ocrelizumab in patients with multiple sclerosis                                                                                                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                        | CN42097, OCARINA II, EUDRACT number: 2020 -005448- 48, NCT number: NCT05232825                                                                                                                                                                                                                                                                                                                                     | CN42097, OCARINA II, EUDRACT number: 2020 -005448- 48, NCT number: NCT05232825                                                                                                                                                                                                                                                                                                                                     | CN42097, OCARINA II, EUDRACT number: 2020 -005448- 48, NCT number: NCT05232825                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                                                                  | CN42097 is a Phase III non - inferiority, randomized, open - label, parallel group, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, radiological, and clinical effects of SC administration of ocrelizumab compared with the IV infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | CN42097 is a Phase III non - inferiority, randomized, open - label, parallel group, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, radiological, and clinical effects of SC administration of ocrelizumab compared with the IV infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | CN42097 is a Phase III non - inferiority, randomized, open - label, parallel group, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, radiological, and clinical effects of SC administration of ocrelizumab compared with the IV infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). |
|                                                                                                                                                                                                                                                                                                         | Duration of main phase: Duration of Run - in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                   | Duration of main phase: Duration of Run - in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                   | approximately 24 weeks (controlled period) followed by approximately 24 weeks (SC treatment period) not applicable not applicable                                                                                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                                                                                                              | Non - inferiority                                                                                                                                                                                                                                                                                                                                                                                                  | Non - inferiority                                                                                                                                                                                                                                                                                                                                                                                                  | Non - inferiority                                                                                                                                                                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                                                                       | OCR SC treatment arm                                                                                                                                                                                                                                                                                                                                                                                               | OCR SC treatment arm                                                                                                                                                                                                                                                                                                                                                                                               | Single doses of 920 mg ocrelizumab SC (23 mL volume) at Day 1, Week 24, and Week 48; n=118                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                         | OCR IV treatment arm                                                                                                                                                                                                                                                                                                                                                                                               | OCR IV treatment arm                                                                                                                                                                                                                                                                                                                                                                                               | Patients received a 600 mg IV infusion of ocrelizumab as the first dose in this study as two 300 mg IV infusions 14 days apart (Day 1 and Day 14); n=118 Single doses of 920 mg ocrelizumab SC (23 mL volume) were administered at Week 24 and Week 48                                                                                                                                                             |
| Endpoints and definitions                                                                                                                                                                                                                                                                               | Primary endpoint (the primary endpoint of this study is PK, not efficacy)                                                                                                                                                                                                                                                                                                                                          | Serum ocrelizumab area under the concentration - time curve (AUC W1 - 12 ) after SC administration compared to IV infusion from Day 1 to Week 12                                                                                                                                                                                                                                                                   | Linear regression model to estimate the geometric mean ratio of OCR SC in comparison with OCR IV                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary radiological endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Total number of T1Gd+ lesions as detected by brain MRI at Weeks and 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Total number of T1Gd+ lesions as detected by brain MRI at Weeks and 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Summarized using descriptive statistics at each visit. Negative binomial or Poisson regression used to estimate adjusted lesion rates. Unadjusted lesion rates also reported. No hypothesis testing was performed.                                                                                                                                                                                                                                                                                                                                                                                  | Summarized using descriptive statistics at each visit. Negative binomial or Poisson regression used to estimate adjusted lesion rates. Unadjusted lesion rates also reported. No hypothesis testing was performed.                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary radiological endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Total number of new or enlarging T2 lesions as detected by brain MRI Weeks 12 and 24 relative to the previous scan, respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Total number of new or enlarging T2 lesions as detected by brain MRI Weeks 12 and 24 relative to the previous scan, respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Summarized using descriptive statistics at each visit. Negative binomial or Poisson regression used to estimate adjusted lesion rates. Unadjusted lesion rates also reported. No hypothesis testing was performed.                                                                                                                                                                                                                                                                                                                                                                                  | Summarized using descriptive statistics at each visit. Negative binomial or Poisson regression used to estimate adjusted lesion rates. Unadjusted lesion rates also reported. No hypothesis testing was performed.                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                 | Exploratory radiological endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Total number of T1Gd+ lesions as detected by brain MRI at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Total number of T1Gd+ lesions as detected by brain MRI at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not presented, Week 48 data not available at the time of database lock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Not presented, Week 48 data not available at the time of database lock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                 | Exploratory radiological endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Total number of new or enlarging T2 lesions as detected by brain MRI at Weeks 8 and 48 relative to the previous scan, respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Total number of new or enlarging T2 lesions as detected by brain MRI at Weeks 8 and 48 relative to the previous scan, respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Summarized using descriptive statistics at each visit. Negative binomial or Poisson regression used to estimate adjusted lesion rates. Unadjusted lesion rates also reported. No hypothesis testing was performed. Week 48 data not available at the time of database lock                                                                                                                                                                                                                                                                                                                          | Summarized using descriptive statistics at each visit. Negative binomial or Poisson regression used to estimate adjusted lesion rates. Unadjusted lesion rates also reported. No hypothesis testing was performed. Week 48 data not available at the time of database lock                                                                                                                                                                                                                                                                                                                          |
|                                                 | Exploratory clinical endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Annualized protocol - defined relapse rate by Weeks 24 and 48 in RMS patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Annualized protocol - defined relapse rate by Weeks 24 and 48 in RMS patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Defined as number of relapses per patient - year. Week 48 data not available at the time of database lock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Defined as number of relapses per patient - year. Week 48 data not available at the time of database lock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                 | Exploratory clinical endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Change from baseline in the EDSS at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Change from baseline in the EDSS at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Not presented, Week 48 data not available at the time of database lock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Not presented, Week 48 data not available at the time of database lock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Database lock                                   | Clinical cutoff date (CCOD): 10 March 2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Clinical cutoff date (CCOD): 10 March 2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Clinical cutoff date (CCOD): 10 March 2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Clinical cutoff date (CCOD): 10 March 2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Clinical cutoff date (CCOD): 10 March 2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Analysis Set and time point description         | other: PK - Evaluable Analysis Set All patients who have received the full assigned dose of ocrelizumab and have measurable serum concentrations of ocrelizumab unless major protocol deviations or unavailability of information (e.g., exact blood sampling time, exact dosing information or incomplete dose administration, missing concentration data) occurred, or if data are unavailable, not plausible, or incomplete, that may interfere with the PK evaluation. Patients were grouped according to the actual dose and actual route of administration. time point: From Day 1 to Week 12 | other: PK - Evaluable Analysis Set All patients who have received the full assigned dose of ocrelizumab and have measurable serum concentrations of ocrelizumab unless major protocol deviations or unavailability of information (e.g., exact blood sampling time, exact dosing information or incomplete dose administration, missing concentration data) occurred, or if data are unavailable, not plausible, or incomplete, that may interfere with the PK evaluation. Patients were grouped according to the actual dose and actual route of administration. time point: From Day 1 to Week 12 | other: PK - Evaluable Analysis Set All patients who have received the full assigned dose of ocrelizumab and have measurable serum concentrations of ocrelizumab unless major protocol deviations or unavailability of information (e.g., exact blood sampling time, exact dosing information or incomplete dose administration, missing concentration data) occurred, or if data are unavailable, not plausible, or incomplete, that may interfere with the PK evaluation. Patients were grouped according to the actual dose and actual route of administration. time point: From Day 1 to Week 12 | other: PK - Evaluable Analysis Set All patients who have received the full assigned dose of ocrelizumab and have measurable serum concentrations of ocrelizumab unless major protocol deviations or unavailability of information (e.g., exact blood sampling time, exact dosing information or incomplete dose administration, missing concentration data) occurred, or if data are unavailable, not plausible, or incomplete, that may interfere with the PK evaluation. Patients were grouped according to the actual dose and actual route of administration. time point: From Day 1 to Week 12 | other: PK - Evaluable Analysis Set All patients who have received the full assigned dose of ocrelizumab and have measurable serum concentrations of ocrelizumab unless major protocol deviations or unavailability of information (e.g., exact blood sampling time, exact dosing information or incomplete dose administration, missing concentration data) occurred, or if data are unavailable, not plausible, or incomplete, that may interfere with the PK evaluation. Patients were grouped according to the actual dose and actual route of administration. time point: From Day 1 to Week 12 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | OCR IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | OCR IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | OCR SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 116                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 116                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 116                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                                 | Serum ocrelizumab area under the concentration - time curve (AUC W1 - 12 ) from Day 1 to Week 12 mean (SD) (µg/mL•day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2750 (796)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 3500 (914)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | median (µg/mL•day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2570                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 3500                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                 | min - max (µg/mL•day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1390 - 4690                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1180 -5940                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                  | Serum ocrelizumab area under the concentration - time curve (AUC W1 - 12 ) after SC administration compared to IV infusion from Day 1 to Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | OCR SC vs OCR IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Serum ocrelizumab area under the concentration - time curve (AUC W1 - 12 ) after SC administration compared to IV infusion from Day 1 to Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Geometric mean ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.2851                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | Serum ocrelizumab area under the concentration - time curve (AUC W1 - 12 ) after SC administration compared to IV infusion from Day 1 to Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 90% confidence interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1.2258 - 1.3473                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Notes                                           | The primary objective for OCARINA II is to establish the non - inferiority of ocrelizumab SC to ocrelizumab IV based on serum ocrelizumab AUC W1 - 12 . Non - inferior ocrelizumab exposure for the SC formulation versus the IV formulation is expected to translate into comparable efficacy outcomes, as per the principle of PK bridging. In line with this, OCARINA II was not specifically designed nor powered to formally test non - inferior efficacy of ocrelizumab SC to ocrelizumab IV. However, secondary and exploratory radiological and clinical endpoints were included to evaluate and explore the effects of ocrelizumab SC compared with ocrelizumab IV in patients with MS and the results from these endpoints are presented below. | The primary objective for OCARINA II is to establish the non - inferiority of ocrelizumab SC to ocrelizumab IV based on serum ocrelizumab AUC W1 - 12 . Non - inferior ocrelizumab exposure for the SC formulation versus the IV formulation is expected to translate into comparable efficacy outcomes, as per the principle of PK bridging. In line with this, OCARINA II was not specifically designed nor powered to formally test non - inferior efficacy of ocrelizumab SC to ocrelizumab IV. However, secondary and exploratory radiological and clinical endpoints were included to evaluate and explore the effects of ocrelizumab SC compared with ocrelizumab IV in patients with MS and the results from these endpoints are presented below. | The primary objective for OCARINA II is to establish the non - inferiority of ocrelizumab SC to ocrelizumab IV based on serum ocrelizumab AUC W1 - 12 . Non - inferior ocrelizumab exposure for the SC formulation versus the IV formulation is expected to translate into comparable efficacy outcomes, as per the principle of PK bridging. In line with this, OCARINA II was not specifically designed nor powered to formally test non - inferior efficacy of ocrelizumab SC to ocrelizumab IV. However, secondary and exploratory radiological and clinical endpoints were included to evaluate and explore the effects of ocrelizumab SC compared with ocrelizumab IV in patients with MS and the results from these endpoints are presented below. |
| Analysis description Analysis Set               | Secondary and exploratory analysis These analyses were pre - specified. MRI Analysis - Analysis set: Efficacy - evaluable - MRI Analysis set - All randomized patients who received, during the controlled period (i.e., time until the Week 24 dose of ocrelizumab SC), at least one infusion (partial or complete) or injection (partial or complete) of study drug (ocrelizumab IV or ocrelizumab SC) and having at least one brain MRI scan with measurement taken. Patients were grouped according to the treatment they were assigned. Annualized protocol-defined relapse rate analysis                                                                                                                                                            | Secondary and exploratory analysis These analyses were pre - specified. MRI Analysis - Analysis set: Efficacy - evaluable - MRI Analysis set - All randomized patients who received, during the controlled period (i.e., time until the Week 24 dose of ocrelizumab SC), at least one infusion (partial or complete) or injection (partial or complete) of study drug (ocrelizumab IV or ocrelizumab SC) and having at least one brain MRI scan with measurement taken. Patients were grouped according to the treatment they were assigned. Annualized protocol-defined relapse rate analysis                                                                                                                                                            | Secondary and exploratory analysis These analyses were pre - specified. MRI Analysis - Analysis set: Efficacy - evaluable - MRI Analysis set - All randomized patients who received, during the controlled period (i.e., time until the Week 24 dose of ocrelizumab SC), at least one infusion (partial or complete) or injection (partial or complete) of study drug (ocrelizumab IV or ocrelizumab SC) and having at least one brain MRI scan with measurement taken. Patients were grouped according to the treatment they were assigned. Annualized protocol-defined relapse rate analysis                                                                                                                                                            |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | OCR IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | OCR SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 118                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 118                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Total number of T1Gd+ lesions as detected by brain MRI at Week 8 (Number of patients with a readable MRI assessment at the visit)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 112                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 112                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Total number of lesions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Lesion rate, unadjusted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.14, 0.32)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (0.09, 0.24)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | number of patients in the analysis model                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 98                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 98                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                 | Lesion rate, adjusted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 95% CI                                                                                                                                                                         | (0.04, 0.32)   | (0.04, 0.33)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------|
| Total number of T1Gd+ lesions as detected by brain MRI at Week 24 (Number of patients with a readable MRI assessment at the visit)                                             | 65             | 61             |
| Total number of lesions                                                                                                                                                        | 0              | 2              |
| Lesion rate, unadjusted                                                                                                                                                        | 0.00           | 0.03           |
| 95% CI                                                                                                                                                                         | (0.00, 0.06)   | (0.00, 0.12)   |
| number of patients in the analysis model                                                                                                                                       | 52             | 49             |
| Lesion rate, adjusted                                                                                                                                                          | 0.00           | 0.00           |
| 95% CI                                                                                                                                                                         | (0.00, 0.00)   | (0.00, 0.00)   |
| Total number of new or enlarging T2 lesions as detected by brain MRI at Week 12 relative to the previous scan (Number of patients with a readable MRI assessment at the visit) | 116            | 116            |
| Total number of lesions                                                                                                                                                        | 7              | 6              |
| Lesion rate, unadjusted                                                                                                                                                        | 0.06           | 0.05           |
| 95% CI                                                                                                                                                                         | (0.02, 0.12)   | (0.02, 0.11)   |
| number of patients in the analysis model                                                                                                                                       | 116            | 116            |
| Lesion rate, adjusted                                                                                                                                                          | 0.05           | 0.04           |
| 95% CI                                                                                                                                                                         | (0.01, 0.23)   | (0.01, 0.18)   |
| Total number of new or enlarging T2 lesions as detected by brain MRI at Week 24 relative to the previous scan (Number of patients with a readable MRI assessment at the visit) | 65             | 61             |
| Total number of lesions                                                                                                                                                        | 0              | 2              |
| Lesion rate, unadjusted                                                                                                                                                        | 0.00           | 0.03           |
| 95% CI                                                                                                                                                                         | (0.00, 0.06)   | (0.00, 0.12)   |
| number of patients in the analysis model                                                                                                                                       | 65             | 61             |
| Lesion rate, adjusted                                                                                                                                                          | 0.00           | 0.00           |
| 95% CI                                                                                                                                                                         | (0.00, 0.00)   | (0.00, 0.00)   |

<div style=\"page-break-after: always\"></div>

|                                 | Total number of new or enlarging T2 lesions as detected by brain MRI at Week 8 relative to the previous scan (Number of patients with a readable MRI assessment at the visit)                                                                                                                                                                                                                                             | 113                                                                                                                                                                                                                                                                                                                                                                                                                       | 113                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                 | Total number of lesions                                                                                                                                                                                                                                                                                                                                                                                                   | 159                                                                                                                                                                                                                                                                                                                                                                                                                       | 87                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                 | Lesion rate, unadjusted                                                                                                                                                                                                                                                                                                                                                                                                   | 1.41                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.77                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                    | (1.20, 1.64)                                                                                                                                                                                                                                                                                                                                                                                                              | (0.62, 0.95)                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                 | number of patients in the analysis model                                                                                                                                                                                                                                                                                                                                                                                  | 113                                                                                                                                                                                                                                                                                                                                                                                                                       | 113                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                 | Lesion rate, adjusted                                                                                                                                                                                                                                                                                                                                                                                                     | 1.04                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.58                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.56, 1.91)                                                                                                                                                                                                                                                                                                                                                                                                              | (0.32, 1.07)                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                 | Annualized protocol-defined relapse rate by Week 24 in RMS patients (Number of patients with an available assessment at the visit)                                                                                                                                                                                                                                                                                        | 106                                                                                                                                                                                                                                                                                                                                                                                                                       | 107                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                 | Number of patients with 0 relapses 1 relapse 2 relapses >3 relapses                                                                                                                                                                                                                                                                                                                                                       | 105 (99.1%) 1 (0.9%) 0 0                                                                                                                                                                                                                                                                                                                                                                                                  | 106 (99.1%) 1 (0.9%) 0 0                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                 | Total number of relapses                                                                                                                                                                                                                                                                                                                                                                                                  | 1                                                                                                                                                                                                                                                                                                                                                                                                                         | 1                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                 | Total follow - up time (patient - years)                                                                                                                                                                                                                                                                                                                                                                                  | 42.53                                                                                                                                                                                                                                                                                                                                                                                                                     | 42.33                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                 | Relapse rate (per year), unadjusted                                                                                                                                                                                                                                                                                                                                                                                       | 0.02                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.02                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimates per comparison | Not applicable, no hypothesis testing was performed for the secondary radiological and the exploratory radiological and clinical endpoints.                                                                                                                                                                                                                                                                               | Not applicable, no hypothesis testing was performed for the secondary radiological and the exploratory radiological and clinical endpoints.                                                                                                                                                                                                                                                                               | Not applicable, no hypothesis testing was performed for the secondary radiological and the exploratory radiological and clinical endpoints.                                                                                                                                                                                                                                                                               |
| Notes                           | The results presented above are based on the protocol - defined CCOD for the primary analysis (10 March 2023). An additional CCOD for study CN42097 is planned for early December 2023, which will include the complete data for the secondary radiological (MRI) endpoints at Week 24. Furthermore, data will also be available for the exploratory radiological (MRI) and clinical (ARR and EDSS) endpoints at Week 48. | The results presented above are based on the protocol - defined CCOD for the primary analysis (10 March 2023). An additional CCOD for study CN42097 is planned for early December 2023, which will include the complete data for the secondary radiological (MRI) endpoints at Week 24. Furthermore, data will also be available for the exploratory radiological (MRI) and clinical (ARR and EDSS) endpoints at Week 48. | The results presented above are based on the protocol - defined CCOD for the primary analysis (10 March 2023). An additional CCOD for study CN42097 is planned for early December 2023, which will include the complete data for the secondary radiological (MRI) endpoints at Week 24. Furthermore, data will also be available for the exploratory radiological (MRI) and clinical (ARR and EDSS) endpoints at Week 48. |

<div style=\"page-break-after: always\"></div>

## 2.6.5.3 Clinical studies in special populations

N/A

## 2.6.5.4 In vitro biomarker test for patient selection for efficacy

N/A

## 2.6.5.5 Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## 2.6.5.6 Supportive studies

N/A

## 2.6.6 Discussion on clinical efficacy

As an open label study with descriptive statistics, the efficacy data should be considered exploratory/supportive  data  only.  The  secondary  and  exploratory  efficacy  endpoints  do  not  raise concerns on any imbalance between arms. Long-term efficacy data for ocrelizumab SC are not available in order to assess persistence of efficacy or tolerance.

## 2.6.7 Conclusions on the clinical efficacy

Clinical efficacy is not the primary focus of the main study submitted for approval. The submitted efficacy data do not raise immediate concerns.

## 2.6.8 Clinical safety

## 2.6.8.1 Patient exposure

Table 19 Summary of studies contributing to safety evaluation

<!-- image -->

| Study Number, Phase            | Study Design                                                          | Population                        | No.ofPatients EvaluableforSafety                                                                                                                                                                      | Dose,Route,andRegimen                                                                                                                                                                                                                                                                                                                                                                                                                                       | Data Cut- offDate             |
|--------------------------------|-----------------------------------------------------------------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| CN42097 (OCARINAII),， PhaseIlI | Non- inferiority, randomized, open-label, parallel group, multicenter | Adult patients with RMS or PPMS a | 236patients randomized1:1to receiveeither ocrelizumabSCorIV asfirstdose                                                                                                                               | ControlledPeriod: 920mgocrelizumabadministeredassingleSCinjection,or600 mg ocrelizumab administered as two 300mg IV infusions SCOcrelizumabTreatmentPeriod: 181patients(asof theCCOD):920mgocrelizumabadministered assingleSCinjection,every24weeks.                                                                                                                                                                                                        | Primary analysis: 10 Mar 2023 |
| CN41144 (OCARINAI), PhaseIb    | Open-label, multicenter                                               | Adult patients with RMS or PPMS b | Cohort A1:4 patients Cohort A2:4 patients Cohort A3:4patients CohortA4:4patients CohortA5:35patients CohortAA:35patients CohortB1:3patients CohortB2:3patients CohortB3:3patients CohortB4:37patients | DoseEscalationPhase? CohortA1/B1d:singledoseof40mgocrelizumabSC CohortA2/B2d:singledoseof200mgocrelizumabSC CohortA3/B3°:singledoseof600mgocrelizumabSC Cohort A4/B4:single dose of1200mg ocrelizumabSC CohortA5:singledoseof1200mg(or920mg)ocrelizumabSC CohortAA:600mgocrelizumabIV DoseContinuationPhase: 131patients(as of theCCOD):candidatedoseof 1200mg ocrelizumabSC,andthen920mgocrelizumabSConceit had beenselectedasthefinalSCdose,every24weeks. | Interim analysis: 27 Jan 2023 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Ocarina II

During the controlled period, 118 patients received one injection of 920 mg ocrelizumab SC and 118 patients received one infusion of 600 mg ocrelizumab IV. The median treatment duration was 23.50 weeks (range: 12.3 -27.7 weeks) in OCR SC and 23.43 weeks (range: 0.1 -34.7 weeks) in OCR IV.

As of the clinical cut-off date, the total observation time per arm in the controlled period was 47 patientyears (PY; 47.17 PY in OCR IV and 47.52 PY in OCR SC).

<div style=\"page-break-after: always\"></div>

Table 20 Exposure to OCR SC/IV during controlled period (controlled period analysis), safety-evaluable - all set

Exposure to Sc/IvocR during Controlled Period (Controlled PeriodAnalysis),Safety-evaluable-Al1 Set Protocol:CN42097 （ClinicalCut-off Date:10MAR2023)

<!-- image -->

|                                                        | OCRIV (N-118)                        | OCR SC (N-118)                       |
|--------------------------------------------------------|--------------------------------------|--------------------------------------|
| Treatment duration (a) (Weeks)                         |                                      |                                      |
| n >0-<2 >2-<-24 >24-<-48                               | 118 1(0.8) 71(60.2) 46(39.08)        | 118 0 72(61.0%) 46(39.0%)            |
| n Mean (SD) Median Min -Max                            | 118 20.86(4.98) 23.43 0.1-34.7       | 118 21.01(4.09) 23.50 12.3-27.7      |
| Number of Doses                                        |                                      |                                      |
| n 1                                                    | 118 118(100%)                        | 118 118(100%)                        |
| n Mean (SD) Median Min-Max                             | 118 1.00(0.00) 1.00 1.0-1.0          | 118 1.00(0.00) 1.00 1.0-1.0          |
| Total Cumulative Dose （mg) n Mean (SD) Median Min -Max | 118 595.29(25.17) 598.00 325.2-600.0 | 118 919.66(12.26) 920.00 800.0-960.0 |

The firstdoseof intravenous Ocrelizumab (ocR IV group)is given in two infusions administered two weeks apart.

exceed 600 mg.

End date is defined as the earliest between

(a)Treatment duration is the end date minus the date offirst study drug administration plus one day.

Start ofotherDisease modifying therapies,or commercialocrelizumab

Withdrawalfromstudy/death

Start of 1st Sc dose in the Sc ocrelizumab treatment phase-l second

- -Withdrawal from treatment

Percentages are calculated based on the number ofpatients in the treatment amm (N).

CCOD

Program:root/clinical\\_studies/R04964913/cDT30233/cN42097/data\\_analysis/CsR/prod/program/

t\\_exp\\_cp.sas texp cp\\_SEALL.out

04AUG202316:08

## Ocarina I

In total, 131 patients received at least one dose of ocrelizumab 1200 mg SC or 920 mg SC. Across both these doses, starting from the first dose of ocrelizumab 1200 mg SC or 920 mg SC.

Page1of1

<div style=\"page-break-after: always\"></div>

Table 21

Protocol:CN41144 (C1in1calCut-off Dato:27JAN2023)

|                                                          | A-OCR 9C 920/1200mg (N=86)                     | B-OCRSC 920/1200mg (3=45)                 | All Patients (N=131)             |
|----------------------------------------------------------|------------------------------------------------|-------------------------------------------|----------------------------------|
| Owerall sc 7roatnent                                     |                                                |                                           |                                  |
| Duratlon (weoka)                                         |                                                |                                           |                                  |
| Mean (SD) Nedian Min -Max                                | 86 87.23(40.19) 72.57 0.1-159.1                | 45 107.86 (33.90) 119.14 0.1-157.1        | 131 94.32(39.27) 96.00 0.1-159.1 |
| Owerall sc Treatnent Duration (waeks) (categorlcal)      |                                                | 45                                        |                                  |
| 0-<24                                                    | 86 2（2.35) 6(7.0) 19(22.1) 24(27.95) 15(17.45) | 1（2.20） 1（2.2） 3(6.75) 8(17.B) 11(24.4)   | 131 3（2.3） 7（5.3) 22（16.8%)      |
| 24-<48                                                   |                                                |                                           |                                  |
| 48-<72 72-<96 96-<120                                    |                                                |                                           | 32(24.4) 26(19.8)                |
|                                                          | 6(7.05)                                        | 14(31.10) 7(15.6)                         | 20(15.3)                         |
| 120-<144 144-<168                                        | 14(16.34)                                      |                                           |                                  |
| Nunbor of Overall sc                                     |                                                |                                           | 21(16.0)                         |
|                                                          | 86 2（2.3) 3（3.54)                              | 45 1（2.25）                                | 131 3（2.35) 4(3.16) 19(14.55)    |
| Doses 1 2 3                                              | 17(19.8) 27(31.45) 17(19.84)                   | 1（2.26） 2(4.45) 6(13.34) 11(24.40)        | 33(25.2)                         |
| 4 5 6                                                    | 3（3.51)                                        | 17(37.86) 7(15.65)                        | 28(21.46) 20(15.3)               |
| 7                                                        | 1(1.2)                                         | 口                                         | 23(17.66)                        |
|                                                          | 16(18.6)                                       |                                           |                                  |
| Total nunbor of patients withatloastonoscdoso            | 1200.0-7840.0 2（2.3）                           |                                           |                                  |
|                                                          | 4723.02(1634.77) 4240.00                       | 45 5686.22(1369.09) 6040.00 1200.0-7840.0 | 5053.89(1610.16) 5160.00         |
| Mean (SD) Median Hin-Hax                                 |                                                | D                                         | 1（0.8） 131                       |
| Ovorall sc Total Cunulative Dose (ng)                    | 86                                             |                                           |                                  |
|                                                          |                                                |                                           | 2（1.5）                           |
|                                                          |                                                |                                           | 1200.0-7840.0                    |
| moditication                                             |                                                |                                           |                                  |
| Reason for dose Sc                                       | 1 (50.05) (50.05)                              | 0                                         | D (50.0)                         |
| modirication Advorso Event Leakage Equipnent Malfunction |                                                |                                           |                                  |
| Medication Error other                                   | 0                                              |                                           | (50.05)                          |

Theoverallsctroatmont durationisthodateorcho The percentages in Total nunber of patiants with at least one Sc dose modirication are calculated based on the nunber ofpatients in the treatnent arm (N).

10MAY2023 12:36

## Analysis of adverse events

## Ocarina II

Safety data reported during the treatment phase up to the clinical cut-off were summarized in the form of three different safety analyses. These comprised:

- Controlled period analysis, based on data collected during the controlled period. This analysis compared the OCR SC arm with the OCR IV arm.
- OCR SC all exposure analysis, based on data collected during the OCR SC all exposure period. This analysis presented data on the OCR SC All group (181 patients, 63 of which received two doses of ocrelizumab SC and 118 of which received exactly one dose of ocrelizumab SC).
- Switchers analysis, based on data collected during the OCR SC all exposure period. This analysis compared the  OCR  IV/SC  group  (63/118  patients  initially  assigned  to  the  OCR  IV  arm  that switched to receive one dose of ocrelizumab SC) with the OCR SC/SC group (118 patients initially assigned to the OCR SC arm, 63 of which proceeded to receive a second dose of ocrelizumab SC). As of the cut-off date, the extent of exposure among the switchers contributing to this analysis was considered sufficient to allow for a meaningful comparison only for the selected AE of IRs that occurred with the second ocrelizumab dose, in each group.

<div style=\"page-break-after: always\"></div>

## Ocarina I

- The Summary of clinical safety presents AEs observed during the dose escalation phase or the dose continuation phase in patients who received either ocrelizumab doses of 1200 mg SC or 920 mg SC. Safety data observed with the lower ocrelizumab doses other than 1200 mg and 920 mg are not presented in the Summary of clinical safety.

## 2.6.8.2 Adverse events

An  overview  of  the  key  safety  results  of  OCARINA  II  alongside  key  safety  results  of  OCARINA  I  is presented in Table 22.

Table 22 Summary of adverse events across studies

|                                                  | OCARINAII                | OCARINAII                | OCARINAII               | OCARINAI                |
|--------------------------------------------------|--------------------------|--------------------------|-------------------------|-------------------------|
|                                                  | ControlledPeriodAnalysis | ControlledPeriodAnalysis | OCRSCAllExposure        | OcrevusSC(atLeastOne    |
|                                                  |                          |                          | Analysis a              | Doseof920or1200mg)      |
|                                                  | IV                       | SC                       |                         |                         |
| Totalnumberofinfusions/injections                | 118infusions 47.17 PY    | 118injections 47.52 PY   | 244 injections 70.46 PY | 608injections 258.63PY  |
| Totalsafetyobservationtime                       |                          | 118                      | 181                     | 131                     |
| Totalnumberofpatients                            | 118                      |                          |                         |                         |
| Tolalnumberofpalienlswithatleastone Adverseevent | 54 (45.8%)               | 87 (73.7%)               | 115 (63.5%) 4 (2.2%)    | 127 (96.9%) 31 (23.7%)  |
| AdverseeventofGrade23                            | 7 (5.9%)                 | 4 (3.4%)                 |                         |                         |
| Seriousadverseevent                              | 4 (3.4%)                 | 3 (2.5%)                 | 3 (1.7%)                | 16 (12.2%)              |
| Adverseeventwithfataloutcome                     | 0                        | 0                        | 0                       | 1 (0.8%)                |
| Adverseeventleadingtowithdrawalfromtrealment     | 0                        | 0                        | 0                       | 2 (1.5%)                |
| IRR                                              | 20 (16.9%)               | 0                        | 0                       | 0                       |
| IR                                               | 0                        | 57 (48.3%)               | 86 (47.5%)              | 107 (81.7%) 102 (77.9%) |
| LocalIRs                                         | 0 0                      | 54 (45.8%) 13 (11.0%)    | 81 (44.8%) 22 (12.2%)   | 31 (23.7%)              |
| Systemic IRs Infeclions b                        |                          |                          | 47 (26.0%)              |                         |
|                                                  | 33 (28.0%)               | 41 (34.7%)               |                         | 89 (67.9%)              |
| SeriousInfections                                | 4 (3.4%)                 | 0                        | 0                       | 13 (9.9%)               |
| Medicalconcepls Malignancies c                   | 0                        | 0                        | 0                       | 2 (1.5%)                |
| Anaphylaclic reaclion d                          | 3 (2.5%)                 | 5 (4.2%)                 | 8 (4.4%)                | 18 (13.7%)              |
| Hypersensilivity                                 | 23 (19.5%)               | 58 (49.2%)               | 85 (47.0%)              | 44 (33.6%)              |

Source:OCARINAIICSR1121154,t\\_eXp\\_cp\\_SEALL,t\\_ae\\_py\\_CP\\_SEALL,t\\_eXp\\_ocr\\_tp\\_SW\\_SESC.tae\\_py\\_SC\\_SESC,tae\\_prf\\_CP\\_SEALL,t\\_ae\\_ctc\\_AE35\\_CP\\_SEALL, tae\\_socpt\\_INFECT\\_CP\\_SEALL,t\\_ae\\_prfl\\_SC\\_SESC,t\\_ae\\_ctc\\_AE35\\_SC\\_SESC,tae\\_socpt\\_INFECT\\_SC\\_SESC.OCARINAICSR1118563,tex\\_ettrtrec\\_ALL.

AE=adverseevent;IR=injectionreaction;IRR=infusionrelatedreaction;IV=intravenous;MedDRA=Medical DictionaryforRegulatoryActivities;SC=subcutaneous;SMQ= StandardisedMedDRAQuery;PY=patient-years.

texp\\_cdosepy\\_SE\\_sC,t ae1\\_SE\\_SC,t\\_ae ctc AE35\\_SE SC.

Multipleoccurrencesof thesameAEinoneindividualarecountedonlyonceexceptforTotal numberofAEs'rowinwhichmultipleoccurrencesof thesameAEarecounted separately.

Notes:InvestigatortextforAEsencodedusingMedDRAverslon26.0forOCARINAllandMedDRA25.1forOCARINA1.

Percentagesarecalculatedbasedonthenumberofpatientsinthetreatment arm(N).

Per definitionpatientswhgreceived ocreizumabSCas theirfirst dose areincluded inboth controlledperiod analysis and the OcRSC all exposure analysis from the timethey areincludedintheOcRSCallexposureanalysisfromthetimetheyreceived theirseconddose(i.e.,ocrelizumabSC).

Identified by MedDRASystem OrganClass\"Infections and Infestations'.

*Identified using the \"Anaphylactic reactions (SMQ).

Identified using the Malignant tumours (SMQ) narrow.

*Identified using the “Hypersensitivity (SMQ).

## Ocarina I:

Table 23 and Table 24 presents a summary of safety events in patients who received 1200 mg ocrelizumab SC (Table 23) and 920 mg ocrelizumab SC (Table 24) respectively.

<div style=\"page-break-after: always\"></div>

```
Adverse Events,Safety-Evaluable Set,1200 mg SC cohort (All Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC) Protocol:CN41144 (Clinical Cut-off Date:27JAN2023) A-OCR SC 1200mg B-OcR SC 120Omg Al1 Patients (08-N) (N=45) (N=125) Total number of events 401 347 748 Total number of IR 106 95 201 Total number of local IR 83 84 167 Total number of systemic IR 23 11 34 Total number of IRR 0 0 0 Total number of patients with at least one Any AE 73(91.38) 44(97.88) 117(93.68) AE suspected to be caused by Iv Ocrelizumab 1（1.3%) 1（2.28） 2(1.6) AE suspected to be caused by Sc Ocrelizumab 56(70.08) 41(91.18) 97(77.6) AE with fatal outcome 1(1.39) 0 1（0.8） Serious AE 10 (12.58) (4.4%) 12 (9.68) Infection* 44 (55.0%) 26(57.88) 70 (56.0%) Serious Infection* 10 (12.58) 1(2.28) 11 (8.8) Serious AE leading to withdrawal from treatment Serious AE leading to dose modification/interruption 0 1 (1.38) 1 0 （2.2名） 1 1 （0.8%) （0.8%) AE leading to dose modification/interruption AE leading to withdrawal from treatment Adverse Events of Special Interest* 0 2 0 (2.5%) 0 （2.2%） （2.28） 0 3 （2.48) （0.8） IR 54 (67.59) 40(88.9) 94(75.2) LocalIR 50 (62.58) 40(88.98) 90 (72.0) Systemic IR 16 (20.0%) 9(20.08) 25(20.0%) IRR 0 0 IRRs leading to withdrawal treatment 0 0 0 IRs leading to withdrawal treatment 0 0 0 Medical concepts:patients with Malignancies.** 0 （2.28) （0.88) Anaphylactic reactions ***业 8 (10.08) 5 (11.18) 13 (10.48) Hypersensitivity*.... 23(28.8) 14(31.18) 37(29.6) Investigator text for AEs encoded using MedDRA version 25.1. Multiple occurrences of the same AE in one individual are counted only once except for Total munber of eventsrow in which multiple occurrences of the same AE are counted separately. Percentages are calculated based on the number of patients in the treatment arm (N). IdentifiedbyMedDRA System Organ Class\"Infections and Infestations\". combination with either elevated bilirubin or clinical jaundice or cases of suspected transmission of an infectious agent by the study drug. Non-Serious Relapses are excluded. IR-Injection Reaction;IRR-Infusion Related Reaction. s 10MAY2023 13:34 Page1of1
```

Table 23 Summary of adverse events in patients who received at least one dose of 1200mg Ocrelizumab SC (safety-evaluable set)

```
Protocol:CN41144(ClinicalCut-off Date:27JAN2023) A-OCR SC920mg B-OCR SC 920mg All Patients (N=79) (N=39) (N-118) Total number of events 181 129 310 Total number of IR 67 45 112 Total numberof 1ocalIR 54 44 98 Total number of systemic IR 13 1 14 Total number of IRR 0 0 0 Total number of patients with at least one Any AE 62(78.58) 32(82.18) 94(79.7%) AE suspected to be caused by Iy ocrelizumab 0 0 0 AE suspected to be caused by sc Ocrelizumab 42 (53.2) 26 (66.78) 68(57.6) AE with fatal outcome Serious AE 0 2 (2.58) 0 2 （5.1) 4 0 (3.4%) Infection' 34 (43.08) 13 (33.38) 47 (39.86) Serious Infection* 2 (2.58) 0 2(1.7%) Serious AE leading to withdrawal from treatment 0 0 0 Serious AE leading to dose mcdification/interruption 0 1 (2.6%) 1 (0.8%) Adverse Events of Special Interest** 0 0 0 AE leading to withdrawal from treatment 0 1 （2.6) 1 (0.8%) AE leading to dose modification/interruption C 4 (10.3%) 4 (3.48) IR 42 (53.2) 26(66.78) 68(57.6%) Local IR 36 (45.68) 26 (66.78) 62(52.58) Systemic IR 12 (15.28) 1（2.6%） 13(11.08) IRR 0 0 0 IRRs leading to withdrawal treatment 0 0 0 IRs leading to withdrawal treatment 0 0 0 Medical concepts:patients with Malignancies..* 0 1 （2.6%） 1(0.8%) Anaphylactic reactions *** 4(5.19) 3 7.78) 7（5.9%) Hypersensitivity***.* 13(16.58) 3(7.78) 16(13.6) Multiple occurrences of the same AE in one individual are counted only once except for Total number of eventsrow in which multiple occurrences of the same AE are counted separately. Percentages are calculated based on the number ofpatients in the treatment arm (N). Identified by MedDRA System Organ Class \"Infections and Infestations\" combination with either elevated bilirubin or clinical jaundice or cases of suspected transmission of an infectious agent by the study drug. *****Identified using theHypersensitivity（SMQ)\" Non-Serious Relapses are excluded. IR-Injection Reaction;IRR-Infusion Related Reaction. s Output:root/clinical_studies/RO4964913/cDT30233/CN41144/data_analysis/CSR/prod/output/t_ae1_SE_SC920.out 10MAY2023 13:36 Page1of1
```

Table 24 Summary of adverse events in patients who received at least one dose of 920mg Ocrelizumab SC (safety-evaluable set)

## Common Adverse Events

## OCARINA II

## Controlled Period Analysis

<div style=\"page-break-after: always\"></div>

## The most frequent AEs by PT ( ≥ 3% of patients in either arm) are presented in Table 25.

Table 25 Adverse events with an incidence rate of at least 3% by preferred term during controlled period

Adverse Events with an Incidence Rate of at least 3&amp; by Preferred Term during Controlled Period (Controlled Period Analysis),Safety-evaluable-All Set Protocol:CN42097 (C1inical Cut-off Date:10MAR2023)

| MedDRA Preferred Term             | OCRIV (N-118)   | OCRIV (N-118)   |   OCRSC (N-118) | OCRSC (N-118)   |
|-----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Injection related reaction        | 0               |                 |              55 | (46.68)         |
| Infusionrelated reaction          | 20              | (16.98)         |               0 |                 |
| Upper respiratory tract infection | 9               | (7.6%)          |               8 | (6.88)          |
| Headache                          |                 | (2.58)          |              12 | (10.28)         |
| COVID-19                          | 5               | (4.2%)          |               8 | (6.89)          |
| Bronchitis                        | 6               | (5.1$)          |               2 | (1.78)          |
| Urinary tract infection           | 5               | (4.2)           |               3 | （2.58)          |
| Arthralgia                        | 5               | (4.28）          |               2 | 1.78)           |
| Nasopharyngitis                   | 2               | (1.78)          |               5 | 4.29)           |
| Dizziness                         | 4               | (3.48)          |               2 | 1.78)           |
| Fall                              | 4               | (3.48)          |               2 | (1.78)          |
| Oral herpes                       | 1               | (0.8)           |               4 | (3.48)          |

Investigator text for AEs encoded usingMedDRA version 26.0.

For frequency counts by preferred term,multiple occurrences of the same AE in an individual arecounted onlyonce.

Only treatment emergent adverse events （TEAE) are included in the outputs.

For frequency counts of Total number of events\"rows,multiple occurrences of the same AE in an individual arecounted separately.

Medical occurrences or symptoms of deterioration anticipated as part ofMs are not recorded as adverse events.

Percentages are calculated based on the number of patients in the treatment arm (N).

t\\_ae\\_pt 3p.9as

Output:root/clinical\\_studies/R04964913/cDr30233/CN42097/data\\_analysis/CsR/prod/output/ taept 3p CPSEALL.out

06JUL202318:44

Page1of1

## OCR SC All Exposure Analysis

The most frequent AEs by PT ( ≥ 3% of patients) are presented in Table 26.

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term           | OCR SC A11 (N-181)   |
|---------------------------------|----------------------|
| Injection relatedreaction       | 81(44.88)            |
| Headache                        | 12 (6.6)             |
| COVID-19                        | 9 (5.0%)             |
| Upperrespiratory tractinfection | 9(5.0%)              |
| Nasopharyngitis                 | 6(3.38)              |

Table 26 Adverse events with an incidence rate of at least 3% by preferred term during OCR SC all exposure period (OCR SC all exposure analysis)

<!-- image -->

OCARINA I: Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC Among patients who received at least one dose of ocrelizumab 1200 mg SC:

- The most frequent AEs by SOC ( ≥ 30% of patients) were:
- o General disorders and administration site conditions: 75.2% (94 patients)
- o Infections and infestations: 56.0% (70 patients)
- o Injury, poisoning and procedural complications: 35.2% (44 patients)
- o Musculoskeletal and connective tissue disorders: 32.8% (41 patients)
- The most frequent AEs by PT ( ≥ 10% of patients) were:
- o Injection site reaction: 72.0% (90 patients)
- o COVID-19: 33.6% (42 patients)
- o Injection related reaction: 20.8% (26 patients)
- o Fatigue: 16.0% (20 patients)
- o Headache: 13.6% (17 patients)
- o Urinary tract infection: 11.2% (14 patients)

Among patients who received at least one dose of ocrelizumab 920 mg SC:

- The most frequent AEs by SOC ( ≥ 15% of patients) were:
- o General disorders and administration site conditions: 55.9% (66 patients)
- o Infections and infestations: 39.8% (47 patients)
- o Injury, poisoning and procedural complications: 16.9% (20 patients)
- o Nervous system disorders: 15.3% (18 patients)

<div style=\"page-break-after: always\"></div>

- The most frequent AEs by PT ( ≥ 10% of patients) were:
- o Injection site reaction: 52.5% (62 patients)
- o COVID-19: 21.2% (25 patients)
- o Injection related reaction: 11.0% (13 patients)

## 2.6.8.3 Serious adverse events, deaths, and other significant events

## Serious adverse events

## Ocarina II

## Controlled Period Analysis

The proportions of patients with at least one SAE were comparable between the two treatment arms (2.5 % in the OCR SC arm vs. 3.4% in the OCR IV arm).

In the OCR SC arm, the SAEs were Multiple sclerosis pseudo relapse, Multiple sclerosis relapse, Eye pain, and Anxiety, reported at least once in one patient (0.8 %). All SAEs resolved as of the cut-off date, and none  led  to  dose  schedule  modification  or  treatment  discontinuation.  All  were  considered  by  the investigator to not be related to study treatment.

In the OCR IV arm, the SAEs were Appendicitis, Cellulitis staphylococcal, Pneumonia, Subcutaneous abscess, Upper respiratory tract infections, and Diabetes mellitus, each reported at least once (0.8 %). All SAEs resolved as of the cut-off date, except for the SAE of Diabetes mellitus. None of the SAEs led to infusion  modification,  dose  schedule  modification  or  treatment  discontinuation,  except  for  the  AE  of Diabetes mellitus which led to a 3-month delay of the next ocrelizumab dose. All SAEs were considered by the investigator to not be related to study treatment, except for the AE of Upper respiratory tract infection.

## OCR SC All Exposure Analysis

The proportions of patients with at least one SAE in the OCR SC All group was 1.7%. The SAEs were Multiple sclerosis pseudo relapse, Multiple sclerosis relapse, Eye pain, and Anxiety, each reported at least once in one patient (0.6 %). All SAEs were reported during the controlled period, and are as such, discussed above.

## Ocarina I: Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC

Among patients who received at least one dose of ocrelizumab 1200 mg SC:

- The proportion of patients with at least one SAE was 9.6% (12 patients).
- The SAEs were: COVID-19 (3.2% [4 patients]); COVID-19 pneumonia (3.2% [4 patients]); pneumonia (2.4% [3 patients]); multiple sclerosis relapse (1.6% [2 patients]); and encephalitis, asthenia, muscular weakness, and pulmonary embolism (0.8% [1 patient] each).

Among patients who received at least one dose of ocrelizumab 920 mg SC:

- The proportion of patients with at least one SAE was 3.4% (4 patients).
- The SAEs were (0.8% [1 patient] each): COVID-19, COVID-19 pneumonia, pneumonia, papillary thyroid cancer, and nephrolithiasis.

## Deaths

As of the clinical cut-off date, no deaths were reported in Ocarina II.

One patient died due to an SAE of COVID-19 pneumonia in Ocarina I.

## Adverse events of special interest

Ocarina II Controlled Period and OCR SC All Exposure Analyses

<div style=\"page-break-after: always\"></div>

As of the clinical cut-off date, no AESIs (cases of potential drug-induced liver injury, cases of suspected transmission  of  an  infectious  agent  by  the  study  drug,  or  cases  of  Grade  3  or  higher  injection  site reactions) were reported.

## Ocarina I Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC

As of the clinical cut-off date, no AESIs (cases of potential drug-induced liver injury or cases of suspected transmission of an infectious agent by the study drug) were reported.

## Selected adverse events

## Injection Reactions

## Ocarina II

## Controlled Period Analysis

The proportion of patients in OCR SC (i.e., ocrelizumab-naïve) who experienced at least one IR with the first injection was 48.3% (57/118 patients; see Table 4). Overall, 57 IRs were reported in OCR SC. None were serious.

Of the 57 patients in OCR SC who experienced at least one IR with the first injection, 41 had IRs of Grade 1 maximum severity (71.9%) and 16 had IRs of Grade 2 maximum severity (28.1%). No patients had an IR of Grade 3 or higher. No actions were taken with ocrelizumab SC in response to an IR (including LIRs and SIRs).

Of these IRs, most (26/30 reactions [86.7%]) occurred within 6 hours of the injection. The median time from the end of injection administration to IR onset was 0.265 hours (range: -0.15 to 14.85). Overall,

among patients in OCR SC who experienced at least one IR, most (82.5%) had it within 24 hours after the end of injection as opposed to during the injection. Among patients in OCR SC who experienced at least one IR with the first injection, treatment was provided to 16/57 patients (28.1%). Treatment for IRs was standard of care treatments, including mostly analgesics (e.g., ibuprofen, paracetamol), and oral or topical antihistamines (e.g., diphenhydramine, cetirizine).

## Local Injection Reactions

The proportion of patients in OCR SC (i.e., ocrelizumab-naïve) who experienced at least one LIR with the first injection was 45.8% (54/118 patients; see Table 4). Overall, 54 LIRs were reported in OCR SC. None were serious.

Among patients in OCR SC, the most common symptoms of LIRs (reported in ≥ 3% of patients) were:

- Erythema: 29.7% (35/118 patients)
- Pain: 14.4% (17/118 patients)
- Swelling: 8.5% (10/118 patients)
- Pruritus: 6.8 % (8/118 patients)

## Systemic Injection Reactions

The proportion of patients in OCR SC (i.e., ocrelizumab-naïve) who experienced at least one SIR with the first injection was 11.0% (13/118 patients; see Table 4). Overall, 13 SIRs were reported in OCR SC. None were serious.

Among patients in OCR SC, symptoms of SIRs reported in ≥ 1 patients were:

- Headache: 2.5% (3/118 patients)
- Nausea: 1.7 % (2/118 patients)

## Switchers Analysis

<div style=\"page-break-after: always\"></div>

The proportion of patients who experienced at least one IR was comparable between OCR IV patients at their first SC injection and OCR SC patients at their second SC injection (i.e., both groups having been previously exposed to one dose of ocrelizumab):

- 36.5% (23/63 patients) in OCR IV/SC
- 41.3% (26/63 patients) in OCR SC/SC

## Local Injection Reactions

The proportion of patients who experienced at least one LIR was comparable between OCR IV patients at their first SC injection and OCR SC patients at their second SC injection (i.e., both groups having been previously exposed to one dose of ocrelizumab):

- 34.9% (22/63 patients) in OCR IV/SC
- 36.5% (23/63 patients) in OCR SC/SC

## Systemic Injection Reactions

The proportion of patients who experienced at least one SIR was comparable between OCR IV patients at their first SC injection and OCR SC patients at their second SC injection (i.e., both groups having been previously exposed to one dose of ocrelizumab):

- 9.5% (6/63 patients) in OCR IV/SC
- 6.3% (4/63 patients) in OCR SC/SC

## OCR SC All Exposure Analysis

The proportion of patients in OCR SC All who experienced at least one IR with any injection was 47.5% (86/181 patients; see Table 4). Overall, 106 IRs were reported in OCR SC All. None were serious.

With repeated injections, in OCR SC All (i.e., including both first injections in ocrelizumab-naïve patients and second injections in pre-treated patients), the incidence of IRs decreased from 44.2% (80/181 patients) at the first injection to 41.3% (26/63 patients) at the second injection.

Of the 86 patients in OCR SC All who experienced at least one IR with any injection, 66 had IRs of Grade 1 maximum severity (76.7%) and 20 had IRs of Grade 2 maximum severity (23.3%). No patients had an IR of Grade 3 or higher.

With repeated injections, the intensity of IRs decreased:

- Of the 80 patients that experienced at least one IR at the first injection, 61 had IRs of Grade 1 maximum severity (76.3%) and 19 had IRs of Grade 2 maximum severity (23.8%).

- Of the 26 patients that experienced at least one IR at the second injection, 23 had IRs of Grade 1 maximum severity (88.5%) and 3 had IRs of Grade 2 maximum severity (11.5%).

Overall, among patients in OCR SC All who experienced at least one IR, most (75.6%) had it within 24 hours after the end of injection as opposed to during the injection.

Among patients in OCR SC All who experienced at least one IR at any injection, treatment was provided to 18/86 patients (20.9%).

With  repeated  injections,  fewer  patients  required  treatment.  Among  patients  in  OCR  SC  All  who experienced at least one IR, treatment was provided to 18/80 patients (22.5%) after the first injection and 3/26 patients (11.5%) after the second injection.

## Local Injection Reactions

The proportion of patients in OCR SC All who experienced at least one LIR with any injection was 44.8% (81/181 patients; see Table 4). Overall, 99 LIRs were reported in OCR SC All. None were serious.

Among patients in OCR SC All, the most common symptoms of LIRs (reported in ≥ 3% of patients) were:

<div style=\"page-break-after: always\"></div>

- Erythema: 32.6% (59/181 patients)
- Pain: 14.9% (27/181 patients)
- Swelling: 8.3% (15/181 patients)
- Pruritus: 5.0 % (9/181 patients)

## Systemic Injection Reactions

The proportion of patients in OCR SC All who experienced at least one SIR with any injection was 12.2% (22/181 patients; see Table 4). Overall, 23 SIRs were reported in OCR SC All. None were serious.

Among patients in OCR SC All, symptoms of SIRs reported in &gt;1 patients were:

- Headache: 1.7 % (3/181 patients)
- Fever: 1.1 % (2/181 patients)
- Flushing: 1.1 % (2/181 patients)
- Nausea: 1.1 % (2/181 patients)
- Pain: 1.1% (2/181 patients)

## Ocarina I: Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC

Among patients  who  received  at  least  one  dose  of  ocrelizumab  1200  mg  SC,  75.2%  (94  patients) experienced IRs (Table 5).

Among  patients  who  received  at  least  one  dose  of  ocrelizumab  920  mg  SC,  57.6%  (68  patients) experienced IRs (Table 6).

Among patients who received at least one dose of ocrelizumab 1200 mg SC:

- The majority of IRs were Grade 1 or 2.

- 1 patient had a Grade 3 systemic IR (previously treated with ocrelizumab IV prior to study, after first injection of ocrelizumab 1200 mg SC, the patient experienced symptoms of dyspnea and wheezing, 4 hours following completion of ocrelizumab 1200 mg SC, which resolved with anti-allergy treatment after another hour). Further details on this case are included in the patient narratives.

Among patients who received at least one dose of ocrelizumab 920 mg SC, all IRs were Grade 1 or 2. No patients had IRs of Grade 3 or higher.

## Local Injection Reactions

Among patients  who  received  at  least  one  dose  of  ocrelizumab  1200  mg  SC,  72.0%  (90  patients) experienced LIRs (Table 5).

Among  patients  who  received  at  least  one  dose  of  ocrelizumab  920  mg  SC,  52.5%  (62  patients) experienced LIRs (Table 6).

## Systemic Injection Reactions

Among patients  who  received  at  least  one  dose  of  ocrelizumab  1200  mg  SC,  20.0%  (25  patients) experienced SIRs (Table 5).

Among  patients  who  received  at  least  one  dose  of  ocrelizumab  920  mg  SC,  11.0%  (13  patients) experienced SIRs (Table 6).

## Infusion Related Reactions

## Ocarina II Controlled Period Analysis

The proportion of patients in OCR IV who experienced at least one IRR was 16.9% (20/118 patients; see Table 4). Overall, 27 IRRs were reported in OCR IV. None were serious.

<div style=\"page-break-after: always\"></div>

Split by infusion, the incidence of IRRs decreased from 16.1% (19/118 patients) at the Day 1 infusion to 6.0% (7/117 patients) at the Day 14 infusion. Among patients in OCR IV, the most common symptom of IRRs (reported in &gt;3% of patients) was Pruritus: 3.4% (4/118 patients). In addition, the symptoms reported in &gt;1 patient were:

- Headache: 2.5% (3/118 patients
- Erythema: 1.7% (2/118 patients)
- Tachycardia: 1.7% (2/118 patients)
- Throat irritation: 1.7% (2/118 patients)

Of the 20 patients in OCR IV who experienced at least one IRR, 9 had IRRs of Grade 1 maximum severity (45.0%) and 11 had IRRs of Grade 2 maximum severity (55.0%). No patients had an IRR of Grade 3 or higher.

Among patients in OCR IV who experienced at least one IRR with any infusion, treatment was provided to 9/20 patients (45.0%).

Treatment  for  IRRs  was  standard  of  care  treatments,  including  mostly  IV  corticosteroids  (e.g., hydrocortisone),  analgesics  (e.g.,  paracetamol),  and  oral  or  IV  antihistamines  (e.g.,  loratadine, chlorphenamine, promethazine).

The median duration of IRRs was 1 day (range: 1 to 10 days). Most IRRs (23/27 reactions [85.2%]) resolved within 3 days of onset.

## Infections

## Ocarina II

## Controlled Period Analysis

The proportion of patients with an infection was 34.7% in the OCR SC arm and 28.0% in the OCR IV arm. The most frequent infections by PT ( ≥ 5% of patients in either arm) were (OCR SC arm vs. OCR IV arm, respectively):

- Upper respiratory tract infection (6.8% vs. 7.6%)
- COVID-19 (6.8% vs. 4.2%)
- Bronchitis (1.7% vs. 5.1%)

No patients in the OCR SC arm had a serious infection (see Table 4). In the OCR IV arm, 4 patients (3.4%)  had  a  serious  infection  (see  Table  4).  The  serious  infections  were  Appendicitis,  Cellulitis staphylococcal, Pneumonia, Subcutaneous abscess, Upper respiratory tract infection.

No infections of Grade 3 were reported in the OCR SC arm. All serious infections in the OCR IV arm were of Grade 3.

## OCR SC All Exposure Analysis

The proportions of patients with an infection in the OCR SC All group was 26.0%. The most frequent infections by PT ( ≥ 5% of patients) were:

- Upper respiratory tract infection (5.0%)
- COVID-19 (5.0%)

No patients in the OCR SC All group had a serious infection (see Table 4). No infections of Grade ≥ 3 in severity were reported. No patients had a serious infection lasting more than 4 weeks (&gt;28 days).

## Ocarina I: Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC

Among patients who received at least one dose of ocrelizumab 1200 mg SC:

<div style=\"page-break-after: always\"></div>

- The proportion of patients who experienced infections and serious infections, respectively was 56.0% (70 patients) and 8.8% (11 patients; Table 5).

- 11 patients (8.8%) had Grade 3 infection AEs and 1 patient (0.8%) had a Grade 5 infection AE. All other infections were Grade 1 or 2.

- The Grade 3 infections were: COVID-19 (5 patients [4.0%]), pneumonia (3 patients [2.4%]), COVID19  pneumonia  (1  patient  [0.8%]),  encephalitis  (1  patient  [0.8%]),  SARS-CoV-2  sepsis  (1  patient [0.8%]), and tooth abscess (1 patient [0.8%]).

- The Grade 5 infection AE was COVID-19 pneumonia.
- The most frequent infections by PT ( ≥ 3% of patients) were:
- COVID-19: 33.6% (42 patients)
- Urinary tract infection: 11.2% (14 patients)
- Nasopharyngitis: 7.2% (9 patients)
- Sinusitis: 4.8% (6 patients)
- Pneumonia: 4.0% (5 patients)
- COVID-19 pneumonia: 3.2% (4 patients)
- The serious infections were:
- COVID-19: 3.2% (4 patients)
- COVID-19 pneumonia: 3.2% (4 patients)
- Pneumonia: 2.4% (3 patients)
- Encephalitis: 0.8% (1 patient)

Among patients who received at least one dose of ocrelizumab 920 mg SC:

- The proportion of patients who experienced infections and serious infections, respectively was 39.8% (47 patients) and 1.7% (2 patients; Table 6).

-  4 patients (3.4%) had Grade 3 infections. All other infections were Grade 1 or 2. The Grade 3 infections were: COVID-19 (2 patients [1.7%]), pneumonia (1 patient [0.8%]), COVID-19 pneumonia (1 patient [0.8%]), and Clostridium difficile infection (1patient [0.8%]).

- The most frequent infection AEs by PT ( ≥ 3% of patients) were:
- COVID-19: 21.2% (25 patients)
- Urinary tract infection: 6.8% (8 patients)
- Bronchitis: 5.1% (6 patients)
- Nasopharyngitis: 4.2% (5 patients)
- Upper respiratory tract infection: 4.2% (5 patients)
- The serious infections were:
- COVID-19: 0.8% (1 patient)
- COVID-19 pneumonia: 0.8% (1 patient)
- Pneumonia: 0.8% (1 patient)

## Hypersensitivity and Anaphylactic Reaction Events

In both studies, AEs potentially representing hypersensitivity and anaphylactic reactions were retrieved using the MedDRA Anaphylactic reactions SMQ [Broad] and the Hypersensitivity SMQ [Broad]. All AEs

<div style=\"page-break-after: always\"></div>

were subsequently medically reviewed for identification of an event representing a hypersensitivity or anaphylactic reaction related to ocrelizumab.

None of the AEs were confirmed to be hypersensitivity or anaphylactic reactions but rather IRs, IRRs or respective symptoms of the LIRs, SIRs and IRRs.

## Malignancies

Ocarina II Controlled Period and OCR SC All Analyses

As of the clinical cut-off date, no malignancies were reported.

Ocarina I: Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC

A total of 2 patients in the Safety-Evaluable Set (i.e., all patients who received at least one dose of study drug) experienced AEs retrieved by the Malignant Tumours SMQ:

One patient experienced a Grade 2 AE of basal cell carcinoma and one patient experienced a Grade 3 AE of papillary thyroid cancer.

## 2.6.8.4 Laboratory findings

## Hematology and Chemistry

## Ocarina II Controlled Period Analysis

The marked laboratory abnormalities reported in &gt;1 patient in either arm were (OCR SC arm vs. OCR IV arm, respectively):

- Low neutrophils, total, absolute: 3.4% (4/118 patients) vs. 3.4% (4/118 patients)
- High neutrophils, total, absolute: 0 vs. 1.7 % (2/118 patients)
- Low lymphocytes, absolute: 1.7 % (2/118 patients) vs. 1.7 % (2/118 patients)

Shifts to NCI CTCAE Grade 3 or 4 post-baseline abnormalities are presented in Table 27.

<div style=\"page-break-after: always\"></div>

Table 27

(Controlled Period Analysis),Safety-evaluable-All Set Protoco1:CN42097 (Clinical Cut-off Date:10MAR2023)

<!-- image -->

| Laboratory Test            | Direction of Abnormality   | OCRIV (N-118)   | OCR SC (N-118)   |
|----------------------------|----------------------------|-----------------|------------------|
| Chemistry                  |                            |                 |                  |
| Alkaline Phosphatase       | High                       | 0/115           | 0/115            |
| ALT                        | High                       | 0/112           | 0/114            |
| Amylase                    | High                       | 0/116           | 0/116            |
| AST                        | High                       | 0/116           | 0/117            |
| Creatinine                 | High                       | 0/115           | 0/115            |
| Gamma Glutamyl Transferase | High                       | 0/115           | 0/115            |
| Potassium                  | LOw                        | 0/115           | 0/115            |
|                            | High                       | 0/115           | 0/115            |
| Sodium                     | LOW                        | 0/115           | 0/115            |
|                            | High                       | 0/115           | 0/115            |
| Bilirubin                  | High                       | 0/115           | 0/116            |
| Hematology                 |                            |                 |                  |
| Hemoglobin                 | LOw                        | 0/111           | 0/114            |
|                            | High                       | 0/111           | 0/114            |
| Lymphocytes Abs            | LOw                        | 1/110 （0.98)    | 1/114(0.98)      |
|                            | High                       | 0/111           | 0/114            |
| Neutrophils,Total,Abs      | LOw                        | 2/112 (1.88)    | 0/114            |
| Platelet                   | Low                        | 0/110           | 0/114            |
| Total Leukocyte Count      | LOw                        | 1/111(0.98)     | 0/114            |
|                            | High                       | 0/111           | 0/114            |

denominator is the number of patients with baseline NCI-CTcAE Grade O-2 in the specified direction of abnormality,or Grade 1-4 in the opposite direction of abnormality.Patients with missing baseline values are included in the denominator.

```
Program:root/clinical studies/R04964913/cDT30233/cN42097/data_analysis/cSR/prod/program/ t_lb shift.sas tlb_shiftCPSEALL.out 07JUL20230:19 Page1of1
```

## Liver Tests

No clinically meaningful difference was observed between the OCR SC and OCR IV arms with respect to liver tests.

All reported liver enzyme elevations were of Grade 1 maximum severity. In the majority of cases, the observed elevation in liver enzymes were single occurrences or sustained baseline elevations.

No cases of potential drug-induced liver injury were reported.

Ocarina I Patients who Received at Least One Dose of Ocrelizumab SC

The most common marked laboratory abnormalities were:

- High neutrophils, total, absolute: 40.5% (51/126 patients)

- High neutrophils, total, percentage: 16.7% (5/30 patients)

- Low lymphocytes, absolute: 15.9% (20/126 patients)

- Low lymphocytes, percentage: 40.0% (12/30 patients)

<div style=\"page-break-after: always\"></div>

- High total leukocyte count: 13.7% (18/131 patients)

For the majority of patients ( ≥ 85% of patients with abnormalities), the marked laboratory abnormalities were single occurrences and were not sustained or replicated.

## Elevated Liver Enzymes

Post-baseline elevations in liver enzymes were as follows (N=131):

- High ALT: 20.6% (27 patients)
- High AST: 11.5% (15 patients)
- High bilirubin: 3.8% (5 patients)

All post-baseline liver enzyme elevations were Grade 1, except for one Grade 2 bilirubin elevation. In the majority of cases, the observed elevation in liver enzymes were single occurrences and were not sustained or replicated and not requiring symptomatic treatment or treatment interruption.

There were no reported cases of potential drug-induced liver injury.

Shifts to NCI CTCAE Grade 3 or 4 post-baseline abnormalities are presented in Table 28.

## Table 28

Laboratory Test Shifts to NCI-CTCAE Grade 3-4 Post-Baseline, Safety-Evaluable Set, 920 or 1200 mg SC cohort （A11 Patientswho Received at Least One Dose of Ocrelizumab 920 mg SC or 1200 mg SC) Protocol:CN41144(C1inicalCut-offDate:27JAN2023)

| Laboratory Test       | Direction of Abnormality   | A-0CRSC 920/1200mg (N=86)   | B-0CR SC 920/1200mg A11 Patients (N=45)   |         | (N=131)   |             |
|-----------------------|----------------------------|-----------------------------|-------------------------------------------|---------|-----------|-------------|
| Chemistry             |                            |                             |                                           |         |           |             |
| Amylase               | High                       | 1/86(1.28)                  | 0/45                                      |         |           | 1/131(0.88) |
| Creatinine            | High                       | 1/86(1.28)                  | 0/45                                      |         | 1/131     | (0.88)      |
| Potassium             | Low                        | 3/86(3.58)                  | 0/45                                      |         | 3/131     | (2.38)      |
|                       | High                       | 0/86                        | 0/45                                      |         | 0/131     |             |
| Sodium                | Low                        | 1/86(1.28)                  | 0/45                                      |         | 1/131     | (0.88)      |
|                       | High                       | 0/86                        | 0/45                                      |         | 0/131     |             |
| Hematology            |                            |                             |                                           |         |           |             |
| Hemoglobin            | LOw                        | 1/86(1.28)                  | 0/45                                      |         | 1/131     | (0.88)      |
|                       | High                       | 0/86                        | 0/45                                      |         | 0/131     |             |
| LymphocytesAbs        | Low                        | 3/80(3.88)                  | 5/45                                      | (11.18) | 8/125     | (6.48)      |
|                       | High                       | 0/80                        | 0/45                                      |         | 0/125     |             |
| Neutrophils,Total,Abs | Low                        | 0/80                        | 0/45                                      |         | 0/125     |             |
| Platelet              | LOw                        | 0/86                        | 0/45                                      |         | 0/131     |             |
| Total Leukocyte Count | LOw                        | 0/86                        | 0/45                                      |         | 0/131     |             |
|                       | High                       | 0/86                        | 0/45                                      |         | 0/131     |             |

Baseline is defined as the latest assessment prior to the first exposure of any dose of 920 or 1200mg Sc ocR. For each laboratory test, patients with at least l post-baseline assessment are included in the analysis. For each cell,the denominator is the number of patients with baseline NCI-cTcAE Grade O-2in the specified direction ofabnormality,or Grade 1-4 in the opposite direction ofabnormality. Patients with missing baseline values are included in the denominator.

10MAY202311:46

## Vital signs

## OCARINA II

Overall, the proportions of patients with vital signs abnormalities, regardless of abnormality at baseline, were comparable between the two treatment arms (Table 29).

Page1of1

<div style=\"page-break-after: always\"></div>

| Assessment                                                                                                                                                                                                                                                                                                                                                                                       | Direction of Abnormality                                                                                                                                                                                                                                                                                                                                                                         | OCR IV (N-118)                                                                                                                                                                                                                                                                                                                                                                                   | OCR IV (N-118)                                                                                                                                                                                                                                                                                                                                                                                   | OCR SC (N-118)                                                                                                                                                                                                                                                                                                                                                                                   | OCR SC (N-118)                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Oxygen Saturation                                                                                                                                                                                                                                                                                                                                                                                | Low High                                                                                                                                                                                                                                                                                                                                                                                         | 6/105 0/105                                                                                                                                                                                                                                                                                                                                                                                      | (5.78]                                                                                                                                                                                                                                                                                                                                                                                           | 0/103                                                                                                                                                                                                                                                                                                                                                                                            | 3/103 ( 2.96)                                                                                                                                                                                                                                                                                                                                                                                    |
| Diastolic Blood Pressure, Sitting                                                                                                                                                                                                                                                                                                                                                                | Low High                                                                                                                                                                                                                                                                                                                                                                                         | 12/117 70/117                                                                                                                                                                                                                                                                                                                                                                                    | (10.38) (59.86)                                                                                                                                                                                                                                                                                                                                                                                  | 2/118 64/118                                                                                                                                                                                                                                                                                                                                                                                     | [1.78] (54.26)                                                                                                                                                                                                                                                                                                                                                                                   |
| Systolic Blood Pressure, Sitting                                                                                                                                                                                                                                                                                                                                                                 | Low High                                                                                                                                                                                                                                                                                                                                                                                         | 3/117 54/117                                                                                                                                                                                                                                                                                                                                                                                     | (.2.64) (46.2%)                                                                                                                                                                                                                                                                                                                                                                                  | 3/118 46/118                                                                                                                                                                                                                                                                                                                                                                                     | ( 2.56] (39.0%)                                                                                                                                                                                                                                                                                                                                                                                  |
| Pulse Rate, Sitting                                                                                                                                                                                                                                                                                                                                                                              | Low High                                                                                                                                                                                                                                                                                                                                                                                         | 21/117 5/117                                                                                                                                                                                                                                                                                                                                                                                     | (17.98) 4.38)                                                                                                                                                                                                                                                                                                                                                                                    | 11/118 0/118                                                                                                                                                                                                                                                                                                                                                                                     | (9.38]                                                                                                                                                                                                                                                                                                                                                                                           |
| phase in the direction specified, regardless_ of abnormality at baseline. Abnormalities reported in patients with missing baseline values are included. Baseline: the assessment taken \"within 45 minutes prior to premedication\" of Week 1 on IV arm and \"before premedication prior to the ocrelizumab injection\" of Meek 1 on SC amm; if not available the screening assessment will be used. | phase in the direction specified, regardless_ of abnormality at baseline. Abnormalities reported in patients with missing baseline values are included. Baseline: the assessment taken \"within 45 minutes prior to premedication\" of Week 1 on IV arm and \"before premedication prior to the ocrelizumab injection\" of Meek 1 on SC amm; if not available the screening assessment will be used. | phase in the direction specified, regardless_ of abnormality at baseline. Abnormalities reported in patients with missing baseline values are included. Baseline: the assessment taken \"within 45 minutes prior to premedication\" of Week 1 on IV arm and \"before premedication prior to the ocrelizumab injection\" of Meek 1 on SC amm; if not available the screening assessment will be used. | phase in the direction specified, regardless_ of abnormality at baseline. Abnormalities reported in patients with missing baseline values are included. Baseline: the assessment taken \"within 45 minutes prior to premedication\" of Week 1 on IV arm and \"before premedication prior to the ocrelizumab injection\" of Meek 1 on SC amm; if not available the screening assessment will be used. | phase in the direction specified, regardless_ of abnormality at baseline. Abnormalities reported in patients with missing baseline values are included. Baseline: the assessment taken \"within 45 minutes prior to premedication\" of Week 1 on IV arm and \"before premedication prior to the ocrelizumab injection\" of Meek 1 on SC amm; if not available the screening assessment will be used. | phase in the direction specified, regardless_ of abnormality at baseline. Abnormalities reported in patients with missing baseline values are included. Baseline: the assessment taken \"within 45 minutes prior to premedication\" of Week 1 on IV arm and \"before premedication prior to the ocrelizumab injection\" of Meek 1 on SC amm; if not available the screening assessment will be used. |
| Program: root/clinical_studies/R04964913/cDr30233/cN42097/data_analysis/csR/prod/program/t_v8_abn.8as t_Vs_abn_CP_SEALL.out 07JUL2023 0:31 Page l of 1                                                                                                                                                                                                                                           | Program: root/clinical_studies/R04964913/cDr30233/cN42097/data_analysis/csR/prod/program/t_v8_abn.8as t_Vs_abn_CP_SEALL.out 07JUL2023 0:31 Page l of 1                                                                                                                                                                                                                                           | Program: root/clinical_studies/R04964913/cDr30233/cN42097/data_analysis/csR/prod/program/t_v8_abn.8as t_Vs_abn_CP_SEALL.out 07JUL2023 0:31 Page l of 1                                                                                                                                                                                                                                           | Program: root/clinical_studies/R04964913/cDr30233/cN42097/data_analysis/csR/prod/program/t_v8_abn.8as t_Vs_abn_CP_SEALL.out 07JUL2023 0:31 Page l of 1                                                                                                                                                                                                                                           | Program: root/clinical_studies/R04964913/cDr30233/cN42097/data_analysis/csR/prod/program/t_v8_abn.8as t_Vs_abn_CP_SEALL.out 07JUL2023 0:31 Page l of 1                                                                                                                                                                                                                                           | Program: root/clinical_studies/R04964913/cDr30233/cN42097/data_analysis/csR/prod/program/t_v8_abn.8as t_Vs_abn_CP_SEALL.out 07JUL2023 0:31 Page l of 1                                                                                                                                                                                                                                           |

Table 29 Vital sign parameters outside normal limits regardless of abnormality at baseline during controlled period

<!-- image -->

## OCARINA I

Vital  signs  were  measured  at  dosing  visits  prior  to  study  drug  administration.  Vital  signs  were  also measured 1, 4, and 24 hours after the end of the infusion/injection.

4  patients  (2  treated  with  ocrelizumab  1200  mg  SC  and  2  treated  with  ocrelizumab  600  mg  IV) experienced blood pressure abnormalities reported as AEs (2 AEs of hypertension, 1 AE of blood pressure increased, and 1 AE of hypotension). All 4 events were non-serious, Grade 2, and were resolved or resolving at the time of clinical cut-off date. None of them were symptoms of IRs or IRRs.

When comparing patients in Dose Escalation Group A who received ocrelizumab SC (920 mg or 1200 mg) vs. ocrelizumab 600 mg IV, there were no clinically relevant differences between the OCR SC arm and the OCR IV arm with respect to vital sign parameters. The incidence of vital signs abnormalities was generally higher in the OCR SC arm compared with the OCR IV arm; however, the majority of the vital signs abnormalities were not considered clinically significant and were not reported as AEs.

## Electrocardiography

No clinically meaningful trends and no safety concerns had been observed from the analysis of ECG data collected in OCARINA I, up to the clinical cut-off date of 9 November 2021 used to select the ocrelizumab dose to be evaluated in OCARINA II. ECG assessments were not conducted in OCARINA II.

No patients had absolute QTcF values &gt;500 msec. One patient had a change from baseline in QTcF of &gt;60 msec that occurred 60 minutes after their fifth injection of ocrelizumab 1200 mg SC at Week 96.

Clinical significance of ECG results was determined by the investigator's medical judgment and reported on the eCRF. Two patients had clinically significant ECG abnormalities, both of which were reported as AEs. One patient had a Grade 2 sinus tachycardia event after receiving their fifth dose of ocrelizumab 1200 mg SC at Week 96 (and experienced the &gt;60 msec change from baseline in QTcF described above). One patient had a Grade 1 atrioventricular block first degree approximately 5 months after receiving their  first  dose  of  ocrelizumab  920  mg  SC  at  Week  48  that  led  to  interruption  of  ocrelizumab  SC treatment. Treatment was resumed with a delay of approximately 6 weeks. Both AEs were ongoing at the time of clinical cut-off date.

<div style=\"page-break-after: always\"></div>

## 2.6.8.5 In vitro biomarker test for patient selection for safety

Not applicable. There are no in vitro biomarker tests relevant for patient selection for safety.

## 2.6.8.6 Safety in special populations

## Intrinsic factors

No AE analyses were performed by any intrinsic factors.

## Extrinsic factors

No AE analyses were performed by any extrinsic factors.

## 2.6.8.7 Immunological events

Prevalence of ADAs at baseline was defined as the proportion of the evaluable patient population in a study that is ADA positive at the baseline timepoint. The incidence of ADAs (at post-baseline timepoints) was defined as the proportion of the study population found to have seroconverted (i.e., developed treatment-induced ADAs).

In both studies, no patients developed treatment-emerged anti-drug antibodies (ADAs) to ocrelizumab SC, as of the clinical cut-off date.

## Ocarina II: Controlled Period Analysis

At  baseline,  among  the  baseline-evaluable  patients  of  the  immunogenicity-evaluable  -  all  set,  the prevalence  of  anti-ocrelizumab  antibodies  was  0.9%  (1/117  patients)  in  OCR  SC  and  0.9%  (1/116 patients) in OCR IV.

At  baseline,  among  the  baseline-evaluable  patients  of  the  immunogenicity-evaluable  all  set,  the prevalence of anti-rHuPH20 antibodies was 5.8% (3/52 patients) in OCR SC and 6.5% (4/62 patients) in OCR IV.

No treatment-emergent ADAs to ocrelizumab or anti-rHuPH20 were reported in either treatment arm based on, respectively, serum and plasma samples collected up to the clinical cut-off date.

## Ocarina I

At baseline, 85/88 patients in Group A and 45/46 patients in Group B were evaluable for anti-ocrelizumab antibodies, and the baseline prevalence of ADAs was 0% in both groups. Post-baseline, the incidence of treatment-emergent ADAs to ocrelizumab was 0 of 88 post-baseline evaluable patients (0%) in Group A, and 0 of 46 post-baseline evaluable patients (0%) in Group B.

In  Group  A,  82/88  patients  were  evaluable  for  anti-rHuPH20  antibody  assessment  at  baseline.  The baseline prevalence of anti-rHuPH20 antibodies was 11.0% (9/82 patients). Post-baseline, the incidence of treatment-emergent anti-rHuPH20 antibodies was 1 of 87 post-baseline evaluable patients (1.1%) in Group A.

In  Group  B,  44/46  patients  were  evaluable  for  anti-rHuPH20  antibody  assessment  at  baseline.  The baseline prevalence of anti-rHuPH20 antibodies was 9.1% (4/44 patients).

Post-baseline, the incidence of treatment-emergent anti-rHuPH20 antibodies was 2 of 45 post-baseline evaluable patients (4.4%) in Group B.

No safety concerns have been observed in patients with anti-rHuPH20 antibodies.

## 2.6.8.8 Safety related to drug-drug interactions and other interactions

No formal drug-drug or drug-food interaction assessments were conducted.

<div style=\"page-break-after: always\"></div>

## 2.6.8.9 Discontinuation due to adverse events

## Ocarina II Controlled Period and OCR SC All Exposure Analyses

As of the clinical cut-off date, no AEs led to discontinuation of treatment.

## Ocarina I Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC

One patient (0.8%) who received ocrelizumab 1200 mg SC experienced an SAE of Grade 3 multiple sclerosis relapse that led to study drug discontinuation.

One patient (0.8%) who received ocrelizumab 920 mg SC experienced a Grade 2 AE of multiple sclerosis (verbatim  term  recorded  by  investigator:  'worsening  multiple  sclerosis')  that  led  to  study  drug discontinuation.

## 2.6.8.10 Post marketing experience

Post-marketing data summarized in this section originates from the experience with ocrelizumab IV, the only formulation of ocrelizumab marketed to date.

Ocrelizumab was first granted marketing authorization on 28 March 2017, in the United States. In the European Union (EU), ocrelizumab was approved on 8 January 2018, and as of 27 March 2023, it is approved in over 100 countries worldwide.

Since the Developmental International Birth Date on 23 December 2003 and until 31 March 2023, the estimated cumulative exposure to ocrelizumab (both IV and SC formulations) in clinical trials is 13,087 patients, of which 5,790 patients with RMS, 3,378patients with PPMS; and the rest in other no longer pursued  indications  or  different  categories  (e.g.,  studies  in  both  RMS  and  PPMS  patients,  or  high ocrelizumab dose studies).

Since the International Birth Date (IBD) on 28 March 2017 and until 31 March 2023, the estimated cumulative  market  exposure  to  ocrelizumab  is  302,199  patients.  This  corresponds  to  an  estimated 721,879 PYs of exposure since IBD. The safety data from post-marketing experience and from the ongoing clinical trials overall remained consistent with that observed in the controlled periods of the pivotal  clinical  trials,  with  longer  treatment  duration,  as  well  as  with exposure  of  broader  and  more heterogeneous population.

## 2.6.9 Discussion on clinical safety

## Safety data

The clinical safety database for the SC formulation of ocrelizumab is based on a phase 1b and a phase 3 study (OCARINA I and OCARINA II) in the targeted population. The safety database was summarised in three different safety analyses for OCARINA II (Controlled period analysis, OCR SC all exposure analysis and Switchers analysis) and one for OCARINA I (Patients who Received at Least One Dose of Ocrelizumab 1200 mg SC or 920 mg SC).

In the following assessment the controlled period analysis will be used as main safety analysis, since the main aim is to compare the IV formulation with the SC formulation. The OCR SC all exposure analysis, switchers analysis and OCARINA I analysis will be used as supportive safety analysis.

Ocarina II: During the controlled period, 118 patients received one injection of 920 mg ocrelizumab SC and 118 patients received one infusion of 600 mg ocrelizumab IV. The median treatment duration was 23.50 weeks (range: 12.3-27.7 weeks) in OCR SC and 23.43 weeks (range: 0.1-34.7 weeks) in OCR IV.

63 patients (53.4%) in ocrelizumab SC received a second ocrelizumab SC injection (Dose 2) at Week 24 and 63 patients (53.4%) in ocrelizumab IV received their first ocrelizumab SC injection (Dose 2) at Week 24. As of the clinical cut-off date, no patients in either arm had reached Week 48 of the study and therefore none received Dose 3.

<div style=\"page-break-after: always\"></div>

Throughout the treatment phase, 181 patients received at least one injection of ocrelizumab SC with a median treatment duration of 17.71 weeks (range 0.1 - 44.6 weeks) and a total observation time on ocrelizumab SC of 70.46 PY. A total of 244 ocrelizumab SC injections were administered throughout the study.

Ocarina I: In total,  125  patients  received  at least one injection of  ocrelizumab  1200  mg  SC,  and  a maximum of 5 consecutive injections of this dose have been administered. Overall, 346 injections of 1200 mg ocrelizumab SC were administered in OCARINA I.

In  total,  118  patients  received  at  least  one  injection  of  ocrelizumab  920  mg  SC.  A  maximum  of  4 consecutive  injections  of  920  mg  SC  have  been  administered  as  of  the  cut-off  date.  Overall,  262 injections of 920 mg ocrelizumab SC have been administered in OCARINA I, as of the cut-off date.

In total, 131 patients received at least one dose of ocrelizumab 1200 mg SC or 920 mg SC. The median overall SC ocrelizumab treatment duration was 96.0 weeks (range: 0.1-159.1). 92.4% of patients were treated  with  SC  ocrelizumab  for ≥ 48 weeks and 94.7% of patients received 3 or more doses of SC ocrelizumab.

Overall, the safety database consisted of a total of 312 patients treated with at least one injection of ocrelizumab SC. A total of 246 patients were treated with ocrelizumab SC for at least 24 weeks and 121 patients were treated with ocrelizumab SC beyond 48 weeks and 99 were treated with ocrelizumab SC beyond 96 weeks. The SC safety database is limited with regard to the total exposure. However, since the safety profile is well-known from the ocrelizumab IV, the total exposure is considered acceptable since  the  patient  population  and  active  substance  is  the  same.  Furthermore,  long-term  safety  of ocrelizumab treatment is missing information in the safety specification in the RMP and two PASS studies are  ongoing  for  the  IV  formulation.  The  MAH  states  that  the  safety  data  from  the  OCARINA  I  and OCARINA II studies will be presented in the final CSRs, which will be submitted when they are available.

## Adverse events

OCARINA II: Controlled Period Analysis: AEs were reported more frequent in the OCR SC arm (73.7%) compared to the OCR IV arm (45.8%).

The difference in AEs is primarily due to the difference reported in Injection reactions (IRs) in the OCR SC arm and infusion related reactions (IRRs) in the OCR IV arm; 48.3% patients experienced at least one IR in the OCR SC arm and 16.9% patients experienced at least one IRR in the OCR IV arm.

With regard to the IRs in the OCR SC arm, 45.8% patients experienced at least one local injection reaction (LIR) and 11.0% patients experienced at least one systemic injection reaction (SIR).

Anaphylactic reactions and hypersensitivity (identified using the' Anaphylactic reaction' and 'hypersensitivity' (SMQ)) were reported more often in the OCR SC arm compared to the OCR IV arm (4.2%  and  49.2%  vs.  2.5%  and  19.5%).  The  SmPC  have  been  updated  to  reflect  the  risk  of hypersensitivity and appropriate risk minimisation measures.

Infections were also reported more frequent in the OCR SC arm (34.7%) compared to the OCR IV arm (28.0%). However, serious infections were only observed in the OCR IV arm (3.4%).

AEs of grade ≥ 3 and serious were reported slightly more frequent in the OCR IV arm (5.9% and 3.4%) compared  to  the  OCR  SC  arm  (3.4%  and  2.5%).  No  deaths  were  reported,  and  no  AEs  led  to discontinuation of treatment.

OCARINA II: OCR SC All Exposure Analysis: AEs were reported in 63.5% of patients in the OCR SC All group. 47.5% patients in the OCR SC All group experienced at least one IR; 44.8% patients experienced at least one LIR and 12.2% patients experienced at least one SIR. No deaths were reported, and no AEs led to discontinuation of treatment.

OCARINA I: Ocrevus SC (at Least One Dose of 920 or 1200 mg): AEs were reported in 96.9% in patients receiving OCR SC 920 or 1200 mg. 23.7% had AEs of grade 3 and 12.2% has serious adverse events. One adverse event with fatal outcome were reported and 2 (1.5%) AEs leading to withdrawal from treatment. The AE leading to death were in the ocrelizumab 1200 mg dose. IRs were reported more

<div style=\"page-break-after: always\"></div>

frequent in the ocrelizumab 1200 mg group compared to 900 mg (75.2% vs. 57.6%) and the same pattern was seen with anaphylactic reactions and hypersensitivity (10.4% 29.6% vs. 5.9% and 13.6%).

Overall, AEs were reported more frequent in OCR SC compared to OCR IV. The difference in AEs is primarily due to the difference reported in Injection reactions (IRs) in the OCR SC arm and infusion related reactions (IRRs) in the OCR IV arm. Anaphylactic reactions and hypersensitivity were reported more often in the OCR SC compared to OCR IV. Appropriate risk minimisation measures have been added to the SmPC section 4.2 to minimise this risk for the SC formulation.

## Common adverse events

OCARINA II: Controlled Period Analysis: In the Controlled Period Analysis, the most common reported AEs were Injection related reaction (46.6% in OCR SC), Headache (10.2% in OCR SC vs. 2.5% in OCR IV), Infusion related reactions (16.9% in OCR IV), Upper respiratory tract infection (6.8% in OCR SC vs. 7.6% in OCR IV) Covid-19 (6.8% in OCR SC vs. 4.2% in OCR IV) and Bronchitis (1.7% in OCR SC vs. 5.1% in OCR IV). Headache is not in the Adverse reaction table in the SmPC section 4.8. The MAH states that, among the 12 patients in the OCR SC arm that experienced an AE of Headache, 5 had a medical history of headache, and 3 reported the headache more than 4 months after the last ocrelizumab dose. Three AEs of Headache occurred 1-4 days after ocrelizumab SC and were considered by the investigator to be related to study treatment. The imbalance for headache observed in the OCARINA II study (10.2% in the SC arm versus 2.5% in the IV arm), were mainly driven by events assessed as not related to ocrelizumab SC by the investigator and caused by other causes (other/concomitant medications). None of the 3 events of headache in the IV group were assessed by the investigator as related to ocrelizumab IV and none had a history of headache reported. Most of the reported AEs of headache were causally not associated with ocrelizumab treatment as assed by the investigator. The remaining AEs, assessed as to be causally associated with ocrelizumab, had an onset time indicative of them being a symptom of systemic IR (1-4 days).

Overall, the Applicant has justified not including headache as a separate ADR for ocrelizumab SC. Since headache is characterized as a common symptom associated with systemic injection reactions in Section 4.4 and Section 4.8, it is considered acceptable not to include headache as a separate ADR in section 4.8.

Overall, the proportions of patients with AEs of Grade 3 were comparable between the two treatment arms (3.4% in the OCR SC arm vs. 5.9% in the OCR IV arm).

OCARINA II: OCR SC All Exposure Analysis: In the OCR SC All Exposure Analysis, the most common reported AEs were Injection related reaction (44.8%) and Headache (6.6%), COVID-19 (5.0%), Upper respiratory tract infection (5.0%) and Nasopharyngitis (3.3%). All AEs of Headache were reported during the controlled period.

The proportion of patients with AEs of Grade 3 was 2.2%. The Grade 3 AEs by PT were: Eye pain, Lymphocyte count decreased, Back pain and Multiple sclerosis  relapse,  each  reported  at  least  once (0.6%).

OCARINA I: Ocrevus SC (at Least One Dose of 920 or 1200 mg): In OCARINA I, the most common reported AES were similar to OCARINA II; Injection site reaction (52.5%), COVID-19: (21.2%) and Injection related reaction (11.0%) in the 920 mg dose group and Injection site reaction (72.0%), COVID19 (33.6%), Injection related reaction (20.8%), Fatigue (16.0%), Headache (13.6%) and Urinary tract infection (11.2%).

The majority of patients who experienced AEs had AEs of Grade 1 or 2 (89.4% in 920mg dose and 80.3% in 1200 mg dose).

Overall, the most comment reported adverse events were generally mild in severity and manageable. The most common AEs are represented in the ADR table in the SmPC section 4.8, except for Headache and Covid-19. Due to the Covid-19 pandemic and the lack of a placebo arm, causal relationship between Covid-19 and ocrelizumab cannot be concluded.

## Serious adverse events and Deaths, other significant events

<div style=\"page-break-after: always\"></div>

## Serious adverse events

OCARINA  II:  Controlled  Period  Analysis:  The  proportions  of  patients  with  at  least  one  SAE  were comparable between the two treatment arms (2.5 % in the OCR SC arm vs. 3.4% in the OCR IV arm).

In the OCR SC arm, the SAEs were Multiple sclerosis pseudo relapse, Multiple sclerosis relapse, Eye pain, and Anxiety, reported at least once in one patient (0.8 %). All were considered by the investigator to not be related to study treatment.

In the OCR IV arm, the SAEs were Appendicitis, Cellulitis staphylococcal, Pneumonia, Subcutaneous abscess, Upper respiratory tract infections, and Diabetes mellitus, each reported at least once (0.8 %). All SAEs were considered by the investigator to not be related to study treatment, except for the AE of Upper respiratory tract infection.

OCARINA II: OCR SC All Exposure Analysis. The proportions of patients with at least one SAE in the OCR SC All group was 1.7%. All SAEs were reported during the controlled period and are described above.

OCARINA I: Ocrevus SC (at Least One Dose of 920 or 1200 mg): Among patients who received at least one dose of ocrelizumab 1200 mg SC, the proportion of patients with at least one SAE was 9.6% (12 patients).  The  SAEs  were:  COVID-19  (3.2%);  COVID-19  pneumonia  (3.2%);  pneumonia  (2.4%); multiple  sclerosis  relapse  (1.6%);  and  encephalitis,  asthenia,  muscular  weakness,  and  pulmonary embolism (0.8% each).

Among patients who received at least one dose of ocrelizumab 920 mg SC, the proportion of patients with  at  least  one  SAE  was  3.4%.  The  SAEs  were  (0.8%  each):  COVID-19,  COVID-19  pneumonia, pneumonia, papillary thyroid cancer, and nephrolithiasis.

Overall, no SAEs in the OCR SC 920 mg group were reported in more than one patient each.

## Deaths

One death was reported in a patient who received OCR SC 1200 mg. The patient died due to an SAE of COVID-19  pneumonia.  It  was  reported  that  pneumothorax  and  renal  failure  were  complications  of COVID-19. The investigator assessed the event of COVID-19 pneumonia as unrelated to ocrelizumab SC.  Comorbidities  have  probably  contributed  to  the  outcome  of  death.  However,  ocrelizumab  are associated  with  a  higher  risk  of  infections,  infections  are  an  important  identified  risk  in  the  safety specification in the RMP, and serious infections were especially reported in the SC 1200 mg dose group. Any sound conclusion on the risk cannot be made, but it is reassuring that the MAH has chosen the 920 mg dose and nor the 1200 mg dose.

## Adverse events of special interest

None of the predefined adverse events of special interest (cases of potential drug-induced liver injury, cases of suspected transmission of an infectious agent by the study drug, or cases of Grade 3 or higher injection site reactions) were reported in OCARINA II or OCARINA I. Dedicated analysis was performed for IRRs, IRs, infections, hypersensitivity, anaphylactic reactions and malignancies. These are assessed below.

## Selected adverse events

## Injection Reactions

OCARINA II: Controlled Period Analysis: Injection reactions were reported in 48.3% patients with the first injection. None were serious. 71.9% were of Grade 1 severity and 28.1% were of grade 2 severity. No patients had an IR of Grade 3 or higher. Most (86.7%) occurred within 6 hours of the injection. The median time from the end of injection administration to IR onset was 0.265 hours (range: -0.15 to 14.85).  Treatment  was  provided  to  28.1%  of  patients.  Treatment  for  IRs  was  standard  of  care treatments, including mostly analgesics (e.g., ibuprofen, paracetamol), and oral or topical antihistamines (e.g., diphenhydramine, cetirizine).

Local  Injection  Reactions  were  reported  in  45.8%  of  the  patients  with  the  first  injection.  The  most common symptoms were Erythema (29.7%), Pain (14.4%), Swelling  (8.5%)  and  Pruritus  (6.8  %).

<div style=\"page-break-after: always\"></div>

64.3% occurred within 1 hours of the injection. The median time from the end of injection administration to LIR onset was 0.265 hours (range: -0.15 to 14.85).

Systemic Injection Reactions were reported in 11.0% of the patients with the first injection. The most common symptoms were Headache (2.5%) and Nausea (1.7 %). 46.2% were of Grade 1 maximum severity and 53.8% were Grade 2 maximum severity. Treatment was provided to 38.5% of the patients with SIRs. The median duration of SIRs was 3 days (range: 1 to 16 days). The majority of SIRs (53.8%) resolved within 3 days of onset.

OCARINA  II:  Switchers  Analysis:  The  proportion  of  patients  who  experienced  at  least  one  IR  was comparable between OCR IV patients at their first SC injection and OCR SC patients at their second SC injection (36.5% in OCR IV/SC vs. 41.3% in OCR SC/SC). The intensity of IRs was comparable between OCR IV patients at their first SC injection and OCR SC patients at their second SC injection (87.0% Grade 1 and 13.0% Grade 2 in OCR IV/SC vs. 88.5% Grade 1 and 11.5% Grade 2 in OCR SC/SC). Treatment for IRs was provided in 8.7% in OCR IV/SC and 11.5% in OCR SC/SC.

Local Injection Reactions were reported in 34.9% in OCR IV/SC and 36.5% in OCR SC/SC.

Systemic Injection Reactions were reported in 9.5% in OCR IV/SC and 6.3% (4/63 patients) in OCR SC/SC.

OCARINA II: OCR SC All Exposure Analysis: Injection reactions were reported in 47.5% of patients with any injection. None were serious. 76.7% were of Grade 1 severity and 23.3% were of grade 2 severity. No patients had an IR of Grade 3 or higher. With repeated injections, the incidence of IRs decreased from 44.2% at the first injection to 41.3% at the second injection and the intensity of IRs decreased (76.3% Grade 1 and 23.8% Grade 2 at the first injection vs. 88.5% Grade 1 and 11.5% Grade 2 at the second injection). Treatment was provided to 20.9% of patients and fewer patients required treatment with repeated injections (22.5% after first injection and 11.5% after second injection).

Local Injection Reactions were reported in 44.8%. The incidence of LIRs decreased from 42.0% at the first injection to 36.5% at the second injection. The most common symptoms of LIRs were Erythema (32.6%), Pain (14.9%), Swelling (8.3%) and Pruritus (5.0 %).

Systemic Injection Reactions were reported in 12.2%. The incidence of SIRs decreased from 10.5% at the first injection to 6.3% at the second injection. The most common symptoms of SIRs were Headache (1.7 %), Fever (1.1 %), Flushing (1.1 %), Nausea (1.1 %) and Pain (1.1%).

OCARINA I: Ocrevus SC (at Least One Dose of 920 or 1200 mg): Injection reactions were reported in 75.2% of patients receiving ocrelizumab 1200 mg SC and 57.6% receiving ocrelizumab 920 mg SC.

In the 1200 mg group, 1 patient had a Grade 3 systemic IR (previously treated with ocrelizumab IV prior to study, after first injection of ocrelizumab 1200 mg SC, the patient experienced symptoms of dyspnea and wheezing, 4 hours following completion of ocrelizumab 1200 mg SC, which resolved with anti-allergy treatment after another hour. No other patients had Grade 3 or higher IRs. Treatment was provided to 24.5% of patients who experienced IRs in the 1200 mg dos group and 10.3% in the 920 mg dose group. Concomitant medications received for injection reaction symptoms were standard treatments, mostly analgesics  (e.g.,  paracetamol,  ibuprofen),  antihistamines  (e.g.,  diphenhydramine,  loratadine),  and corticosteroids (e.g., hydrocortisone, prednisone).

Local Injection Reactions were reported in 72.0% of patients receiving 1200 mg SC and 52.5% receiving 920 mg SC. The most common LIR symptoms were: Injection site erythema (46.4%), Injection site pain: (46.4%), Injection site swelling (27.2%) and Injection site bruising (15.2%) in the 1200 mg dose group  and  Injection  site  pain  (33.9%),  Injection  site  erythema  (23.7%)  and  Injection  site  swelling (22.0%) in the 920 mg dose group.

Systemic Injection Reactions were reported in 20.0% of patients receiving ocrelizumab 1200 mg SC and 11.0% of patients receiving ocrelizumab 920 mg SC. The most common SIR symptoms were Headache (8.8%), Flushing (3.2%) and Tachycardia (1.6%) in the 1200 mg dose group and headache (2.5%) in the 920 mg dose group. All other SIR symptoms occurred in only 1 patient each. One patient had a

<div style=\"page-break-after: always\"></div>

Grade 3 SIR in the 1200 mg dose group, as described above. In the 920 mg dose group, all SIRs were Grade 1 or 2.

Overall, the frequency of IRs was high throughout the studies. The reported injection reactions were mild or moderate in intensity and none were severe. Only one IR in a patient receiving 1200 gm SC were a grade 3 SIR. Local reactions were reported more frequent than systemic reactions. Even though IRs were mostly mild and moderate in intensity, the risk for more severe injection reactions is not completely ruled out and a signal has been seen in the 1200 mg dose for a severe systemic injection reaction. Appropriate risk minimisation measures have been added to the SmPC section 4.2 to minimise the risk for injection reactions, hypersensitivity reactions and anaphylactic reactions for the SC formulation.

## Infusion Related Reactions

Infusion related reactions were reported in 16.9% of patients receiving ocrelizumab IV in OCARINA II. None IRRs were serious. The incidence of IRRs decreased from 16.1% at the Day 1 infusion to 6.0% at the Day 14 infusion. Among patients in OCR IV, the most common symptom of IRRs was Pruritus (3.4%), Headache (2.5%), Erythema (1.7%), Tachycardia (1.7%) and Throat irritation (1.7%). All the IRRs were Grade 1 (45.0%) or Grade 2 (55.0%) severity. Treatment was provided to 45.0% of the patients with IRRs. Treatment for IRRs was standard of care treatments, including mostly IV corticosteroids (e.g., hydrocortisone),  analgesics  (e.g.,  paracetamol),  and  oral  or  IV  antihistamines  (e.g.,  loratadine, chlorphenamine, promethazine).

Overall,  the  IRRs  observed  in  OCARINA  II  support  the  known  safety  profile  with  regard  to  IRRs  in ocrelizumab IV.

## Infections

OCARINA II: Controlled Period Analysis: Infections were reported in 34.7% in the OCR SC arm and 28.0% in the OCR IV arm. The most frequent infections by PT were Upper respiratory tract infection (6.8% vs. 7.6%), COVID-19 (6.8% vs. 4.2%) and Bronchitis (1.7% vs. 5.1%). No patients in the OCR SC arm had a serious infection. In the OCR IV arm, 4 patients (3.4%) had a serious infection. The serious infections  were  Appendicitis,  Cellulitis  staphylococcal,  Pneumonia,  Subcutaneous  abscess  and  Upper respiratory  tract  infection.  No  infections  of  Grade  3  were  reported  in  the  OCR  SC  arm.  All  serious infections in the OCR IV arm were of Grade 3.

OCARINA II: OCR SC All Exposure Analysis: Infections were reported in 26.0% in the OCR SC All group. The most frequent infections by PT were Upper respiratory tract infection (5.0%) and COVID-19 (5.0%). No patients in the OCR SC All group had a serious infection. No infections of Grade 3 or more in severity were reported.

OCARINA I: Ocrevus SC (at Least One Dose of 920 or 1200 mg): In the ocrelizumab 1200 mg SC group, infections were reported in 56.0% and 8.8% had a serious infection. 8.8% was a Grade 3 infection and 1 patient (0.8%) had a Grade 5 infection. All other infections were Grade 1 or 2. The Grade 3 infections were: COVID-19 (4.0%), pneumonia (2.4%), COVID-19 pneumonia (0.8%), encephalitis (0.8%), SARSCoV-2 sepsis (0.8%), and tooth abscess (0.8%). The Grade 5 infection AE was COVID-19 pneumonia. The  most  frequent  infections  by  PT  were  COVID-19  (33.6%),  Urinary  tract  infection  (11.2%), Nasopharyngitis (7.2%), Sinusitis (4.8%), Pneumonia (4.0%), COVID-19 pneumonia (3.2%).

In  the  ocrelizumab  920  mg  SC  group,  infections  were  reported  in  39.8%  and  1.7%  had  a  serious infection. 3.4% had Grade 3 infections. All other infections were Grade 1 or 2. The Grade 3 infections were  COVID-19  (1.7%),  pneumonia  (0.8%),  COVID-19  pneumonia  (0.8%),  and  Clostridium  difficile infection (0.8%). The most frequent infections by PT were COVID-19 (21.2%), Urinary tract infection (6.8%), Bronchitis (5.1%), Nasopharyngitis: 4.2% and Upper respiratory tract infection (4.2%). The serious infections were COVID-19 (0.8%), COVID-19 pneumonia (0.8%) and Pneumonia (0.8%).

Overall, infections were reported more frequent in OCR SC compared to OCR IV in OCARINA II. However, the infections in OCR SC were less severe and none were serious compared to OCR IV.

In OCARINA I, infections were reported more frequent and the infections were more frequent severe and serious in the 1200 mg dose group compared to the 920 mg dose group, which support the chosen dose

<div style=\"page-break-after: always\"></div>

of 920 mg. The most common infections reported are all included in the ADR table in the SmPC section 4.8,  except  for  Covid-19.  Due  to  the  Covid-19  pandemic  and  the  lack  of  a  placebo  arm,  causal relationship between Covid-19 and ocrelizumab cannot be concluded.

## Hypersensitivity and Anaphylactic Reaction Events

Anaphylactic reactions and hypersensitivity (identified using the' Anaphylactic reaction' and 'hypersensitivity' (SMQ)) were reported more often in the OCR SC arm compared to the OCR IV arm (4.2% and 49.2% vs. 2.5% and 19.5%). In OCARINA I 13.7% had Anaphylactic reactions and 33.6% Hypersensitivity.

The MAH states that none of the AEs were confirmed to be hypersensitivity or anaphylactic reactions but rather  IRs,  IRRs  or  respective  symptoms  of  the  LIRs,  SIRs  and  IRRs.  The  MAH  described  how hypersensitivity and anaphylactic reactions were distinguish from IRs or IRRs. Different criteria were set up  for  infusion  related  reactions,  injection  reactions,  hypersensitivity  and  anaphylactic  reactions  in OCARINA I and II. Hypersensitivity can be difficult to distinguish from IR and IRR in terms of symptoms. This is reflected in the SmPC section 4.4.

The MAH discussed the Grade 3 IR with symptoms of dyspnoea and wheezing in Study OCARINA I.  The adverse event occurred in a patient who was treated with ocrelizumab IV prior to entering the study, and reported repeated mild hypersensitivity reactions upon prior IV administration. This was not known when  enrolling  the  patient.  This  patient  should  not  have  been  included  in  the  clinical  study,  as hypersensitivity to the studied drugs was an exclusion criterion.

The symptoms of dyspnoea and wheezing were assessed by the Applicant as a Grade 3 IR, that was clinically difficult to distinguish from a hypersensitivity reaction. In the SmPC section 4.4, hypersensitivity reactions are described as a potential risk with ocrelizumab, and the difficulties in distinguishing it from IRs/IRRs is described. This is considered acceptable.

## Malignancies

In OCARINA II, no malignancies were reported.

In OCARINA I, two malignancies were reported. One patient experienced a Grade 2 AE of basal cell carcinoma and one patient experienced a Grade 3 AE of papillary thyroid cancer. Both were assessed as unrelated to ocrelizumab SC by the investigator.

Malignancies including breast cancer, is included in the safety specification in the RMP as an important potential risk. No sound conclusion can be made on the risk at this point. A PASS is ongoing for the IV formulation. This is considered to also inform on the SC formulation.

## Laboratory findings

## Hematology and Chemistry

Ocarina II: Controlled Period Analysis: No clinically relevant changes from baseline were observed for mean or median values of any laboratory parameter, in either arm (Data not shown her, but available in the OCARINA II study report).

The proportions of patients with marked laboratory abnormalities were low and comparable between the two treatment arms (Low neutrophils: 3.4% in both arms, High neutrophils: 0 in OCR SC vs. 1.7% in OCR IV, and Low lymphocytes: 1.7% in both arms).

Shifts to NCI CTCAE Grade 3 or 4 post-baseline abnormalities were observed in few patients in both arms (Low lymphocytes: 0.9% in both arms, Low neutrophils: 0 in OCR SC vs. 1.8% in OCR IV and Low leukocyte count: 0 in OCR SC vs. 0.9% in OCR IV).

No clinically meaningful difference was observed between the OCR SC and OCR IV arms with respect to liver tests. All reported liver enzyme elevations were of Grade 1 maximum severity and no cases of potential drug-induced liver injury were reported.

<div style=\"page-break-after: always\"></div>

Ocarina I: Patients who Received at Least One Dose of Ocrelizumab SC: No clinically relevant changes from baseline were observed for mean or median values of any laboratory parameter, in either arm (Data not shown her, but available in the OCARINA I study report).

The most common marked laboratory abnormalities were High neutrophils (40.5%), Low lymphocytes (15.9%), and High total leukocyte count (13.7%). High ALT was observed in 20.6%, High AST in 11.5% and High bilirubin in 3.8%.

All post-baseline liver enzyme elevations were Grade 1, except for one Grade 2 bilirubin elevation. In the majority of cases, the observed elevation in liver enzymes were single occurrences and were not sustained or replicated and not requiring symptomatic treatment or treatment interruption. There were no reported cases of potential drug-induced liver injury.

Shifts  to  NCI  CTCAE  Grade  3  or  4  post-baseline  abnormalities  were  observed  in  a  small  number  of patients for the following laboratory parameters: Low lymphocytes (6.4%), Low potassium (2.3%), High amylase (0.8%), High creatinine (0.8%), Low sodium (0.8%) and Low haemoglobin (0.8%).

Overall, no clinically relevant changes from baseline were observed for mean or median values of any laboratory parameter. The proportions of patients with marked laboratory abnormalities were low and comparable  between  the  two  treatment  arms  in  OCARANA  II.  In  OCARINA  I,  marked  laboratory abnormalities  were  observed  more  frequent.  Shifts  to  NCI  CTCAE  Grade  3  or  4  post-baseline abnormalities were observed in few patients in both studies. No new safety concerns were identified from the laboratory findings.

## Vital signs and ECG

No relevant differences were observed between ocrelizumab SC and ocrelizumab IV with respect to changes in vital signs in OCARINA II or OCRARINA I (Data not shown here for OCARINA I, but available in OCRARINA I study report).

4  patients  (2  treated  with  ocrelizumab  1200  mg  SC  and  2  treated  with  ocrelizumab  600  mg  IV) experienced blood pressure abnormalities reported as AEs (2 AEs of hypertension, 1 AE of blood pressure increased, and 1 AE of hypotension). All 4 events were non-serious, Grade 2, and were resolved or resolving at the time of clinical cut-off date.

No patients had absolute QTcF values &gt; 500 msec. One patient had a change from baseline in QTcF of &gt;

60 msec that occurred 60 minutes after their fifth injection of ocrelizumab 1200 mg SC at Week 96. One patient had a Grade 1 atrioventricular block first degree approximately 5 months after receiving their first dose of ocrelizumab 920 mg SC at Week 48 that led to interruption of ocrelizumab SC treatment.

Overall, blood pressure abnormalities and severe ECG abnormalities were in general low in both studies.

## Safety in special populations

The MAH has not provided any analysis for special populations. The MAH have justified not to include an analyses of safety data by special populations, because no issues were identified in subgroup analyses performed  for  the  IV  clinical  trial  population  with  a  longer  exposure  time.  The  ocrelizumab  SC development program followed the principle of PK bridging. The PK results from studies OCARINA II and OCARINA I support a comparable benefit-risk profile for ocrelizumab SC relative to ocrelizumab IV for sex, body weight and age.

In the SmPC it is stated that safety and efficacy of ocrelizumab for patients with hepatic and renal impairment  has  not  been  formally  studied.  Ocrelizumab  is  a  monoclonal  antibody  and  cleared  via catabolism (rather than hepatic metabolism), and a dose adjustment is not expected to be required for patients with hepatic or renal impairment. This is considered acceptable.

## Immunological events

Overall, no treatment-emergent ADAs to ocrelizumab were observed. As stated in the evaluation of pharmacokinetics methods (2.1.2), immunogenicity status following SC ocrelizumab is not considered

<div style=\"page-break-after: always\"></div>

adequately described, due to poor assay sensitivity and sparse sampling. An OC have been raised due to this concern.

A total of 3 out of 132 patients (2.3%) had treatment-emergent anti-rHuPH20 antibodies in OCARINA I and no treatment-emergent anti-rHuPH20 antibodies was observed in OCARINA II. No safety concerns have been observed in patients with anti-rHuPH20 antibodies.

## Drug-drug interactions

No  formal  (PK  or  PD)  drug-drug  interaction  studies  were  performed  in  the  initial  application  for ocrelizumab  IV,  which  is  acceptable  for  a  mAb.  Due  to  the  effective  and  long-lasting  PD  effect  by depleting CD20-expressing B-cells, the efficacy of vaccinations and the safety if giving live attenuated vaccines was questioned by the initial assessment for ocrelizumab IV. This is not expected to be different in SC use. This is adequately reflected in the SmPC section 4.5.

In the SmPC section 4.5 it is stated that it is not recommended to use other immunosuppressive therapies concomitantly with ocrelizumab except corticosteroids for symptomatic treatment of relapses. Since only one  relapse  was  reported  in  the  studies,  an  analysis  cannot  be  made  on  concomitant  use  of corticosteroids with OCR SC for symptomatic treatment of relapses at this point.

## Discontinuations due to adverse events

No AEs led to discontinuation of treatment in OCARINA II and two AEs led to study drug discontinuation in OCARINA I; SAE of Grade 3 multiple sclerosis relapse in the 1200 mg dose group and a Grade 2 AE of multiple sclerosis (worsening multiple sclerosis) in the 920 mg dose group.

Overall, AEs leading to discontinuations were low. The discontinuation data does not raise any new safety concerns.

## Post marketing experience

The MAH states that the safety data from post-marketing experience and from the ongoing clinical trials remained consistent with that observed in the controlled periods of the pivotal clinical trials. No new concerns are raised for ocrelizumab IV.

## 2.6.10 Conclusions on the clinical safety

Overall, the safety database consisted of a total of 312 patients treated with at least one injection of ocrelizumab SC. A total of 246 patients were treated with ocrelizumab SC for at least 24 weeks and 121 patients were treated with ocrelizumab SC beyond 48 weeks and 99 were treated with ocrelizumab SC beyond  96  weeks.  The  SC  safety  database  is  limited  with  regard  to  the  total  exposure.  Since  the application  relies  on  safety  data  from  the  ocrelizumab  SC,  with  well-known  safety  data  from  the ocrelizumab  IV,  the  total  exposure  is  considered  acceptable  since  the  patient  population  and  active substance is the same.

Overall, available safety data from the clinical development program show that ocrelizumab SC were generally  well  tolerated  and  comparable  to  ocrelizumab  IV.  More  AEs  were  reported  in  the  SC  arm compared to the IV arm in OCARINA II. Injection reactions contributed to the higher frequency in the SC arm. No treatment-emergent ADAs to ocrelizumab were observed. However, immunogenicity status following SC ocrelizumab is not considered adequately described.

## 2.7 Risk Management Plan

The applicant submitted an updated RMP version 9.1 addressing the requests regarding RMP core document and annexes. Further the applicant confirmed that patients with SC administration of ocrelizumab can be included in the ongoing Category 3 studies BA39730 and BA39732 without the need to make additional updates.

<div style=\"page-break-after: always\"></div>

## 2.7.1 Safety concerns

## Summary of safety concerns

The applicant proposed the following summary of safety concerns in the RMP:

Table SVIII.1: Summary of safety concerns

IV=intravenous;SC=subcutaneous

| Summary ofsafety concerns   | Summary ofsafety concerns                                                                                                           |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks  | Infusion-related reactions (observed with the IV formulation) and injection reactions (observed with the SC formulation) Infections |
| Importantpotential risks    | Malignanciesincludingbreast cancer Progressivemultifocal leukoencephalopathy                                                        |
| Missing information         | Safety in pregnancy and lactation Long-termsafetyofocrelizumabtreatment Safety in pediatric population                              |

## Discussion on safety specification

The MAH has updated the important identified risk of infusion related reactions to infusion-related reactions (observed with the IV formulation) and injection reactions (observed with the SC formulation). The other identified risks and missing information was kept from the IV RMP. This is considered appropriate.

## Conclusions on the safety specification

Having considered the data in the safety specification, it is agreed that the safety concerns listed by the applicant are appropriate.

## 2.7.2 Pharmacovigilance plan

| Study/ Status                                                                                                                                                                                                              | Summary of Objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| BA39730- A Long-Term Surveillance of Ocrelizumab- Treated Patients with                                                                                                                                                    | The primary objective is: ● To estimate (overall and by MS type) the event rates of SAEs, including malignancy and serious infections, following ocrelizumab treatment in patients with MS. The secondary objective is:    | Malignancies including breast cancer Progressive multi focal leukoencephalopath y                                                                                                                                          | Start date of study End of study Semi- annual                                                                                                                                                                              | 2019 2028 Cumulative reports submitted with                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Study/ Status                                                                                                                                  | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Safety concerns addressed                            | Milestones                                                                                      | Due dates                                |
|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------|
| Multiple Sclerosis Ongoing                                                                                                                     | ● To compare the incidence of each serious safety event between ocrelizumab-exposed patients with RMS and patients with RMS exposed to other approved disease modifying therapies (DMTs: overall, and by individual DMTs if possible), within the same data source. If sufficient data are available, an exploratory objective of this study is to compare the safety profile of patients with PPMS exposed to ocrelizumab to the safety profile of patients with PPMS not exposed to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Long-term safety of ocrelizumab treatment Infections | safety reports Interim report 1 Interim report 2 Interim report 3 Final report of study results | PBRER 2022 2024 2026 2029                |
| BA39732- A multi-source surveillance study of pregnancy and infant outcomes in ocrelizumab- exposed women with multiple sclerosis (MS) Ongoing | any DMTs. ● To estimate the frequency of selected adverse pregnancy outcomes in women with MS exposed to ocrelizumab during the defined exposure window (i.e., spontaneous abortions, fetal death/stillbirths, elective abortions, preterm births, C- sections, and urinary and other infections in pregnancy) ● To estimate the frequency of selected adverse fetal/neonatal/infant outcomes at birth and up to the first year of life of infants from pregnancies in women with MS exposed to ocrelizumab-i.e., major congenital malformations, small for gestational age, adverse effects on immune system development (e.g., severe infectious disease in the first year of life) ● To compare the frequency of each safety event of interest between ocrelizumab-exposed pregnant women with MS and two comparison cohorts: (1) primary comparison cohort -pregnancies in women with MS who have not been exposed to ocrelizumab (overall and in two strata- pregnancies exposed to any non- ocrelizumab DMTs approved for the treatment of MS or any new DMT approved during the study period [subcohort 1a], and pregnancies not exposed to these | Safety in pregnancy and lactation                    | Protocol Submission : Start of study dataset creation: Study finish Final report                | November 2019 2018 March 2029 March 2030 |

<div style=\"page-break-after: always\"></div>

| Study/ Status                                                                                                                                                                                                | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Safety concerns addressed                                                                | Milestones   | Due dates   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------|-------------|
|                                                                                                                                                                                                              | DMTs [subcohort 1b]) and (2) secondary comparison cohort- pregnancies in women without MS who have not been exposed to ocrelizumab.                                                                                                                                                                                                                                                                                                                                                |                                                                                          |              |             |
| Study WA40404- A Phase IIIb Multicenter, Randomised, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ongoing | To evaluate the safety and efficacy of ocrelizumab (Ocrevus → ) compared with placebo in patients EDSS 3 to 8 using 9HPT as the primary efficacy outcome, and 12 week confirmed disability progression as a key secondary endpoint. Baseline assessment of features characteristic of imaging inflammatory activity (T1 Gd enhancing MRI lesions and/or new/enlarging T2 lesions) will be undertaken to explore treatment effect in subgroups with different inflammatory profiles | Infection Malignancies including breast cancer Long-term safety of ocrelizumab treatment | Final report | June 2024   |

Routine pharmacovigilance is considered sufficient to identify and characterise the risks of the product. The  applicant  confirmed  that  patients  with  SC  administration  of  ocrelizumab  can  be  included  and evaluated in the ongoing category 3 studies BA39730 and BA39732. Also, routine pharmacovigilance is sufficient to monitor the effectiveness of the risk minimisation measures.

## 2.7.3 Risk minimisation measures

## Summary table of pharmacovigilance activities and risk minimization activities by safety concern

| Safety concern                                                                                                           | Risk minimization measures                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Infusion-related reactions (observed with the IV formulation) and injection reactions (observed with the SC formulation) | Routine risk communication: Section 4.2 of the EU SmPC-Posology and method of administration Section 4.4 of the EU SmPC- Special warnings and precautions for use Section 4.8 of the EU SmPC-Undesirable effects Sections 2, 3, and 4 of the EU Package Leaflet Routine risk minimization activities recommending specific clinical measures to address the risk: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Pharmacovigilance activities   |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
|                  | Injection reactions (observed with SC formulation) ● Physicians should alert patients that injection reactions can within 24 hours of injection. ● Patients should be observed for at least one hour after the initial dose of the medicinal product for any symptom of severe injection reactions. ● Appropriate resources for the management of severe reactions of severe injection reactions, hypersensitivity reactions and/or anaphylactic reactions should be available for the initial dose of the medicinal product. ● Shortly before injection, patients should receive premedication to reduce the potential for occurrence of injection reactions. Refer to Section 4.2 of the EU SmPC for ocrelizumab SC-(Posology and method of administration) and to Section 4.4 (Special warnings and precautions for use) for detailed information. Infusion-related reactions (observed with the IV formulation) ● Withholding of antihypertensive treatments should be considered for 12 hours prior to and throughout each ocrelizumab infusion. ● Premedication for infusion-related reactions is required. ● Appropriate resources for the management of severe reactions such as serious IRR, hypersensitivity reactions and/or anaphylactic reactions should be available. ● Patients should be observed for at least one hour after the completion of the ocrelizumab infusion for any symptom of IRR. Physicians should alert patients that an IRR can occur within 24 hours of infusion. Refer to Section 4.2 of the EU SmPC-Posology and method of administration) and to Section 4.4 (Special warnings and precautions for use) for detailed information. Other risk minimization measures beyond the Product Information: Medicine's legal status : Ocrelizumab is a medicinal product subject to restricted medical prescription: Section 4.2 of the EU SmPC states: SC formulation : Treatment should be initiated and supervised by specialised physicians experienced in the diagnosis and treatment of neurological conditions. |                                |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pharmacovigilance activities                                                                                                                                            |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | IV formulations : Treatment should be initiated and supervised by specialised physicians experienced in the diagnosis and treatment of neurological conditions and who have access to appropriate medical support to manage severe reactions such as serious infusion related reactions (IRRs). Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                         |
| Infections       | Routine risk communication: Section 4.3 of the EU SmPC- Contraindications Section 4.4 of the EU SmPC- Special warnings and precautions for use Section 4.8 of the EU SmPC-Undesirable effects Section 2 and 4 of the EU Package Leaflet Routine risk minimization activities recommending specific clinical measures to address the risk: ● An active infection must be excluded prior to ocrelizumab administration, because the infusion must be delayed in patients with an active infection until the infection is resolved. ● It is recommended to verify the patient's immune status before dosing since severely immunocompromised patients should not be treated. ● Physicians should take prompt action for patients presenting with pneumonia because there may be an increased risk of aspiration pneumonia and severe pneumonia in patients treated with ocrelizumab. ● HBV screening should be performed before initiation of treatment with ocrelizumab as per local guidelines because patients with active HBV infection should not be treated with ocrelizumab. Patients with positive serology; carriers of HBV should be referred to a liver disease expert before start of treatment and should be monitored and managed following local medical standards to prevent hepatitis B reactivation. ● For PML, see under respective risk. Refer to Section 4.3 of the EU SmPC- (Contraindications) and to Section 4.4 (Special warnings and precautions for use) for detailed information. Other risk minimization measures beyond the Product Information: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study BA39730 Study WA40404 |

<div style=\"page-break-after: always\"></div>

| Safety concern                              | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pharmacovigilance activities                                                                                                                                                 |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                             | Ocrelizumab is a medicinal product subject to restricted medical prescription. Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                              |
| Malignancies including breast cancer        | Routine risk communication: Section 4.3 of the EU SmPC- Contraindications Section 4.4 of the EU SmPC- Special warnings and precautions for use Section 5.3 of the EU SmPC- Preclinical safety data Section 2 of the EU Package Leaflet Routine risk minimization activities recommending specific clinical measures to address the risk: ● Patients should be asked whether they have an active malignancy, are actively being monitored for a malignancy, or have known risk factor for malignancy, because patients with a known active malignancy should not be treated with ocrelizumab, and individual benefit risk should be considered in patients with known risk factors for malignancies and in patients who are being actively monitored for recurrence of malignancy. Patients should be instructed to follow standard breast cancer screening per local guidelines. Refer to Section 4.3 of the EU SmPC- (Contraindications) and to Section 4.4 (Special warnings and precautions for use) for detailed information. Other risk minimization measures beyond the Product Information: Medicine's legal status : Ocrelizumab is a medicinal product subject to restricted medical prescription. Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study BA39730 Study WA40404      |
| Progressive multifocal leukoencephalopath y | Routine risk communication: Section 4.4 of the EU SmPC- Special warnings and precautions for use Section 2 of the EU Package Leaflet Routine risk minimization activities recommending specific clinical measures to address the risk: ● Physicians should be vigilant for the early signs and symptoms of PML, which can include any new onset, or worsening of neurological signs or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Follow-up questionnaire Additional pharmacovigilance activities: Study BA39730 |

<div style=\"page-break-after: always\"></div>

| Safety concern                    | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pharmacovigilance activities                                                                                                                                              |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   | symptoms. If PML is suspected, dosing with ocrelizumab must be withheld. Evaluation including MRI scan preferably with contrast (compared with pre-treatment MRI), confirmatory CSF testing for JCViral Deoxyribonucleic acid and repeat neurological assessments, should be considered. If PML is confirmed treatment must be discontinued permanently. As for any other active infection, current PML is a contraindication for treatment with ocrelizumab. Refer to Section 4.3 of the EU SmPC- (Contraindications) and to Section 4.4 (Special warnings and precautions for use) for detailed information. Other risk minimization measures beyond the Product Information: Medicine's legal status : Ocrelizumab is a medicinal product subject to restricted medical prescription. Additional risk minimization measures:                                                                                                                                                                            |                                                                                                                                                                           |
| Safety in pregnancy and lactation | Routine risk communication: Section 4.4 of the EU SmPC- Special warnings and precautions for use Section 4.6 of the EU SmPC- Section 4.6 Fertility, pregnancy and lactation Section 5.3 of the EU SmPC-Preclinical safety data Section 2 of the EU Package Leaflet. Routine risk minimization activities recommending specific clinical measures to address the risk: ● Women of childbearing potential should be instructed that they should use contraception while receiving ocrelizumab and for 12 months after the last infusion of ocrelizumab. ● For activities required in case that an infant is exposed in utero to ocrelizumab, please refer to the risk of impaired immunisation response. ● Women should be advised to discontinue breast-feeding during ocrelizumab therapy. Refer to Section 4.4 (Special warnings and precautions for use) and Section 4.6 (Fertility, pregnancy and lactation) for detailed information. Other risk minimization measures beyond the Product Information: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Guided questionnaire Additional pharmacovigilance activities: Study BA39732 |

<div style=\"page-break-after: always\"></div>

| Safety concern                            | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance activities                                                                                                                                            |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                           | Ocrelizumab is a medicinal product subject to restricted medical prescription. Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                         |
| Long-term safety of ocrelizumab treatment | Routine risk communication: Section 3 of the EU Package Leaflet. Routine risk minimization activities recommending specific clinical measures to address the risk: None Other risk minimization measures beyond the Product Information: Medicine's legal status : Ocrelizumab is a medicinal product subject to restricted medical prescription. Additional risk minimization measures:                                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study BA39730 Study WA40404 |
| Safety in pediatric population            | Routine risk communication: Section 4.2 of the EU SmPC 'Posology and method of administration' Section 2 of the EU Package Leaflet. Routine risk minimization activities recommending specific clinical measures to address the risk: None Other risk minimization measures beyond the Product Information: Medicine's legal status : Ocrelizumab is a medicinal product subject to restricted medical prescription. Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                        |

The PRAC Rapporteur agrees that routine risk minimisation activities are considered sufficient to manage the safety concerns of the medicinal products.

## 2.7.4 Conclusion

The CHMP and PRAC considered that the risk management plan version 9.1 is acceptable.

## 2.8 Pharmacovigilance

## 2.8.1 Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

<div style=\"page-break-after: always\"></div>

## 2.8.2 Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9 Non-Conformity of paediatric studies

N/A

## 2.10 Product information

## 2.10.1 User consultation

N/A

## 2.10.2 Labelling exemptions

The request to omit certain particulars from the immediate labelling of the vial as per Art.63.3 and display  the  minimum  particulars  has  been  found  acceptable  by  the  QRD  Group  due  to  the  space constraints and the fact that Ocrevus 920 mg solution for injection is to be administered under the supervision of a healthcare professional.

## 2.10.3 Quick Response (QR) code

N/A

## 2.10.4 Additional monitoring

N/A

## 3. Benefit-Risk Balance

## 3.1 Therapeutic Context

## 3.1.1 Disease or condition

MS  is  a  chronic  autoimmune  and  neurodegenerative  disorder  of  the  CNS  that  is  characterised  by inflammation, demyelination, and oligodendrocyte and neuronal loss.

## 3.1.2 Available therapies and unmet medical need

Patients with MS are offered a number of biologic therapies that are provided by different administration routes and in a variety of different settings, ranging from in-office neurology practices and hospitalaffiliated settings, to free-standing infusion centers.

An alternative method of administration with a shorter procedure duration, while keeping the 6 monthly administration regimen, could improve treatment access for patients with MS.

The marketed formulation of ocrelizumab is given by IV infusion over 2 to 3.5 hours and patients are observed for at least one hour after the completion of the infusion. Patients go through the procedure of transit to and from the institution, lead time for IV premedication, the infusion itself and the 1-hour postinfusion observation.

<div style=\"page-break-after: always\"></div>

An alternative SC dosing form with a shorter administration time (approximately 10 minutes) could be preferred by some patients and healthcare providers. However, the lead time for premedication and the observation time are still considered necessary.

## 3.1.3 Main clinical studies

The ocrelizumab SC clinical development program consists of two studies:

- Safety and tolerability, PK, pharmacodynamics (PD), and immunogenicity were assessed in the initial study OCARINA I, a dose escalation study in RMS and PPMS patients.
- PK, PD, safety, immunogenicity, radiological and clinical effects of the dose selected based on data obtained in OCARINA I was assessed in the pivotal study OCARINA II.

Studies OCARINA II and OCARINA I are both ongoing in their treatment continuation periods.

## 3.2 Favourable effects

The pivotal OCARINA II was a non-inferiority trial to compare 920 mg SC ocrelizumab to 600 mg (=2x300 mg) IV ocrelizumab. The primary endpoint, AUCW1-12 after SC injection of 920 mg ocrelizumab, was shown to be non-inferior to the 600 mg IV administration (2 x 300 mg infusions given 2 weeks apart). The GMR for AUCW1-12 was 1.2851 (90% CI: 1.2258;1.3473). Non-inferiority was also shown based on the estimated AUC up to Week 24. Ocrelizumab Cmax values were comparable between the 920 mg SC and the 2 x 300 mg IV arm.

Treatment with ocrelizumab SC and ocrelizumab IV led to a rapid and overall sustained depletion of CD19+ B cells in blood. The mean proportion of patients achieving CD19+ B cell ≤ 5 cells/µL and &lt; 10 cells/µL following a single dose up to Week 24 were comparable between ocrelizumab SC and IV.

Detectable MRI lesions were also evaluated as secondary endpoints and did not show any difference between the two administration methods.

## 3.3 Uncertainties and limitations about favourable effects

The mean ratio of the analysis of OCARINA II AUCs W1-12, is 1.29 with a 90%CI of 1.23 - 1.35. The GMR is &gt;0.8 and thus fulfilling the one-sided non-inferiority criteria as outlined in the SAP. The result shows a nominally significant difference between the two treatments and that ocrelizumab SC 920 mg exposure expressed as AUC is higher than ocrelizumab IV 600 mg. The Applicant provided an exposuresafety analysis considering the SC and IV data in different exposure ranges. No meaningful difference was seen over the different exposure quartiles for SAEs, serious infections, infections, IRs and IRRs. The exposure-safety analysis confirms that the increased exposure that is seen for the SC formulation does not translate into a worse safety profile.

Regarding the efficacy, OCARINA II was an open label study with descriptive statistics and the efficacy data should be considered exploratory/supportive only. The secondary and exploratory efficacy endpoints do not raise concerns on any imbalance between arms. Long-term efficacy data for ocrelizumab SC are not available in order to assess persistence of efficacy or tolerance.

In relation to the immunogenicity, validated methods were used for quantification of ocrelizumab and for immunogenicity testing of ADAs against ocrelizumab or the SC vehicle, rHuPH20. The ocrelizumab ADA assay had limited drug tolerance. Samples taken every 24 weeks will allow for detection of persistent ADAs, however, there is potential to miss detection of immunogenicity at early onset.

## 3.4 Unfavourable effects

In OCARINA II, AEs were reported more frequent in the OCR SC arm (73.7%) compared to the OCR IV arm (45.8%). The difference in AEs is primarily due to the difference reported in Injection reactions (IRs)

<div style=\"page-break-after: always\"></div>

in the OCR SC arm and infusion related reactions (IRRs) in the OCR IV arm; 48.3% patients experienced at least one IR in the OCR SC arm and 16.9% patients experienced at least one IRR in the OCR IV arm.

In OCARINA I, AEs were reported in 96.9% in patients receiving OCR SC 920 or 1200 mg. 23.7% had AEs of grade 3 and 12.2% has serious adverse events. One adverse event with fatal outcome were reported and 2 (1.5%) AEs leading to withdrawal from treatment. The AE leading to death were in the ocrelizumab  1200  mg  dose.  IRs  were  reported  more  frequent  in  the  ocrelizumab  1200  mg  group compared to 900 mg (75.2% vs. 57.6%).

With regard to the IRs in the OCR SC arm in OCARINA II, 45.8% patients experienced at least one local injection reaction (LIR) and 11.0% patients experienced at least one systemic injection reaction (SIR). None were serious. 71.9% were of Grade 1 severity and 28.1% were of grade 2 severity. No patients had an IR of Grade 3 or higher. Local Injection Reactions were reported in 45.8% of the patients with the first injection. The most common symptoms were Erythema (29.7%), Pain (14.4%), Swelling (8.5%) and Pruritus (6.8 %). Systemic Injection Reactions were reported in 11.0% of the patients with the first injection. The most common symptoms were Headache (2.5%) and Nausea (1.7 %). 46.2% were of Grade 1 maximum severity and 53.8% were Grade 2 maximum severity. Treatment was provided to 38.5% of the patients with SIRs.

Infections were also reported more frequent in the OCR SC arm (34.7%) compared to the OCR IV arm (28.0%). However, serious infections were only observed in the OCR IV arm (3.4%). The most frequent infections by PT were Upper respiratory tract infection (6.8% vs. 7.6%), COVID-19 (6.8% vs. 4.2%) and Bronchitis (1.7% vs. 5.1%). No patients in the OCR SC arm had a serious infection. In the OCR IV arm, 4 patients (3.4%) had a serious infection.

Overall, AEs of grade ≥ 3 and serious were reported slightly more frequent in the OCR IV arm (5.9% and 3.4%) compared to the OCR SC arm (3.4% and 2.5%). No deaths were reported, and no AEs led to discontinuation of treatment.

In the Controlled Period Analysis, the most common reported AEs were Injection related reaction (46.6% in OCR SC), Headache (10.2% in OCR SC vs. 2.5% in OCR IV), Infusion related reactions (16.9% in OCR IV), Upper respiratory tract infection (6.8% in OCR SC vs. 7.6% in OCR IV) Covid-19 (6.8% in OCR SC vs. 4.2% in OCR IV) and Bronchitis (1.7% in OCR SC vs. 5.1% in OCR IV).

In OCARINA I, the most common reported AES were similar to OCARINA II.

Overall, the most common reported adverse events were generally mild in severity and manageable for the 920 mg dose.

## 3.5 Uncertainties and limitations about unfavourable effects

Overall, the safety database consisted of a total of 312 patients treated with at least one injection of ocrelizumab SC. A total of 246 patients were treated with ocrelizumab SC for at least 24 weeks and 121 patients were treated with ocrelizumab SC beyond 48 weeks and 99 were treated with ocrelizumab SC beyond  96  weeks.  The  SC  safety  database  is  limited  with  regard  to  the  total  exposure.  Since  the application  relies  on  safety  data  from  the  ocrelizumab  SC,  with  well-known  safety  data  from  the ocrelizumab  IV,  the  total  exposure  is  considered  acceptable  since  the  patient  population  and  active substance is the same. However, as ocrelizumab is intended to be used as a chronic therapy, long-term safety of ocrelizumab treatment is missing information in the safety specification in the RMP and two PASS studies are ongoing for the IV formulation.

Anaphylactic reactions and hypersensitivity (identified using the' Anaphylactic reaction' and 'hypersensitivity' (SMQ)) were reported more often in the OCR SC arm compared to the OCR IV arm (4.2% and 49.2% vs. 2.5% and 19.5%). In OCARINA I 13.7% had Anaphylactic reactions and 33.6% Hypersensitivity.  The  MAH  states  that  none  of  the  AEs  were  confirmed  to  be  hypersensitivity  or anaphylactic reactions but rather IRs, IRRs or respective symptoms of the LIRs, SIRs and IRRs. The MAH described how hypersensitivity and anaphylactic reactions were distinguish from IRs or IRRs. Different criteria were set up for infusion related reactions, injection reactions, hypersensitivity and anaphylactic

<div style=\"page-break-after: always\"></div>

reactions in OCARINA I and II. Hypersensitivity can be difficult to distinguish from IR and IRR in terms of symptoms. This is reflected in the SmPC section 4.4.

With regard to injection reactions, even though IRs were mostly mild and moderate in intensity, the risk for more severe injection reactions is not completely ruled out and a signal has been seen in the 1200 mg dose for a severe systemic injection reaction.

In total, two malignancies were reported in the studies. One patient experienced a Grade 2 AE of basal cell carcinoma and one patient experienced a Grade 3 AE of papillary thyroid cancer. Both were assessed as unrelated to ocrelizumab SC by the investigator. Malignancies including breast cancer, is included in the safety specification in the RMP as an important potential risk. No sound conclusion can be made on the risk at this point. A PASS is ongoing for the IV formulation. This is considered to also inform on the SC formulation.

Overall, no treatment-emergent ADAs to ocrelizumab were observed. However, immunogenicity status following  SC  ocrelizumab  is  not  considered  adequately  described,  due  to  poor  assay  sensitivity  and sparse sampling.

## 3.6 Effects Table

Table 30 Effects Table for Ocrevus (RMS and PPMS)

| Effect                           | Short Description                                                                                                                                | Unit                                | Ocrevus IV         | Ocrevus SC         | Uncertainties/ Strength of evidence                                                                                                 | Reference s           |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Favourable Effects               | Favourable Effects                                                                                                                               | Favourable Effects                  | Favourable Effects | Favourable Effects | Favourable Effects                                                                                                                  | Favourable Effects    |
|                                  |                                                                                                                                                  |                                     | N=116              | N=116              |                                                                                                                                     |                       |
| Primary PK endpoint              | Serum ocrelizumab area under the concentration - time curve (AUC W1 - 12 ) after SC administration compared to IV infusion from Day 1 to Week 12 | AUC W1 - 12 mean (SD) (µg/m L•day ) | 2750 (796)         | 3500 (914)         | Unc : Exposure 29% higher (GMR) after SC administration compared to IV administration. This gives uncertainty related to the safety | CN42097 (OCARIN A II) |
| Effect estimate                  |                                                                                                                                                  | GMR (90% CI)                        | 1.29 (1.23 - 1.35) |                    |                                                                                                                                     |                       |
| Secondary radiologica l endpoint | Total number of T1Gd+ lesions at week 8 and 24 detected by brain MRI                                                                             | Total numb er of lesion s           | N=112 24           | N=112 17           | Unc : exploratory analyses (predefined)                                                                                             |                       |
|                                  | Total number of new or enlarging T2 lesions as detected by brain MRI at Weeks 12 and 24 relative to the previous scan, respectively              | Total numb er of lesion s           | N=65 N=0           | N=61 N=2           | Unc : exploratory analyses (predefined)                                                                                             |                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect               | Short Description    | Unit                 | Ocrevus IV           | Ocrevus SC           | Uncertainties/ Strength of evidence   | Reference s           |
|----------------------|----------------------|----------------------|----------------------|----------------------|---------------------------------------|-----------------------|
| Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                  | Unfavourable Effects  |
|                      |                      |                      | N=118                | N=118                |                                       |                       |
| Adverse events       | Incidence            | %                    | 45.8                 | 73.7                 |                                       | CN42097 (OCARIN A II) |
| IRR                  | Incidence            | %                    | 16.9                 | 0                    |                                       | CN42097 (OCARIN A II) |
| IR                   | Incidence            | %                    | 0                    | 48.3                 |                                       | CN42097 (OCARIN A II) |
| Local IRs            | Incidence            | %                    | 0                    | 45.8                 |                                       | CN42097 (OCARIN A II) |
| Systemic IRs         | Incidence            | %                    | 0                    | 11.0                 |                                       | CN42097 (OCARIN A II) |
| Infections           | Incidence            | %                    | 28.0                 | 34.7                 |                                       | CN42097 (OCARIN A II) |
| Headache             | Incidence            | %                    | 2.5                  | 10.2                 |                                       | CN42097 (OCARIN A II) |

Abbreviations: IRR: Infusion related reaction, IR: Injection reaction Notes:

## 3.7 Benefit-risk assessment and discussion

## 3.7.1 Importance of favourable and unfavourable effects

Non-inferior exposure AUC1-12w was shown for ocrelizumab SC compared with the IV formulation and even a significantly higher exposure was seen for the SC version. However, the SC version carries the advantage that the administration time is considerably shorter (10 minutes SC compared to 2-2.5 hours for the IV administration) which may be beneficial for the patients and the caregivers. The exposuresafety  analysis  confirms  that  the  increased  exposure  that  is  seen  for  the  SC  formulation  does  not translate into a worse safety profile.

Overall, available safety data from the clinical development program show that ocrelizumab SC were generally  well  tolerated  and  comparable  to  ocrelizumab  IV.  More  AEs  were  reported  in  the  SC  arm compared to the IV arm in OCARINA II. Injection reactions contributed to the higher frequency in the SC arm. Even though injection reactions were mostly mild and moderate in intensity, the risk for more severe injection reactions is not completely ruled out. No treatment-emergent ADAs to ocrelizumab were observed.  However,  immunogenicity  status  following  SC  ocrelizumab  is  not  considered  adequately described.

## 3.7.2 Balance of benefits and risks

Since the increased exposure of the SC version of ocrelizumab compared to the IV version does not impact the safety profile, the benefit-risk is positive.

## 3.7.3 Additional considerations on the benefit-risk balance

N/A

<div style=\"page-break-after: always\"></div>

## 3.8 Conclusions

The overall B/R of Ocrevus 920 mg solution for injection as SC administration is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality and safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of, Ocrevus 920 mg, solution for injection, subcutaneous use is favourable in the following indication:

Ocrevus is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features, and for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Ocrevus subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.